New substituted fused ring compounds

Abstract

The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b) or (11); or a pharmaceutically acceptable salt thereof. This compound provides a prophylactic or therapeutic agent effective for bacterial infections when used in combination with β-lactam-based drugs or used as a single agent. The present invention also provides a prophylactic or therapeutic agent effective for treating various diseases, by being used in combination with β-lactam-based drugs.

Description

[Technical Field]

[0001] The present invention relates to a substituted ring-fused compound or a pharmaceutically acceptable salt thereof that is useful as a pharmaceutical, more particularly to a pharmaceutical composition containing a novel substituted ring-fused compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical (e.g., a therapeutic agent, a prophylactic agent, etc.) containing the substituted ring-fused compound or a pharmaceutically acceptable salt thereof. [Background technology]

[0002] Since the discovery of penicillin, antibacterial agents have played an important role in the treatment of infectious diseases.

[0003] Among these, β-lactam antibiotics (e.g., penicillins, cephalosporins, and carbapenems) are the most commonly used drugs for the treatment of bacterial infections due to their strong bactericidal activity and high safety profile. However, with the increased use of β-lactam antibiotics, the emergence and spread of pathogens resistant to these antibiotics has become a global problem. The mechanisms by which these pathogens acquire resistance include the production of β-lactamases, structural changes in the target molecules of β-lactam antibiotics, decreased drug permeability into the bacterial cell, and increased drug efflux. In particular, the production of β-lactamases, which degrade and inactivate β-lactam antibiotics, is one of the factors that most significantly impact the maintenance of β-lactam antibiotic efficacy. Various bacteria have evolved β-lactamases that counteract the efficacy of various β-lactam antibiotics. β-lactamases can be classified into four classes based on their amino acid sequences: Ambler class A, B, C, and D. Class A, C, and D enzymes have a serine residue at the center of their enzymatic activity and are therefore called serine-β-lactamases, while class B enzymes do not have a serine residue at the center of their enzymatic activity and rely on the metal ion zinc (Zn 2+ ), they are called metallo-β-lactamases (zinc-β-lactamases).

[0004] It has already been confirmed that the combined use of β-lactamase inhibitors and β-lactam drugs is effective in solving the problem of resistance due to the production of β-lactamase. The commercially available β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam mainly inhibit class A β-lactamases, excluding KPC (Klebsiella pneumoniae Carbapenemase), and avibactam It is known that β-lactamases inhibit class A β-lactamases including KPC, class C β-lactamases, and some class D β-lactamases including OXA-48 (Non-Patent Document 1). However, these existing β-lactamase inhibitors cannot effectively and broadly inhibit all β-lactamases produced by various bacteria, and for example, they are ineffective against class B metallo-β-lactamases. In addition, in recent years, new β-lactamase inhibitors, collectively known as ESBLs (Extended Spectrum β-lactamases), which are capable of decomposing a greater number of substrates (β-lactam drugs) than conventional β-lactams, have been developed. The isolation of β-lactamases has become a problem in Europe and the United States as new resistant bacteria, particularly as a cause of hospital-acquired infections. In addition, the emergence and spread of metallo-β-lactamase-producing bacteria is becoming a growing problem in Japan. Given this current situation, addressing β-lactamase-producing bacteria, including ESBLs and metallo-β-lactamases, has become an extremely important issue in preventing hospital-acquired infections. Furthermore, the rapid evolution of pathogenic bacteria means that new β-lactamase-resistant bacteria are likely to emerge. Therefore, to address these issues and prepare for future challenges, there is a need for the development of new β-lactamase inhibitors that are structurally distinct from existing β-lactamase inhibitors and therefore offer broader β-lactamase and metallo-β-lactamase inhibitory activity.

[0005] Recently, boronic acid derivatives having β-lactamase inhibitory activity have been reported in Patent Documents 1 to 13, etc. Patent Document 10 discloses a structure in which a saturated cycloalkyl ring or the like is fused to a ring containing boronic acid. However, these patent documents do not disclose any structure relating to the novel substituted fused-ring compounds included in the present invention, i.e., boronic acid compounds having a combination of a non-aryl heterocycle (preferably a nitrogen-containing non-aryl heterocycle, more preferably an azetidine ring) structure having a specific substitution pattern in the side chain at a specific position (here, the specific substitution pattern refers, for example, to a structure in which the non-aryl heterocycle has a specific substituent via an alkylene group, or a structure in which the non-aryl heterocycle has a specific substituent via an oxo substituent (-C(=O)-, -S(=O)-, -S(=O)2-, etc.)) and a cyclopropane ring fused to a ring containing boronic acid. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] WO2014 / 107535 [Patent Document 2] WO2014 / 107536 [Patent Document 3] WO2015 / 179308 [Patent Document 4] WO2016 / 003929 [Patent Document 5] WO2016 / 149393 [Patent Document 6] WO2014 / 089365 [Patent Document 7] WO2014 / 110442 [Patent Document 8] WO2014 / 151958 [Patent Document 9] WO2015 / 191907 [Patent Document 10] WO2018 / 005662 [Patent Document 11] WO2018 / 199291 [Patent Document 12] WO2019 / 009369 [Patent Document 13] WO2019 / 009370 [Non-patent literature]

[0007] [Non-Patent Document 1] Buynak. JD. Expert Opinion on Therapeutic Patents, 2013, 23(11), 1469-1481. Summary of the Invention [Means for solving the problem]

[0008] The present invention provides novel compounds with excellent β-lactamase inhibitory activity, and provides a useful agent for preventing or treating bacterial infections, either in combination with a β-lactam drug or as a single agent. Specifically, the present invention provides a useful agent for preventing or treating diseases, such as sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infections of chronic respiratory lesions, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infections, lymphangitis / lymphadenitis, secondary infections of trauma, burns, and surgical wounds, urinary tract infections, genital infections, eye infections, and dental infections, in combination with a β-lactam drug.

[0009] More specifically, the present inventors have discovered that compounds represented by the following formula (1a), (1b) or (11), or pharmaceutically acceptable salts thereof (hereinafter sometimes referred to as "compounds of the present invention") have excellent β-lactamase inhibitory activity, and have completed the present invention.

[0010] That is, the present invention is as follows. [Term 1] Equation (1a) or (1b): [ka] [In formulas (1a) and (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted alkoxy group, or -NR a2 R b1 and R a1 , R a2 and R b1 are each independently the same or different and represent a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, Here, R a2 and R b1 may be taken together to form an optionally substituted nitrogen-containing non-aryl heterocycle, L 1 is a single bond, an oxygen atom, a sulfur atom, —SO—, —SO2—, an optionally substituted hydrocarbylene group, or an optionally substituted heterohydrocarbylene group, L 2 is a single bond or an optionally substituted hydrocarbylene group, Z is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group; R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and R j is a hydrogen atom, a hydroxyl group, or an optionally substituted hydrocarbyl group, Ring A is an optionally substituted non-aryl heterocycle, L 3is an oxygen atom, a sulfur atom, an optionally substituted hydrocarbylene group or an optionally substituted heterohydrocarbylene group, an optionally substituted —NH—, an optionally substituted —NH—SO—, or —S(═O)— or —S(═O)—; L 4 represents a single bond, an optionally substituted hydrocarbylene group or an optionally substituted heterohydrocarbylene group, or —C(═N—OR h1 )- and R h1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R 5 is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group or an optionally substituted heterohydrocarbyl group, optionally substituted -NHOH, a sulfo group (sulfonic acid group), optionally substituted -SOH, optionally substituted -SO-NH, optionally substituted -S(=O)(=NH)H, optionally substituted -NH-SO-H, optionally substituted -NH-SO-NH, optionally substituted -N=S(=O)H, or optionally substituted -NH; (R 1 , R 2 and R 3 the remaining two (which do not have the structure of formula (2)) are independently the same or different and represent a hydrogen atom, a halogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L 6 -R 8 (In the above formulas 1) and 2), R 8 is a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, and L 6 is a single bond or an optionally substituted hydrocarbylene group), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted heteroaryl, 7) an optionally substituted non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 1), 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a4 and R b3 are each independently the same or different and represent R a1 , R a2 and R b1 where R a4 and R b3 are bonded to the same nitrogen atom, they may be joined together to form an optionally substituted nitrogen-containing non-aryl heterocycle, R m1 is a hydrogen atom or an optionally substituted hydrocarbyl group, However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 may, as alkylene, be combined with the boron atom and two oxygen atoms to form a non-aryl heterocycle (the non-aryl heterocycle may have an optionally substituted alkylene portion), R m2is a hydrogen atom or an optionally substituted hydrocarbyl group, R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom, a halogen atom, an optionally substituted alkyl group, or -L 1 -L 2 -Z.] or a pharmaceutically acceptable salt thereof. [Term 2] Equation (1a) or (1b): [ka] [In formulas (1a) and (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted alkoxy group, or -NR a2 R b1 and R a1 , R a2 and R b1 are each independently the same or different and represent a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, Here, R a2 and R b1 may be taken together to form an optionally substituted nitrogen-containing non-aryl heterocycle, L 1 is a single bond, an oxygen atom, a sulfur atom, —SO—, —SO2—, an optionally substituted hydrocarbylene group, or an optionally substituted heterohydrocarbylene group, L 2 is a single bond or an optionally substituted hydrocarbylene group, Z is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group; R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and R j is a hydrogen atom, a hydroxyl group, or an optionally substituted hydrocarbyl group, Ring A is an optionally substituted non-aryl heterocycle, L 3 is an oxygen atom, a sulfur atom, an optionally substituted hydrocarbylene group or an optionally substituted heterohydrocarbylene group, or —S(═O)— or —S(═O)—; L 4 represents a single bond, an optionally substituted hydrocarbylene group, or -C(=N-OR h1 )- and R h1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R 5 is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, (R 1 , R 2 and R 3 the remaining two (which do not have the structure of formula (2)) are independently the same or different and represent a hydrogen atom, a halogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L 6 -R 8 (In the above formulas 1) and 2), R 8 is a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, and L 6 is a single bond or an optionally substituted hydrocarbylene group), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted heteroaryl, 7) an optionally substituted non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 1), 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a4 and R b3 are each independently the same or different and represent R a1 , R a2 and R b1 where R a4 and R b3 are bonded to the same nitrogen atom, they may be joined together to form an optionally substituted nitrogen-containing non-aryl heterocycle, R m1 is a hydrogen atom or an optionally substituted hydrocarbyl group, However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 may, as alkylene, be combined with the boron atom and two oxygen atoms to form a non-aryl heterocycle (the non-aryl heterocycle may have an optionally substituted alkylene portion), R m2is a hydrogen atom or an optionally substituted hydrocarbyl group, R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom, a halogen atom, an optionally substituted alkyl group, or -L 1 -L 2 -Z.] or a pharmaceutically acceptable salt thereof. [Term 3] Equation (1a) or (1b): [ka] [In formulas (1a) and (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted C 1-6 Alkoxy group, or -NR a2 R b1 and R a1 , R a2 and R b1 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group, or 15)-OR c1 , (However, each of the substituents in 2) to 14) above may be substituted), Here, R a2 and R b1 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), L 1 represents a single bond, oxygen atom, sulfur atom, -SO-, -SO2-, -NR d1 -, -NR d1 C(=O)- or -NR d1 SO2-, L 2 is a single bond or an optionally substituted C 1-6 is an alkylene group, Z is 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) carboxyl group, 5) C 3-10 alicyclic group, 6) C 6-10 aryl, 7) 5- or 6-membered heteroaryl; 8) 4-10 membered non-aryl heterocycle, 9) C 1-6 alkoxy groups, 10) C 3-10 alicyclic oxy groups, 11)C 6-10 aryloxy groups, 12) 5- or 6-membered heteroaryloxy groups, 13) a 4- to 10-membered non-aryl heterocyclic oxy group, 14)C 1-6 alkylthio groups, 15)C 3-10 alicyclic thio group, 16)C 6-10 arylthio groups, 17) 5- or 6-membered heteroarylthio groups, 18) 4- to 10-membered non-aryl heterocyclic thio group, (However, each of the substituents 5) to 18) above may be substituted.) 19)-SO2-NR e1 R f1 , 20)-NR e1 -C(=O)OR f1 , 21)-NR g1 -C(=O)NR e1 R f1 , 22)-NR e1 -C(=S)R f1 , 23)-NR e1 -C(=S)OR f1 , 24)-NR g1 -C(=S)NR e1 R f1 , 25)-NR g1 -CR e1 (=NR f1 ), 26)-NR g1 -CR e1 (=N-OR f1 ), 27)-NR h1 -C(=NR g1 )NR e1 R f1 , 28)-NR h1 -C(=N-OR g1 )NR e1 R f1 , 29)-NR i1 -C(=NR h1 )NR g1 -NR e1 R f1 、 30)-NR i1 -C(=N-OR h1 )NR g1 -NR e1 R f1 、 31)-NR e1 -SO2-R f1 、 32)-NR g1 -SO2-NR e1 R f1 、 33)-C(=O)OR e1 、 34)-C(=S)OR e1 、 35)-C(=S)NR e1 R f1 、 36)-C(=S)NR e1 OR f1 、 37)-C(=S)NR g1 -NR e1 R f1 、 38)-C(=NR e1 )R f1 、 39)-C(=N-OR e1 )R f1 、 40)-C(=NR h1 )NR g1 -NR e1 R f1 、 41)-C(=N-OR h1 )NR g1 -NR e1 R f1 、 42)-NR e1 R f1 、 43)-NR g1 -NR e1 R f1 、 44)-NR e1 OR f1 、 45)-NRe1 -C(=O)R f1 , 46)-C(=O)NR e1 R f1 , 47)-C(=O)NR e1 OR f1 , 48)-C(=O)NR g1 -NR e1 R f1 , 49)-C(=O)R e1 , 50)-C(=NR g1 )NR e1 R f1 ,or 51)-C(=N-OR h1 )NR e1 R f1 Either R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and Ring A is an optionally substituted 4- to 20-membered non-aryl heterocycle, L 3 teeth, 1) oxygen atom, 2) sulfur atoms, 3)-NR d2 -, 4)-NR d2 C(=O)-, 5)-NR d2 SO2-, 6) C 1-6 an alkylene group, 7) C 3-10 a cycloalkylene group, 8) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents in 6) to 8) above may be substituted), 9)-C(=O)-, 10)-S(=O)-, or 11)-S(=O)2- Either L 4 teeth, 1) a single bond, 2) C 1-6 an alkylene group, 3) C 3-10 a cycloalkylene group, 4) C 6-10 Arylene group 5) a 5- or 6-membered heteroarylene group; 6) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents in 2) to 6) above may be substituted), or 7)-C(=N-OR h1 )- Either R 5 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) 4-10 membered non-aryl heterocycle, 5) C 6-10 aryl, 6) 5- to 10-membered heteroaryl, 7) C 1-6 alkylthio groups, (However, each of the substituents 2) to 7) above may be substituted, and when two substituents further substituted with the substituents 1), 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a fused ring structure.) 8)-NR e1 OH, 9) Carboxyl group (-C(=O)OH) 10) Carboxylic acid equivalents (wherein the carboxylic acid equivalent is an ester group -C(=O)OR 20a including 11) sulfo group (sulfonic acid group), 12)-SO2R e1 , 13)-SO2-NR e1 R f1 , 14)-S(=O)(=NR f1 )R e1 , 15)-NR e1 -C(=O)R f1 , 16)-NR e1 -C(=O)OR f1 , 17)-NR g1 -C(=O)NR e1 R f1 , 18)-NR e1 -SO2-R f1 , 19)-NR g1 -SO2-NR e1 R f1 , 20)-N=S(=O)R e1 R f1 , 21)-C(=O)NR 50 R 51 ,or 22)-NR e1 R f1 (However, R 5 When the substituent of 22) is -L 3 -L 4 -R 5 is -(CH2) 1-4 NR e1 R f1 (In the formula, R e1 , R f1 is a hydrogen atom, optionally substituted C 1-4 Alkyl, optionally substituted C 3-7 Alicyclic groups, optionally substituted 4-10 membered non-aryl heterocyclic groups, optionally substituted C 6-10 aryl, or optionally substituted 5-10 membered heteroaryl) Either R 20a teeth, 1) C 1-6 alkyl groups, 2) C 3-10 alicyclic group, 3) C 6-10aryl, 4) a 5- or 6-membered heteroaryl, or 5) 4-10 membered non-aryl heterocycle (However, each of the substituents 1) to 5) above may be substituted.) Either R 50 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) hydroxyl group, 4) C 1-6 alkoxy groups, 5) C 3-6 cycloalkoxy groups, 6) C 3-6 alicyclic group, 7) 4- to 6-membered non-aryl heterocycles, 8) C 6-10 aryl, 9) 5- to 10-membered heteroaryl 10) 4-6 membered non-aryl heterocycle oxy, 11)C 6-10 aryloxy, 12) 5- to 10-membered heteroaryloxy, 13)C 1-6 alkylsulfonyl groups, 14)C 3-6 a cycloalkoxysulfonyl group, or 15) 4-6-membered non-aryl heterocyclic sulfonyl group (However, each of the substituents in 2) and 4) to 15) above may be substituted.) represents one of the following: R 51 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-6 alicyclic group, 4) 4-6 membered non-aryl heterocycle, 5) C 6-10 aryl, or 6) 5- to 10-membered heteroaryl (However, each of the substituents 2) to 6) above may be substituted.) represents one of the following: Alternatively, R 50 and R 51 and may be taken together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle, (R 1 , R 2 and R 3 the remaining two are independently the same or different and are each a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, optionally substituted C 1-6 Alkoxy group, optionally substituted C 1-6 an alkylthio group, an optionally substituted 5- or 6-membered heteroaryl, or —NR a3 R b2 and R d1 , R d2 , R e1 , R f1 , R g1 , R h1 , R i1 and R j are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R e1 and R f1 When the combination of the following is bound to the same nitrogen atom, they may be taken together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L6 -R 8 (In the above formulas 1) and 2), R 8 is -NR a5 R b4 , -NR a5 -L 7 -B(OR m1 )2, -OR m1 , or optionally substituted C 1-6 is an alkyl group, and L 6 is a single bond or -NR a6 -is), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted 5-membered heteroaryl; 7) an optionally substituted 5-membered non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a3 , R a4 , R a5 , R a6 , R b2 , R b3 and R b4 are each independently the same or different and represent R a1 , R a2 and R b1 where R a3 and R b2 , R a4 and R b3 or R a5 and R b4 When the combination of the following is bonded to the same nitrogen atom, they may be combined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R m1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 C 2-4 The alkylene may be taken together with the boron atom and two oxygen atoms to form a 5- to 7-membered non-aryl heterocycle (the alkylene portion of the non-aryl heterocycle may be substituted), R m2 is a hydrogen atom, optionally substituted C 1-6 alkyl group or optionally substituted C 3-10 is an alicyclic group, L 7 may be substituted C 1-3 is an alkylene group, R 61 , R 62 and R 63 Each independently represents a hydrogen atom, a halogen atom, or an optionally substituted C 1-6 is an alkyl group, R 64 is a hydrogen atom, a halogen atom, or an optionally substituted C 1-6 Alkyl group, or -L 1 -L 2 -Z.] Item 3. The compound according to item 1 or 2, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Section 4]L 3 but, 1) C 1-6 an alkylene group, 2) C 3-10 a cycloalkylene group, 3) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents 1) to 3) above may be substituted.) Either L 4 is a single bond or an optionally substituted C 1-5 Item 4. The compound according to any one of items 1 to 3, wherein R is an alkylene group, or a pharmaceutically acceptable salt thereof. [Section 5]L 3 may be substituted C 1-4 is an alkylene group, L 4 is a single bond or an optionally substituted C 1-3 Item 5. The compound according to any one of items 1 to 4, wherein R is an alkylene group, or a pharmaceutically acceptable salt thereof. [Section 6]L 3 But, -(CR 30 R 31 ) n1 - and R 30 and R 31 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a7 R a8 , 3) C 1-4 alkyl groups, 4) C 6-10 aryl, 5) 5- to 10-membered heteroaryl, 6) C 3-6 alicyclic group, 7) 4-10 membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR c2 or R 30 and R 31 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a7 and R a8 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group, or 15)-OR c3 , (However, each of the substituents in 2) to 14) above may be substituted), Here, R a7 and R a8 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c2 and R c3 are each independently 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), n1 is an integer of 1, 2, 3, or 4; L 4 But, -(CR 40 R 41 ) n2 - and R 40 and R 41 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a9 R a10 , 3) C 1-4 alkyl groups, 4) C 6-10 aryl, 5) 5- to 10-membered heteroaryl, 6) C 3-6 alicyclic group 7) 4-10 membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR c4 or R 40 and R 41 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a9 and R a10 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) 5- or 6-membered heteroarylsulfonyl group (However, each of the substituents in 2) to 14) above may be substituted), or 15)-OR c5 , Either Here, R a9 and R a10 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c4 and R c5 are each independently the above R c2 and R c3 is synonymous with n2 is 0 (i.e., L 4 is a single bond), is an integer of 1, 2 or 3, Item 6. The compound according to any one of items 1 to 5, or a pharmaceutically acceptable salt thereof. [Section 7]-L 3 -L 4 -, but optionally substituted C 1-2 Item 7. The compound according to any one of items 1 to 6, wherein R is an alkylene group, or a pharmaceutically acceptable salt thereof. [Section 8]-L 3 -L 4 -But C 1-3 It may be substituted with one or more of an alkyl group, an amino group, or a hydroxymethyl group, which may be the same or different (wherein two C 1-3 When alkyl groups are attached to the same carbon atom, they together with the carbon atom to which they are attached form a C 3-6 (may form an alicyclic group)C 1-2 Item 8. The compound according to any one of items 1 to 7, wherein R is an alkylene group, or a pharmaceutically acceptable salt thereof. [Section 9]R 5 but, 1) C3-10 alicyclic group, 2) C 6-10 aryl, 3) 5- to 10-membered heteroaryl, 4) C 1-6 alkylthio groups, (However, each of the substituents 1) to 4) above may be substituted, and when two substituents which are further substituted on the substituents 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a fused ring structure.) 5)-NR e1 OH, 6)-C(=O)NR 50 R 51 , 7)-SO2-NR e1 R f1 , 8)-NR e1 -SO2-R f1 , 9)-C(=O)OR 20 ,or 10)-NR e1 R f1 (However, R 5 When the substituent of 10) is L 3 and / or L 4 is always substituted with one or more groups other than hydrogen atoms 1-6 an alkylene group (where L 3 or L 4 together with the substituent, C 3-10 It may form an alicyclic group or a 4- to 10-membered non-aryl heterocycle. Either R 20 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either Item 9. The compound according to any one of items 1 to 8, or a pharmaceutically acceptable salt thereof. [Section 10] R 5 teeth, 1) C 6-10 aryl, 2) 5- to 10-membered heteroaryl, 3)-C(=O)NR 50 R 51 , 4)-C(=O)OR 20 ,or 5)-NR e1 R f1 (However, R 5 When the substituent is the substituent of 5), L 3 and / or L 4 is always substituted with one or more groups other than hydrogen atoms 1-6 an alkylene group, and together with the substituent, at least one C 3-10 Forms an alicyclic group or a 4- to 10-membered non-aryl heterocycle (However, each of the substituents in 1) and 2) above may be substituted, and when any two of these groups are bonded to adjacent atoms in the ring, they may be joined together to form a fused ring structure.) Either Item 10. The compound according to any one of items 1 to 9, or a pharmaceutically acceptable salt thereof. [Section 11] ZL 2 -L 1 may be replaced by C 1-6 Item 11. The compound according to any one of items 1 to 10, wherein R is an alkylthio group, or a pharmaceutically acceptable salt thereof. [Section 12] R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom, a fluorine atom, or C optionally substituted with a fluorine atom. 1-3 Item 12. The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 11, wherein R is an alkyl group. [Section 13]R 61 , R 62 , R63 and R 64 Item 13. The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 12, wherein each independently represents a hydrogen atom or a fluorine atom. [Item 14] The compound or pharmaceutically acceptable salt thereof according to any one of items 1 to 13, wherein G is an oxygen atom. [Item 15] X is a hydroxyl group or an optionally substituted C 1-6 Item 15. The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 14, wherein R is an alkoxy group. [Item 16] The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 15, wherein X is a hydroxyl group. [Item 17] The compounds of formula (1a) and (1b) are represented by the following formulas (3a) and (3b), respectively: [ka] [In formulas (3a) and (3b), X, R 1 , R 2 and R 3 is as defined in any one of paragraphs 1 to 16, R 4 teeth, 1)-C(=O)OR m1 (where R m1 is a hydrogen atom, C 1-6 Alkyl group, C 3-10 Alicyclic group, C 6-10 aryl, 5- or 6-membered heteroaryl, or 4- to 10-membered non-aryl heterocycle, 1-6 Alkyl group, the C 3-10 Alicyclic group, said C 6-10 the aryl, the 5- or 6-membered heteroaryl, and the 4- to 10-membered non-aryl heterocycle may each be substituted, and 2) Bioequivalent of 1) is selected from the group consisting of: 17. The compound according to any one of items 1 to 16, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Section 18]R 4 teeth, 1) -C(=O)OH (i.e., a carboxyl group), or 2) Carboxylic acid equivalent Item 18. The compound according to any one of items 1 to 17, wherein: [Item 19] The compounds of formula (1a) and (1b) or the compounds of formula (3a) and (3b) are represented by the following formulas (4a) and (4b), respectively: [ka] [In formulas (4a) and (4b), X, R 4 , Y, Ring A, L 3 , L 4 , and R 5 is as defined in any one of paragraphs 1 to 18, R 1 and R 2 are each independently the same or different and represent a hydrogen atom, a halogen atom, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Alkylthio group (provided that the C 1-6 Alkyl group, C 1-6 Alkoxy groups and C 1-6 The alkylthio group may be optionally substituted. Item 19. The compound according to any one of items 1 to 18, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item 20] The compound according to any one of Items 1 to 19, wherein Ring A is an optionally substituted 4- to 10-membered non-aryl heterocycle, or a pharmaceutically acceptable salt thereof. [Item 21] The compound according to any one of Items 1 to 20, or a pharmaceutically acceptable salt thereof, wherein Ring A is an optionally substituted 4- to 7-membered non-aryl heterocycle. [Item 22] The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 21, wherein Y is an oxygen atom or a sulfur atom. [Item 23] The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 22, wherein Y is an oxygen atom. [Item 24] The compounds of formula (1a) and (1b), or the compounds of formula (3a) and (3b), or the compounds of formula (4a) and (4b) are represented by the following formulas (5a) and (5b), respectively: [ka] [In formulas (5a) and (5b), R 1 , R 2 , Y., L. 3 , L 4 , and R 5 is as defined in any one of items 1 to 23, and ring A is an optionally substituted 4- to 6-membered nitrogen-containing non-aryl heterocycle. 24. The compound according to any one of items 1 to 23, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Section 25] L 3 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3 and items 11 to 24, wherein is -C(=O)- or -S(=O)2-. [Section 26] L 3 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3 and items 11 to 25, wherein is —C(═O)—. [Section 27] L 4 is a single bond, -C(=N-OR h1 )- or optionally substituted C 1-6 an alkylene group, where R h1 is optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3 and items 11 to 26, wherein R is an alkyl group. [Section 28] R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C 1-6 alkyl groups, 4) C 1-6 an alkoxy group, and 5) C 1-6 Alkylthio group (However, each of the substituents 3) to 5) above may be substituted.) 28. The compound according to any one of items 1 to 27, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section 29] R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C 1-6 alkyl groups, 4) C 1-6 an alkoxy group, and 5) C 1-6 Alkylthio group (However, each of the substituents 3) to 5) above may be substituted with a halogen atom.) 29. The compound according to any one of items 1 to 28, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section 30] R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C optionally substituted with a halogen atom 1-6 alkyl groups, 30. The compound according to any one of items 1 to 29, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section 31] R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) fluorine atoms, 3) C optionally substituted with a fluorine atom 1-3 alkyl groups, 31. The compound according to any one of items 1 to 30, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section 32] R 1and R 2 32. The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 31, wherein both are hydrogen atoms. [Item 33] The compounds of formula (1a) and (1b), or the compounds of formula (3a) and (3b), or the compounds of formula (4a) and (4b), or the compounds of formula (5a) and (5b), are represented by the following formulas (6a) and (6b), respectively: [ka] [In formulas (6a) and (6b), L 3 , L 4 , and R 5 is the number of terms 1 to 32 as defined in any one of the preceding claims, m is an integer of 1, 2, or 3; n is an integer of 1, 2, or 3; m+n is 2, 3, or 4. 33. The compound according to any one of items 1 to 32, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item 34] The compounds of formula (6a) and (6b) are, Formulas (7a) and (7b) below: [ka] Or, the following formulas (8a) and (8b): [ka] [In formulas (7a), (7b), (8a) and (8b), L 3 , L 4 , and R 5 is as defined in any one of paragraphs 1 to 33, m and n are defined in Section 33.] Item 34. The compound according to Item 33, which is any one of the optical isomers represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item 35] The compound according to any one of Items 1 to 34, wherein m is 1 or 2, n is 1 or 2, and m+n is 2 or 3, or a pharmaceutically acceptable salt thereof. [Item 36] The compound according to any one of Items 1 to 35, wherein m is 1 and n is 1, or a pharmaceutically acceptable salt thereof. [Section 37]L 3 But, -(CR 30 R 31 ) n1 - or 4- to 10-membered non-aryl heterocyclylene; R 30 and R 31 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2) optionally substituted C 1-4 an alkyl group, or 3) optionally substituted C 6-10 Aryl represents one of the following: n1 is 1, 2 or 3; L 4 is a single bond or -(CR 40 R 41 ) n2 - and R 40 and R 41 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a9 R a10 , 3) optionally substituted C 1-4 an alkyl group, or 4)-OR c4 or R 40 and R 41 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a9 , R a10 and R c4 are each independently the same or different, 1) hydrogen atom, 2) optionally substituted C 1-6 alkyl groups, 3) optionally substituted C 3-10 alicyclic group, Either Here, R a9 and R a10 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, n2 is 0, 1 or 2; The compound according to any one of items 1 to 6, items 9 to 24, and items 28 to 36, or a pharmaceutically acceptable salt thereof. [Item 38] n1 is 1 or 2, and n2 is 0 or 1; Item 38. The compound according to item 37, or a pharmaceutically acceptable salt thereof. [Section 39]L 3 But, -CR 30 R 31 - or 4- to 10-membered non-aryl heterocyclylene; R 30 and R 31 are each independently 1) hydrogen atom, 2) C 1-4 Alkyl groups (the groups are halogen, -NR a11 R a12 , or -OR c6 substituted with 3) C6 aryl (the group is halogen, -NR a13 R a14 , -OR c7 , or C 1-3 Alkyl groups (the groups are halogen, -NR a15 R a16 , or -OR c8 (optionally substituted with) (optionally substituted with) represents one of the following: L 4 is a single bond or -(CR 40 R 41 ) n2 - and R 40and R 41 are each independently 1) hydrogen atom, 2)-NR a9 R a10 , 3) C 1-4 Alkyl groups (the groups are halogen, -NR a17 R a18 , or -OR c9 substituted with 4)-OR c4 or R 40 and R 41 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group, R a9 , R a10 , R a11 , R a12 , R a13 , R a14 , R a15 , R a16 , R a17 , R a18 , R c4 , R c6 , R c7 , R c8 and R c9 are each independently the same or different, 1) hydrogen atom, 2) C 1-4 Alkyl groups (the groups are halogen, -NR a19 R a20 , or -OR c10 (which may be substituted with), represents one of the following: R a19 , R a20 and R c10 are each independently the same or different, 1) a hydrogen atom, or 2) C 1-4 an alkyl group (which may be substituted with halogen); represents one of the following: Here, R a9 and R a10 , R a11 and R a12 , Ra13 and R a14 , R a15 and R a16 , R a17 and R a18 , or R a19 and R a20 may be combined together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle; n2 is 0 or 1, The compound according to any one of items 1 to 6, items 9 to 24, and items 28 to 38, or a pharmaceutically acceptable salt thereof. [Section 40]L 3 is -CH2-, -CH(CH2NH2)-, or -CH(CH2OH)-, L 4 is a single bond, -CH2-, -CH(NH2)-, -CMe(NH2)-, -CEt(NH2)-, -C(iso-Pr)(NH2)-, -CH(CH2NH2)-, -CH(OH)-, -CH(CH2OH)-, -C(CH2OH)2-, or [ka] 39. The compound according to any one of items 1 to 6, 9 to 24, and 28 to 39, wherein: [Section 41]L 3 is a 4- to 10-membered non-aryl heterocyclylene, or a pharmaceutically acceptable salt thereof. [Section 42]L 3 is a 5-membered non-aryl heterocyclylene, or a pharmaceutically acceptable salt thereof. [Section 43]L 3 but, [ka] [ka] [ka] or [ka] The compound according to any one of items 1 to 6, 9 to 24, 28 to 39, and 41 to 42, wherein R is a hydrogen atom or a pharmaceutically acceptable salt thereof. [Section 44]L 4 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 6, 9 to 24, 28 to 39, and 41 to 43, wherein is a single bond. [Section 45]R 5 teeth, 1) C 6-10 aryl, or 2) 5- to 10-membered heteroaryl, (However, each of the substituents 1) and 2) above may be substituted, and when two substituents further substituted with the substituents 1) or 2) are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a condensed ring structure.) The compound according to any one of items 1 to 24 and items 28 to 40, or a pharmaceutically acceptable salt thereof. [Section 46]R 5 is a C6 aryl (i.e., phenyl) or a 5-, 6-, 9-, or 10-membered heteroaryl; These R 5 Each group in the formula (I) is R at all chemically substitutable positions on the carbon or nitrogen atoms in the ring. 6a or R 6b and Here, R is a substituent on a carbon atom. 6a If there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C 1-4 alkyl groups, 6) C 3-10 alicyclic group, 7) C 1-4 alkoxy groups, 8) C 3-10 alicyclic oxy groups, 9) C 6-10 aryloxy groups, 10) 5- or 6-membered heteroaryloxy groups, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO2-NR e2 R f2 , 13)-NR g2 -CR e2 (=NR f2 ), 14)-NR g2 -CR e2 (=N-OR f2 ), 15)-NR h2 -C(=NR g2 )NR e2 R f2 , 16)-NR h2 -C(=N-OR g2 )NR e2 R f2 , 17)-NR i2 -C(=NR h2 )NR g2 -NR e2 R f2 , 18)-NR i2 -C(=N-OR h2 )NR g2 -NR e2 R f2 , 19)-C(=NR e2 )R f2 , 20)-C(=N-OR e2 )R f2 , 21)-C(=NR h2 )-NR e2 R f2 , 22)-C(=NR h2 )NR g2 -NRe2 R f2 , 23)-C(=N-OR h2 )NR g2 -NR e2 R f2 , 24)-NR e2 R f2 , 25)-NR g2 -NR e2 R f2 , 26)-NR e2 OR f2 , 27)-NR e2 -C(=O)R f2 , 28)-C(=O)NR e2 R f2 , 29)-C(=O)NR e2 OR f2 , 30)-C(=O)NR g2 -NR e2 R f2 , 31)-C(=O)R e2 , 32)-C(=O)OR e2 , and 33)-C(=N-OR h2 )NR e2 R f2 selected from the group consisting of R is a substituent on the nitrogen atom 6b If there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl group, 3) C 1-4 alkyl groups, (However, the alkyl group may be substituted.) 4) C 3-10 alicyclic group, (However, the alicyclic group may be substituted.) 5)-C(=NR e2 )R f2 , 6)-C(=N-OR e2 )Rf2 , 7)-SO2-NR e2 R f2 , 8)-C(=NR h2 )-NR e2 R f2 , 9)-C(=NR h2 )NR g2 -NR e2 R f2 , 10)-C(=N-OR h2 )NR g2 -NR e2 R f2 , 11)-C(=O)NR e2 R f2 , 12)-C(=O)NR e2 OR f2 , 13)-C(=O)NR g2 -NR e2 R f2 , 14)-C(=O)R e2 , and 15)-C(=N-OR h2 )NR e2 R f2 selected from the group consisting of Or two R's 6a or R 6a and R 6b When the combination of the following is substituted on adjacent atoms in a ring, the two substituents may be taken together to form an optionally substituted 5- to 6-membered heteroaryl ring or an optionally substituted 5- to 7-membered non-aryl heterocycle which is further fused to the bond between the adjacent atoms in the ring; R e2 , R f2 , R g2 , R h2 , and R i2 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R e2 and R f2 When the combination of the following is bound to the same nitrogen atom, they may be taken together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle. The compound according to any one of items 1 to 24 and items 28 to 45, or a pharmaceutically acceptable salt thereof. [Section 47]R 5 is as follows: [ka] [ka] [ka] [ka] [ka] [ka] C aryl or a 5-, 6-, 9-, or 10-membered heteroaryl selected from the group consisting of: d is R 6a is the number of chemically substitutable positions on the ring of each group, Each R 6a and each R 6b is as defined in paragraph 46, The compound according to any one of items 1 to 24 and items 28 to 46, or a pharmaceutically acceptable salt thereof. [Section 48]R 6aIf there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , -C(=O)OR f2 , -C(=O)NR e2 R f2 , -C(=O)NR e2 (OR f2 ), or may be substituted with a hydroxyl group) 5) C 1-4 alkoxy group 6)-NR e2 R f2 , 7)-C(=O)NR e2 R f2 , and 8)-C(=O)OR e2 selected from the group consisting of Each R 6b If there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl groups, and 3) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , -C(=O)OR f2 , -C(=O)NR e2 R f2 , -C(=O)NR e2 (OR f2 ), or may be substituted with a hydroxyl group) Item 48. The compound according to item 46 or 47, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section 49]R e2 and R f2 are each independently the same or different and represent a hydrogen atom, an optionally substituted C 1-6 alkyl group or optionally substituted C 3-10The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 24 and items 28 to 48, wherein the group is an alicyclic group. [Section 50]R e2 and R f2 are each independently the same or different and represent a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 24 and items 28 to 49, wherein R is an alkyl group. [Section 51]R e2 and R f2 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 24 and items 28 to 50, wherein is a hydrogen atom. [Section 52]R 6a is -NR e2 R f2 and R e2 and R f2 is a hydrogen atom on one side and a C atom on the other side. 1-4 52. The compound according to any one of items 46 to 51, wherein the alkyl group is an alkyl group (which may be substituted with an amino group or a hydroxyl group), or a pharmaceutically acceptable salt thereof. [Section 53]R 5 is -C(=O)NR 50 R 51 45. The compound according to any one of items 1 to 24 and items 28 to 44, wherein: [Section 54]R 50 teeth, 1) hydrogen atom, 2) optionally substituted C 1-4 alkyl groups, 3) hydroxyl group, 4) optionally substituted C 1-4 an alkoxy group, or 5) optionally substituted C 1-6 alkylsulfonyl groups, represents one of the following: R 51 teeth, 1) a hydrogen atom, or 2) optionally substituted C 1-4 Alkyl group represents one of the following: Alternatively, R 50 and R 51 may be joined together to form a 4- to 6-membered nitrogen-containing non-aryl heterocycle; The compound according to any one of items 1 to 24, items 28 to 40, and item 53, or a pharmaceutically acceptable salt thereof. [Section 55]R 50 teeth, 1) hydrogen atom, 2) C 1-4 Alkyl groups (the groups are halogen, C 3-6 Alicyclic group, -NR a21 R a22 , or -OR c11 (which may be substituted with), 3) hydroxyl group, 4) C 1-4 Alkoxy groups (the groups are halogen, C 3-6 Alicyclic group, -NR a23 R a24 , or -OR c12 substituted with 5) C 1-4 Alkylsulfonyl group (the group is halogen, C 3-6 Alicyclic group, -NR a21 R a22 , or -OR c11 (which may be substituted with), represents one of the following: R a21 , R a22 , R a23 , R a24 , R c11 and R c12 are each independently the same or different, 1) a hydrogen atom, or 2) C 1-4 an alkyl group (which may be substituted with halogen); represents one of the following: Here, R a21 and R a22 , or R a23 and R a24may be combined together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle; R 51 is a hydrogen atom or C 1-4 alkyl (which may be substituted with halogen); The compound according to any one of items 1 to 24, items 28 to 40, and items 53 to 54, or a pharmaceutically acceptable salt thereof. [Section 56] R 50 teeth, 1) hydrogen atom, 2) C 1-4 an alkyl group (which may be substituted with a cyclopropyl group, -NH, -NHMe, -C(=O)NH, -C(=O)NHMe, -C(=O)NMe or -hydroxyl group); 3) a hydroxyl group, or 4) C 1-4 an alkoxy group (which may be substituted with a cyclopropyl group, -NH, -NHMe or -hydroxyl group); 5) C 1-4 alkylsulfonyl groups, represents one of the following: R 51 is a hydrogen atom, The compound according to any one of items 1 to 24, items 28 to 40, and items 53 to 55, or a pharmaceutically acceptable salt thereof. [Section 57]R 5 But -C(=O)OR 20 41. The compound according to any one of items 1 to 24 and items 28 to 40, wherein: [Section 58]R 20 teeth, 1) a hydrogen atom, or 2) optionally substituted C 1-4 alkyl groups, Item 58. The compound according to Item 57, wherein the compound is any one of the following: or a pharmaceutically acceptable salt thereof. [Section 59]L 3 is -CH2-, L 4Item 59. The compound according to Item 56 or 58, or a pharmaceutically acceptable salt thereof, wherein R is a single bond, —CH(NH2)—, or —CMe(NH2)—. [Section 60]L 4 but, [ka] , [ka] , [ka] or [ka] Item 60. The compound according to Item 59, wherein: [Section 61]L 4 but, [ka] or [ka] Item 61. The compound according to Item 59 or 60, wherein: [Section 62]R 20 Item 62. The compound or a pharmaceutically acceptable salt thereof according to any one of Items 57 to 61, wherein is a hydrogen atom. [Section 63]R 5 But, -NR e1 R f1 and L 3 is -CH2-, L 4 -CR 40 R 41 - and R 40 and R 41 each independently represents a C substituted with a hydroxyl group; 1-4 Alkyl groups or, together with the carbon atoms to which they are attached, C 3-6The compound according to any one of items 1 to 24 and items 28 to 40, which forms an alicyclic group, or a pharmaceutically acceptable salt thereof. [Section 64]R e1 and R f1 are each independently the same or different, 1) a hydrogen atom, or 2) optionally substituted C 1-3 alkyl groups, Either L 4 teeth, [ka] Item 64. The compound according to Item 63, wherein: [Section 65]R e1 and R f1 are each independently the same or different, 1) a hydrogen atom, or 2) optionally substituted C 1-3 alkyl groups, Either L 4 is a C substituted with a hydroxyl group 1-4 is an alkylene group, Item 64. The compound according to Item 63, or a pharmaceutically acceptable salt thereof. [Section 66]L 4 is a single bond or -NR 21 R 22 or =NOR 23 C optionally substituted with 1-6 an alkylene group, where R 21 , R 22 and R 23 each independently represents a hydrogen atom, an optionally substituted C 1-6 The compound according to any one of items 1 to 3 and items 11 to 36, wherein R is an alkyl group or an optionally substituted 4- to 10-membered non-aryl heterocyclic carbonyl group, or a pharmaceutically acceptable salt thereof. [Section 67]L 4is a single bond, -CH2-, -CH(NH2)-, -CMe(NH2)-, -CH(NHMe)-, -CD(NH2)- (wherein D represents a deuterium atom), -CH2CH2-, or -CH(NH2)-CH2-, where L 4 If an amino group is present in the 3 Item 67. The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3, 11 to 36, and 66, which binds to: [Section 68]L 3 is -C(=O)-, L 4 Item 68. The compound according to Item 67, or a pharmaceutically acceptable salt thereof, wherein - is a single bond, -CH2-, -CH(NH2)-, -CMe(NH2)-, or -CH(NH2)-CH2-. [Section 69]L 4 but, [ka] , [ka] , [ka] [ka] , [ka] , [ka] [ka] ,or [ka] Item 69. The compound according to Item 68, or a pharmaceutically acceptable salt thereof, which has any one of the isomeric structures: [Section 70]L 4but, [ka] or [ka] Item 68. The compound according to Item 68 or 69, wherein: [Section 71]L 4 but, [ka] or [ka] Item 68. The compound according to Item 68 or 69, wherein: [Section 72]L 4 but, [ka] or [ka] Item 68. The compound according to Item 68 or 69, wherein: [Section 73]L 4 but, [ka] or [ka] Item 68. The compound according to Item 68 or 69, wherein: [Section 74]R 5 is a hydrogen atom, optionally substituted C 1-6 alkyl group, optionally substituted C 3-10 Alicyclic groups, optionally substituted 4- to 10-membered non-aryl heterocycles, optionally substituted C 6-10 Aryl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted C1-6 Alkylthio group, or -NR e1 OH, where R e1 is a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3, 11 to 36, and 66 to 73, wherein R is an alkyl group. [Section 75]R 5 is an optionally substituted 5- or 6-membered heteroaryl or an optionally substituted C 6-10 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3, 11 to 36, and 66 to 74, wherein R is aryl. [Section 76]R 5 is an optionally substituted 5- or 6-membered heteroaryl; or a pharmaceutically acceptable salt thereof. [Section 77]R 5 may be substituted C 4-10 The compound according to any one of items 1 to 3, 11 to 36, and 66 to 76, wherein the aryl group is an alicyclic group or an optionally substituted 4- to 10-membered non-aryl heterocycle, or a pharmaceutically acceptable salt thereof. [Section 78]L 4 is a single bond, and R 5 is -NR e1 OH, where R e1 is a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3, 11 to 36, and 66 to 74, wherein R is an alkyl group. [Section 79]L 4 teeth, 1)-(CH2) p -CR 10 (NHR 11 )-, 2)-(CH2) q -CR 12 R 13 -,or 3)-(CH2) p -CR 10 (NHR11 )-(CH2) q -CR 12 R 13 - (wherein p and q are independently 0 or 1); R 10 teeth, 1) hydrogen atom, 2) carboxyl group, 3)-C(=O)NR 10a R 10b and R 11 teeth, 1) hydrogen atom, 2)-C(=O)R 11a ,or 3) an optionally substituted 5- or 6-membered non-aryl heterocyclic carbonyl group, However, R 10 -C(=O)NR 10a R 10b When R 10b and R 11 may be taken together to form -CHCH-, R 12 teeth, 1) a hydrogen atom, or 2) optionally substituted C 1-4 is an alkyl group, R 13 teeth, 1) hydrogen atom, 2) Hydroxyl group 3) optionally substituted C 1-4 Alkyl group 4) sulfanyl group, 5) carboxyl group, 6) optionally substituted C 1-4 alkylthio groups, 7)-NR 13a R 13b , 8)-NR 13a -C(=O)R 13b , 9) an optionally substituted 5- or 6-membered non-aryl heterocyclic carbonylamino group 10)-NR 13a -C(=O)NR 13b R13c , 11)-C(=O)NR 13a R 13b , 12)-C(=O)NR 13a OR 13b , 13)-S(=O)2-R 13a , 14)-S(=O)2-NR 13a R 13b , 15)-C(=O)NR 13a -S(=O)2-R 13b or 16)-C(=O)NR 13a -S(=O)2-NR 13b R 13c and R 10a , R 10b , R 11a , R 13a , R 13b and R 13c are each independently a hydrogen atom or an optionally substituted C 1-4 is an alkyl group, The compound according to any one of items 1 to 3 and items 11 to 36, or a pharmaceutically acceptable salt thereof. [Section 80]R 5 is a hydrogen atom or an optionally substituted C 1-4 is an alkyl group, Item 79. The compound according to item 79, or a pharmaceutically acceptable salt thereof. [Section 81]R 5 is as follows: [ka] [ka] [ka] selected from the group consisting of The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 6a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) a nitro group, 5) halogens, 6) C 1-4 alkyl groups, 7) C 3-10 alicyclic group, 8) C 1-4 alkoxy groups, 9) C 3-10 alicyclic oxy groups, 10) C 6-10 aryloxy groups, 11) 5- or 6-membered heteroaryloxy groups, 12) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 6) to 12) above may be substituted.) 13)-SO2-NR e2 R f2 , 14)-NR g2 -CR e2 (=NR f2 ), 15)-NR g2 -CR e2 (=N-OR f2 ), 16)-NR h2 -C(=NR g2 )NR e2 R f2 , 17)-NR h2 -C(=N-OR g2 )NR e2 R f2 , 18)-NR i2 -C(=NR h2 )NR g2 -NR e2 R f2 , 19)-NR i2 -C(=N-OR h2 )NR g2 -NR e2 R f2 , 20)-C(=NR e2 )R f2 , 21)-C(=N-OR e2 )R f2 , 22)-C(=NR h2 )-NR e2 R f2 , 23)-C(=NR h2 )NR g2 -NR e2 R f2 , 24)-C(=N-OR h2 )NR g2 -NR e2 R f2 , 25)-NR e2 R f2 , 26)-NR g2 -NR e2 R f2 , 27)-NR e2 OR f2 , 28)-NR e2 -C(=O)R f2 , 29)-C(=O)NR e2 R f2 , 30)-C(=O)NR e2 OR f2 , 31)-C(=O)NR g2 -NR e2 R f2 , 32)-C(=O)R e2 , 33)-C(=O)OR e2 , and 34)-C(=N-OR h2 )NR e2 R f2 selected from the group consisting of Each R 6b is independent, 1) hydrogen atom, 2) hydroxyl group, 3) C 1-4 alkyl groups, (However, the alkyl group may be substituted.) 4) C 3-10alicyclic group, (However, the alicyclic group may be substituted.) 5)-C(=NR e2 )R f2 , 6)-C(=N-OR e2 )R f2 , 7)-SO2-NR e2 R f2 , 8)-C(=NR h2 )-NR e2 R f2 , 9)-C(=NR h2 )NR g2 -NR e2 R f2 , 10)-C(=N-OR h2 )NR g2 -NR e2 R f2 , 11)-C(=O)NR e2 R f2 , 12)-C(=O)NR e2 OR f2 , 13)-C(=O)NR g2 -NR e2 R f2 , 14)-C(=O)R e2 , and 15)-C(=N-OR h2 )NR e2 R f2 77. The compound according to any one of items 1 to 3, 11 to 36, and 66 to 76, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section 82]R 5 is as follows: [ka] [ka] [ka] is a 5- or 6-membered aryl or heteroaryl selected from the group consisting of The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 6a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR f2 or hydroxyl group) 5) C 1-4 alkoxy group 6)-NR e2 R f2 , and 7)-C(=O)OR e2 selected from the group consisting of Each R 6b is independent, 1) hydrogen atom, 2) hydroxyl groups, and 3) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , -C(=O)NR e2 R f2 , -C(=O)OR f2 or may be substituted with a hydroxyl group) 82. The compound according to any one of items 1 to 3, 11 to 36, 66 to 76, and 81, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section 83]R 5 but, [ka] The compound according to any one of items 1 to 3, 11 to 36, 66 to 76, and 81 to 82, or a pharmaceutically acceptable salt thereof, wherein: [Section 84]R e2and R f2 are each independently the same or different and represent a hydrogen atom, an optionally substituted C 1-6 alkyl group or optionally substituted C 3-10 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3, 11 to 36, 66 to 76, and 81 to 82, wherein the group is an alicyclic group. [Section 85]R e2 and R f2 are each independently the same or different and represent a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items 1 to 3, 11 to 36, 66 to 76, 81 to 82, and 84, wherein R is an alkyl group. [Section 86]R e2 and R f2 is a hydrogen atom, or a pharmaceutically acceptable salt thereof. [Section 87]R 6a is -NR e2 R f2 and R e2 and R f2 is a hydrogen atom on one side and a C atom on the other side. 1-4 86. The compound according to any one of items 81 to 82 and items 84 to 85, wherein the alkyl group is optionally substituted with an amino group or a hydroxyl group, or a pharmaceutically acceptable salt thereof. [Section 88]R 5 is as follows: [ka] [ka] is a 4- to 6-membered non-aryl heterocycle selected from the group consisting of The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 7a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C 1-4 alkyl groups, 6) C 3-10 alicyclic group, 7) C 1-4 alkoxy groups, 8) C 3-10 alicyclic oxy groups, 9) C 6-10 aryloxy groups, 10) 5- or 6-membered heteroaryloxy groups, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO2-NR e3 R f3 , 13)-NR g2 -CR e3 (=NR f3 ), 14)-NR g2 -CR e3 (=N-OR f3 ), 15)-NR h2 -C(=NR g2 )NR e3 R f3 , 16)-NR h2 -C(=N-OR g2 )NR e3 R f3 , 17)-NR i2 -C(=NR h2 )NR g2 -NR e3 R f3 , 18)-NR i2 -C(=N-OR h2 )NR g2 -NR e3 R f3 , 19)-C(=NR e3 )R f3 , 20)-C(=N-OR e3 )Rf3 , 21)-C(=NR h2 )-NR e3 R f3 , 22)-C(=NR h2 )NR g2 -NR e3 R f3 , 23)-C(=N-OR h2 )NR g2 -NR e3 R f3 , 24)-NR e3 R f3 , 25)-NR g2 -NR e3 R f3 , 26)-NR e3 OR f3 , 27)-NR e3 -C(=O)R f3 , 28)-C(=O)NR e3 R f3 , 29)-C(=O)NR e3 OR f3 , 30)-C(=O)NR g2 -NR e3 R f3 , 31)-C(=O)R e3 , 32)-C(=O)OR e3 , and 33)-C(=N-OR h2 )NR e3 R f3 selected from the group consisting of Each R 7b is independent, 1) hydrogen atom, 2) hydroxyl group, 3) C 1-4 alkyl groups, (However, the alkyl group may be substituted.) 4) C 3-10 alicyclic group, (However, the alicyclic group may be substituted.) 5)-C(=NR e3 )R f3 , 6)-C(=N-OR e3 )R f3 , 7)-SO2-NR e3 R f3 , 8)-C(=NR h2 )-NR e3 R f3 , 9)-C(=NR h2 )NR g2 -NR e3 R f3 , 10)-C(=N-OR h2 )NR g2 -NR e3 R f3 , 11)-C(=O)NR e3 R f3 , 12)-C(=O)NR e3 OR f3 , 13)-C(=O)NR g2 -NR e3 R f3 , 14)-C(=O)R e3 , and 15)-C(=N-OR h2 )NR e3 R f3 selected from the group consisting of R e3 , R f3 , R g2 , R h2 and R i2 is the R described in Section 3 e2 , R f2 , R g2 , R h2 and R i2 The compound according to any one of items 1 to 3, 11 to 36, 66 to 74, and 77, which has the same meaning as the compound or a pharmaceutically acceptable salt thereof. [Section 89]R 5 is as follows: [ka] [ka] is a 4- to 6-membered non-aryl heterocycle selected from the group consisting of The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 7a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C 1-4 alkyl groups, (However, the alkyl group is NR e3 R f3 , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR f3 or may be substituted with a hydroxyl group) 5) C 1-4 alkoxy group 6)-NR e3 R f3 , 7)-C(=O)OR e3 , and 8) C 6-10 Aryl 9)-C(=O)NR e3 R f3 selected from the group consisting of Each R 7b is independent, 1) hydrogen atom, 2) hydroxyl groups, and 3) C 1-4 alkyl groups, (However, the alkyl group is NR e3 R f3 , -C(=O)OR f3 or may be substituted with a hydroxyl group) selected from the group consisting of R e3 and R f3 R according to any one of items 84 to 86 e2 and R f2The compound according to any one of items 1 to 3, 11 to 36, 66 to 74, 77, and 88, which has the same meaning as the compound or a pharmaceutically acceptable salt thereof. [Section 90]R 5 is as follows: [ka] C selected from the group consisting of 4-6 is cycloalkyl, The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 9a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C 1-4 alkyl groups, 6) C 3-10 alicyclic group, 7) C 1-4 alkoxy groups, 8) C 3-10 alicyclic oxy groups, 9) C 6-10 aryloxy groups, 10) 5- or 6-membered heteroaryloxy groups, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO2-NR e3 R f3 , 13)-NR g2 -CR e3 (=NR f3 ), 14)-NR g2 -CR e3 (=N-OR f3 ), 15)-NR h2 -C(=NR g2 )NR e3 R f3 , 16)-NR h2 -C(=N-OR g2 )NRe3 R f3 、 17)-NR i2 -C(=NR h2 )NR g2 -NR e3 R f3 、 18)-NR i2 -C(=N-OR h2 )NR g2 -NR e3 R f3 、 19)-C(=NR e3 )R f3 、 20)-C(=N-OR e3 )R f3 、 21)-C(=NR h2 )-NR e3 R f3 、 22)-C(=NR h2 )NR g2 -NR e3 R f3 、 23)-C(=N-OR h2 )NR g2 -NR e3 R f3 、 24)-NR e3 R f3 、 25)-NR g2 -NR e3 R f3 、 26)-NR e3 OR f3 、 27)-NR e3 -C(=O)R f3 、 28)-C(=O)NR e3 R f3 、 29)-C(=O)NR e3 OR f3 、 30)-C(=O)NR g2 -NR e3 R f3 、 31)-C(=O)R e3 、 32)-C(=O)OR e3 , and 33)-C(=N-OR h2 )NR e3 R f3 selected from the group consisting of R e3 , R f3 , R g2 , R h2 and R i2 is the R described in Section 3 e2 and R f2 The compound according to any one of items 1 to 3, 11 to 36, 66 to 74, and 77, which has the same meaning as the compound or a pharmaceutically acceptable salt thereof. [Section 91]R 5 is as follows: [ka] C selected from the group consisting of 4-6 is cycloalkyl, The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 9a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C 1-4 alkyl groups, (However, the alkyl group is NR e3 R f3 , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR f3 or may be substituted with a hydroxyl group) 5) C 1-4 alkoxy group 6)-NR e3 R f3 , 7)-C(=O)OR e3 , and 8) C 6-10 Aryl 9)-C(=O)NR e3 R f3 selected from the group consisting of R e3and R f3 R according to any one of items 75 to 77 e2 and R f2 The compound according to any one of items 1 to 3, 11 to 36, 66 to 74, 77, and 90, which has the same meaning as the above, or a pharmaceutically acceptable salt thereof. [Section 92]L 4 -CH(NH2)-CHR 13 -, and the carbon to which the NH2 is bonded is L 3 binds to R 5 is a hydrogen atom, R 13 teeth, 1) -NH-C(=O)CH3, 2) -NH-C(=O)NH2, 3)-NH-C(=O)CH(NH2)-CH2C(=O)NH2, 4) -NH-C(=O)CH2-NH2, 5) -NH-C(=O)CH(NH2)-CH2OH, or 6) a pyrrolidin-2-ylcarbonylamino group; The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 93]L 4 -CH(NH2)-CR 12 R 13 -, and the carbon to which the NH2 is bonded is L 3 binds to R 5 is a hydrogen atom or methyl, R 12 is a hydrogen atom or methyl, R 13 is a benzylthio group or a sulfanyl group, The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 94]L 4 is -CH(NH2)-(CH2) q -CHR 13 -, q is 0 or 1, and the carbon to which the NH2 is bonded is L 3binds to R 5 is a hydrogen atom, R 13 teeth, 1) carboxyl group, 2) -C(=O)NH2, 3) -C(=O)NH(CH3), 4)-C(=O)N(CH3)2, 5) -C(=O)NH-(CH2)2-OH, 6) -C(=O)NH-(CH2)2-NH2, 7) -C(=O)NH-S(=O)2-CH3, 8)-C(=O)NHOH, 9)-S(=O)2-NH2, 10)-S(=O)2-CH3, or 11) a hydroxyl group; The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 95]L 4 -CH(NHR 11 )-CH2-, and the NHR 11 The carbon bonded to L 3 binds to R 5 is hydrogen, R 11 teeth, 1)-C(=O)CH(NH2)-CH2C(=O)NH2, 2) -C(=O)CH2-NH2, 3) -C(=O)CH(CH3)-NH2, 4) -C(=O)CH(NH2)-CH2OH, or 5) pyrrolidin-2-ylcarbonyl; The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 96]L 4 -CH(NHR 11 )-CH(COOH)-, and the NHR 11 The carbon bonded to L 3 binds to R5 is hydrogen, R 11 teeth, 1)-C(=O)CH(NH2)-CH2C(=O)NH2, 2) -C(=O)CH2-NH2, 3) -C(=O)CH(CH3)-NH2, 4) -C(=O)CH(NH2)-CH2OH, or 5) pyrrolidin-2-ylcarbonyl; The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 97]L 4 Ha-CHR 13 - or -CH2-CHR 13 - and R 5 is hydrogen, R 13 is -C(=O)NH2, or -C(=O)NHOH; The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 98]L 4 Ha-CH2-CR 10 (NH2)-, and the CH2 group is L 3 binds to R 5 is hydrogen, R 10 is a carboxy group or -C(=O)NH2, The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 99]L 4 Ha-(CH2) p -CR 10 (NHR 11 )-(CH2) q -CHR 13 -or- CHR 13 -(CH2) q -CR 10 (NHR 11 )-(CH2) pwhere q is 0 or 1; R 5 is hydrogen, (1)L 4 Ga-CHR 13 -(CH2) q -CR 10 (NHR 11 )-(CH2) p -When -CHR 13 - group carbon is L 3 binds to p is 0, R 10 is a hydrogen atom, a carboxyl group, or -C(=O)NHR 10b and R 11 is a hydrogen atom, R 10b is a hydrogen atom, However, R 10 -C(=O)NHR 10b When R 10b and R 11 may be taken together to form -CHCH-, R 13 is a hydrogen atom, (2)L 4 Ga-(CH2) p -CR 10 (NHR 11 )-(CH2) q -CHR 13 -When -(CH2) p - group carbon is L 3 binds to p is 1, R 10 and R 11 are both hydrogen atoms, R 13 is a carboxyl group, or -C(=O)NR 13a R 13b and R 13a and R 13b are each independently a hydrogen atom or an optionally substituted C 1-4 is an alkyl group, The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Section 100]L 4 -CR 12 (NH2)-, R 12 is a hydrogen atom or a methyl group, R 5 is C optionally substituted with one hydroxyl group 1-4 is an alkyl group, The compound according to any one of items 1 to 3, 11 to 36, and 79 to 80, or a pharmaceutically acceptable salt thereof. [Item 101] The compound according to Item 1 or 2, selected from the group consisting of compounds represented by the following names or structural formulas, or a pharmaceutically acceptable salt thereof: 5-({1-[amino(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-[2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 5-({1-(2-amino-2-carboxypropyl)azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-(2-amino-2-carboxylatepropyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2R)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2R)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-({1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , and (2S,4R)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] . [Item 102] The compound according to Item 1 or 2, selected from the group consisting of compounds represented by the following names or structural formulas, or a pharmaceutically acceptable salt thereof: 2-Hydroxy-5-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-{1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-{1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-{1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 2-Hydroxy-5-[(1-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-(1-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-[(1-D-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-(1-D-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-[(1-L-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-(1-L-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-[(1-D-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-(1-D-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-[(1-L-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-(1-L-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 2-Hydroxy-5-({1-[4-hydroxy-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-{1-[4-hydroxy-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1a R ,7b S)-2-Hydroxy-5-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 2-Hydroxy-5-{[1-(2-methyl-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-[1-(2-methyl-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-[1-(2-methyl-D-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-[1-(2-methyl-L-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-[1-(2-methyl-D-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-[1-(2-methyl-L-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 2-Hydroxy-5-[(1-{[morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-(1-{[morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2 R ,4 S )-5,5-dihydroxy-9-(1-{[(2 S )-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2S)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2S)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-({1-[2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-(1-{2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-[(1-{2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-(1-{2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-({1-[5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-{1-[5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-{1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-{1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-{1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-{1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-{1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-{1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-{1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-{1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 2-Hydroxy-5-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 5-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-{1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-{1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-{1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-{1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-{1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-{1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 2-Hydroxy-5-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-{1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-{1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-{1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 5-{[1-({4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-({4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.02,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-[(1-{2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-(1-{2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-[(1-Histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-(1-Histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-D-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-L-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-D-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-L-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , 5-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-(2-aminoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-(2-aminoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-(2-aminoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , 5-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , 5-({1-[2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-({1-[2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , 5-({1-[2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-({1-[2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , 2-Hydroxy-5-[(1-{[4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-[(1-{[(4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-5,5-dihydroxy-9-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 5-[(1-{[4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate [ka] , 9-[(1-{[4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate [ka] , (2R,4S)-9-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate [ka] , (2R,4S)-9-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate [ka] , (2S,4R)-9-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate [ka] , (2S,4R)-9-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylic acid [ka] , 2 -Hydroxy-5-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 5,5-Dihydroxy-9-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-5-boranuidatricyclo[5.4.0.02,4]undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-2-Hydroxy-5-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-5,5-dihydroxy-9-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-2-Hydroxy-5-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , and (2R,4S)-5,5-dihydroxy-9-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] . [Term 103] The following formula (11): [ka] [In formula (11), R G is a hydroxyl group, a thiol group, or -NHR a1 and R a1 , X, R 1 , R 2 , R 3 , R 4 , R 61 , R 62 , R 63 and R64 has the same definition as in any one of items 1 to 16, and formula (1a) has the same definition as in item 1 or 2. or a pharmaceutically acceptable salt thereof. [Item 104] The compound of formula (11) is represented by the following formula (12): [ka] [In formula (12), X, R 1 , R 2 , R 3 , and R 4 has the same meaning as in item 17 or item 18] Item 104. The compound according to item 103, represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item 105] The compound of formula (11) or formula (12) is represented by the following formula (13): [ka] [In formula (13), X, Y, rings A, L 3 , L 4 , R 1 , R 2 , R 4 , and R 5 has the same meaning as defined in any one of items 19 to 23 and items 29 to 32], or a pharmaceutically acceptable salt thereof. [Section 106] X and R G is a hydroxyl group, and R 4 Item 106. The compound according to item 105, wherein R is a carboxyl group, and ring A is an optionally substituted 4- to 6-membered nitrogen-containing non-aryl heterocycle, or a pharmaceutically acceptable salt thereof. [Item 107] The compound of formula (11), formula (12) or formula (13) is represented by the following formula (14): [ka] [In formula (14), X, L 3 , L 4 , m, n, and R 5has the same meaning as defined in any one of Items 33 to 64. 107. The compound according to any one of items 103 to 106, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item 108] The compound of formula (14) is represented by the following formula (15): [ka] Or the following equation (16): [ka] [In formulas (15) and (16), X, L 3 , L 4 , m, n, and R 5 has the same meaning as defined in any one of Items 33 to 64. Item 108. The compound according to item 107, which is any one of the optical isomers represented by the following formula: or a pharmaceutically acceptable salt thereof. [Section 109]R G Item 109. The compound or a pharmaceutically acceptable salt thereof according to any one of Items 103 to 108, wherein is a hydroxyl group or a thiol group. [Section 110]R G Item 109. The compound or a pharmaceutically acceptable salt thereof according to any one of Items 103 to 109, wherein is a hydroxyl group. [Item 111] X is a hydroxyl group or C 1-6 Item 111. The compound or a pharmaceutically acceptable salt thereof according to any one of items 103 to 110, wherein R is an alkoxy group. [Item 112] The compound or a pharmaceutically acceptable salt thereof according to any one of items 103 to 111, wherein X is a hydroxyl group. [Section 113] Item 113. The compound according to any one of items 107 to 112, wherein m is 1 or 2, n is 1 or 2, and m+n is 2 or 3, or a pharmaceutically acceptable salt thereof. [Section 114] Item 114. The compound according to any one of items 107 to 113, wherein m is 1 and n is 1, or a pharmaceutically acceptable salt thereof. [Section 115] L 3has the same meaning as defined in item 25 or 26, or a pharmaceutically acceptable salt thereof. [Section 116] L 4 and R 5 is as defined in any one of items 27 and items 66 to 100, or a pharmaceutically acceptable salt thereof. [Item 117] The compound according to Item 104, or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds represented by the following names or structural formulas: 6-({1-[amino(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-Amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-(2-amino-2-carboxypropyl)azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , and 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] . [Item 118] The compound according to Item 104, or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds represented by the following names or structural formulas: 3- (2-boronocyclopropyl ) -2-Hydroxy-6-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[2-Boronocyclopropyl]-2-hydroxy-6-[(1-serylazetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-D-serylazetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-L-serylazetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-D-serylazetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-L-serylazetidin-3-yl)oxy]benzoic acid [ka] , 3-[2-Boronocyclopropyl]-2-hydroxy-6-({1-[4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[2-Boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-seryl)azetidin-3-yl]oxy}benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}benzoic acid [ka] , 3-[(2-boronocyclopropyl]-2-hydroxy-6-[(1-{[morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 6-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 3-[2-Boronocyclopropyl]-6-({1-[(5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid [ka] , 6-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 3-[(2-Boronocyclopropyl]-2-hydroxy-6-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]benzoic acid [ka] , 6-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 3-[2-Boronocyclopropyl]-2-hydroxy-6-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)benzoic acid [ka] , 6-{[1-({4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 3-(2-Boronocyclopropyl)-6-[(1-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid [ka] , 6-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-Amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-Amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-Amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-Amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-Amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 3-[2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid [ka] , 3-[2-Boronocyclopropyl]-6-[(1-{[4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate [ka] , 3-[(1R,2S)-2-Boronocyclopropyl]-6-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-6-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate [ka] , 3-(2-Boronocyclopropyl)-2-hydroxy-6-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)benzoic acid [ka] , 3-[(1S,2R)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)benzoic acid [ka] , and 3-[(1R,2S)-2-Boronocyclopropyl]-2-hydroxy-6-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)benzoic acid [ka] . [Item 119] A pharmaceutical composition comprising the compound according to any one of items 1 to 118 or a pharmaceutically acceptable salt thereof. [Item 120] The pharmaceutical agent according to Item 119, which is a therapeutic or preventive agent for bacterial infections. [Item 121] A β-lactamase inhibitor comprising the compound according to any one of items 1 to 118 or a pharmaceutically acceptable salt thereof as an active ingredient. [Item 122] A pharmaceutical composition comprising the compound according to any one of items 1 to 118 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. [Item 123] The pharmaceutical composition of Item 122, further comprising an additional agent. [Item 124] The pharmaceutical composition of Item 123, wherein the additional agent is selected from the group consisting of antibacterial agents, antifungal agents, antiviral agents, anti-inflammatory agents, and antiallergic agents. [Item 125] A pharmaceutical composition according to Item 123 or 124, wherein the additional drug is a β-lactam drug. [Item 126] The additional drug beta-lactam is amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), epicillin, carbenicillin (carindacillin), ticarcillin, temocillin, azlocillin, piperacillin, mezlocillin, mecillinam (pivmecillinam), sulbenicillin, benzylpenicillin (G), clometocillin, benzathine benzylpenicillin, procaine benzylpenicillin, azidocillin, penamecillin, phenoxymethylpenicillin (V) ), propicillin, benzathine phenoxymethylpenicillin, phenethicillin, cloxacillin (dicloxacillin, flucloxacillin), oxacillin, methicillin, nafcillin, faropenem, biapenem, doripenem, ertapenem, imipenem, meropenem, panipenem, tomopenem, razupenem, cefazolin, cephacetrile, cefadroxil, cephalexin, cephaloglycin, cephalonium, cephaloridine, cephalothin, cephapirin, cefatrizine, cefazedone, cefazaflur, cephradine, cephradine Fluxadine, ceftezole, cefaclor, cefamandole, cefminox, cefonicid, ceforanide, cefotiam, cefprozil, cefbuperazone, cefuroxime, cefuzonam, cefoxitin, cefotetan, cefmetazole, loracarbef, cefixime, ceftazidime, ceftriaxone, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefmenoxime, cefodizime, cefoperazone, cefotaxime, cefpimizole, cefpiramide, cefpodoxime, cefsulodin, cefteram Item 126. The pharmaceutical composition of item 124 or 125, wherein the compound is selected from the group consisting of ceftibuten, ceftiolene, ceftizoxime, flomoxef, latamoxef, cefepime, cefozopran, cefpirome, cefquinome, ceftobiprole, ceftaroline, CXA-101, RWJ-54428, MC-04546, ME1036, BAL30072, SYN2416, ceftiofur, cefquinome, cefovecin, aztreonam, tigenonam, carumonam, RWJ-442831, RWJ-333441, and RWJ-333442. [Item 127] The pharmaceutical composition according to Item 125 or 126, wherein the β-lactam drug is selected from ceftazidime, biapenem, doripenem, ertapenem, imipenem, meropenem, or panipenem. [Item 128] A pharmaceutical composition according to Item 125 or 126, wherein the β-lactam drug is selected from aztreonam, tigenonam, BAL30072, SYN2416 or carumonam. [Item 129] The pharmaceutical composition according to Item 122, which is administered together with an additional drug. [Item 130] The pharmaceutical composition of Item 129, wherein the additional agent is selected from an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, or an antiallergic agent. [Item 131] A pharmaceutical composition according to Item 129 or 130, wherein the additional drug is a β-lactam drug. [Item 132] The additional drug beta-lactam is amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), epicillin, carbenicillin (carindacillin), ticarcillin, temocillin, azlocillin, piperacillin, mezlocillin, mecillinam (pivmecillinam), sulbenicillin, benzylpenicillin (G), clometocillin, benzathine benzylpenicillin, procaine benzylpenicillin, Penicillin, azidocillin, penamecillin, phenoxymethylpenicillin (V), propicillin, benzathine phenoxymethylpenicillin, phenethicillin, cloxacillin (dicloxacillin, flucloxacillin), oxacillin, methicillin, nafcillin, faropenem, biapenem, doripenem, ertapenem, imipenem, meropenem, panipenem, tomopenem, razupenem, cefazolin, cefacetrile , cefadroxil, cephalexin, cephaloglycin, cephalonium, cephaloridine, cephalothin, cephapirin, cefatrizine, cefazedone, cefazaflur, cephradine, cefroxadine, ceftezole, cefaclor, cefamandole, cefminox, cefonicid, ceforanide, cefotiam, cefprozil, cefbuperazone, cefuroxime, cefuzonam, cefoxitin, cefotetan, cefoxitin Fumetazole, loracarbef, cefixime, ceftazidime, ceftriaxone, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefmenoxime, cefodizime, cefoperazone, cefotaxime, cefpimizole, cefpiramide, cefpodoxime, cefsulodin, cefteram, ceftibuten, ceftiolene, ceftizoxime, flomoxef, latamoxef, cefepime, cefozopran, Item 130 or 131. The pharmaceutical composition of item 130 or 131, wherein the compound is selected from the group consisting of cefpirome, cefquinome, ceftobiprole, ceftaroline, CXA-101, RWJ-54428, MC-04546, ME1036, BAL30072, SYN2416, ceftiofur, cefquinome, cefovecin, aztreonam, tigenonam, carumonam, RWJ-442831, RWJ-333441, and RWJ-333442. [Item 133] The pharmaceutical composition of Item 131 or 132, wherein the beta-lactam drug is selected from the group consisting of ceftazidime, biapenem, doripenem, ertapenem, imipenem, meropenem, and panipenem. [Item 134] A pharmaceutical composition according to Item 131 or 132, wherein the β-lactam drug is selected from the group consisting of aztreonam, tigenonam, BAL30072, SYN2416 and carumonam. [Item 135] The compound according to any one of items 1 to 118 or a pharmaceutically acceptable salt thereof for use in treating a bacterial infection. [Item 136] The compound or a pharmaceutically acceptable salt thereof according to Item 135, wherein the bacterial infection is a bacterial infection involving a bacterium capable of having β-lactamase. [Item 137] A compound or a pharmaceutically acceptable salt thereof according to item 135 or 136, wherein the bacterial infection is sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory disease, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infection, lymphangitis / lymphadenitis, secondary infection of trauma / burn, surgical wound, etc., urinary tract infection, genital infection, eye infection or dental infection. [Item 138] A pharmaceutical composition comprising the compound according to any one of items 1 to 118 or a pharmaceutically acceptable salt thereof in combination with at least one drug selected from the group consisting of therapeutic agents for sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infections of chronic respiratory lesions, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infections, lymphangitis / lymphadenitis, secondary infections such as trauma / burn and surgical wound, urinary tract infections, genital infections, eye infections, and dental infections. [Item 139] A pharmaceutical composition comprising a β-lactam drug, wherein the pharmaceutical composition is administered together with the compound according to any one of items 1 to 118 or a pharmaceutically acceptable salt thereof. [Item 140] A method for treating a bacterial infection, comprising administering to a patient in need of treatment a therapeutically effective amount of the compound according to any one of items 1 to 118 or a pharmaceutically acceptable salt thereof. [Item 141] The method described in Item 140, wherein the bacterial infection is a bacterial infection involving a bacterium that may have β-lactamase. [Item 142] The method according to item 140 or 141, wherein the bacterial infection is sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory disease, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infection, lymphangitis / lymphadenitis, secondary infection of trauma / burn and surgical wound, urinary tract infection, genital infection, eye infection or dental infection. [Item 143] The method according to any one of items 140 to 142, wherein the method is administered together with an additional drug.

[0011] That is, the present invention also includes the following. [Term B1] Equation (1a) or (1b): [ka] [In formulas (1a) and (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted alkoxy group, or -NR a2 R b1 and R a1 , R a2 and R b1 are each independently the same or different and represent a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, Here, R a2 and R b1 may be taken together to form an optionally substituted nitrogen-containing non-aryl heterocycle, L 1 is a single bond, an oxygen atom, a sulfur atom, —SO—, —SO2—, an optionally substituted hydrocarbylene group, or an optionally substituted heterohydrocarbylene group, L 2 is a single bond or an optionally substituted hydrocarbylene group, Z is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group; R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and R j is a hydrogen atom, a hydroxyl group, or an optionally substituted hydrocarbyl group, Ring A is an optionally substituted non-aryl heterocycle, L 3 is an oxygen atom, a sulfur atom, an optionally substituted hydrocarbylene group or an optionally substituted heterohydrocarbylene group, or —S(═O)— or —S(═O)—; L 4 represents a single bond, an optionally substituted hydrocarbylene group, or -C(=N-OR h1 )- and R h1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R 5 is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, (R 1 , R 2 and R 3the remaining two (which do not have the structure of formula (2)) are independently the same or different and represent a hydrogen atom, a halogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L 6 -R 8 (In the above formulas 1) and 2), R 8 is a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, and L 6 is a single bond or an optionally substituted hydrocarbylene group), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted heteroaryl, 7) an optionally substituted non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 1), 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a4 and R b3 are each independently the same or different and represent R a1 , R a2 and R b1 where R a4 and R b3 are bonded to the same nitrogen atom, they may be joined together to form an optionally substituted nitrogen-containing non-aryl heterocycle, R m1 is a hydrogen atom or an optionally substituted hydrocarbyl group, However, R m1is bonded to the boron atom through an oxygen atom, two R m1 may, as alkylene, be combined with the boron atom and two oxygen atoms to form a non-aryl heterocycle (the non-aryl heterocycle may have an optionally substituted alkylene portion), R m2 is a hydrogen atom or an optionally substituted hydrocarbyl group, R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom, a halogen atom, an optionally substituted alkyl group, or -L 1 -L 2 -Z.] or a pharmaceutically acceptable salt thereof. [Term B2] Equation (1a) or (1b): [ka] [In formulas (1a) and (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted C 1-6 Alkoxy group, or -NR a2 R b1 and R a1 , R a2 and R b1 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group, or 15)-OR c1 , (However, each of the substituents in 2) to 14) above may be substituted), Here, R a2 and R b1 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), L 1 represents a single bond, oxygen atom, sulfur atom, -SO-, -SO2-, -NR d1 -, -NR d1 C(=O)- or -NR d1 SO2-, L 2 is a single bond or an optionally substituted C 1-6 is an alkylene group, Z is 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) carboxyl group, 5) C 3-10 alicyclic group, 6) C 6-10 aryl, 7) 5- or 6-membered heteroaryl; 8) 4-10 membered non-aryl heterocycle, 9) C 1-6 alkoxy groups, 10) C 3-10 alicyclic oxy groups, 11)C 6-10 aryloxy groups, 12) 5- or 6-membered heteroaryloxy groups, 13) a 4- to 10-membered non-aryl heterocyclic oxy group, 14)C 1-6 alkylthio groups, 15)C 3-10 alicyclic thio group, 16)C 6-10 arylthio groups, 17) 5- or 6-membered heteroarylthio groups, 18) 4- to 10-membered non-aryl heterocyclic thio group, (However, each of the substituents 5) to 18) above may be substituted.) 19)-SO2-NR e1 R f1 , 20)-NR e1 -C(=O)OR f1 , 21)-NR g1 -C(=O)NR e1 R f1 , 22)-NR e1 -C(=S)R f1 , 23)-NR e1 -C(=S)OR f1 , 24)-NR g1 -C(=S)NR e1 R f1 , 25)-NR g1 -CR e1 (=NR f1 ), 26)-NR g1 -CR e1 (=N-OR f1 ), 27)-NRh1 -C(=NR g1 )NR e1 R f1 、 28)-NR h1 -C(=N-OR g1 )NR e1 R f1 、 29)-NR i1 -C(=NR h1 )NR g1 -NR e1 R f1 、 30)-NR i1 -C(=N-OR h1 )NR g1 -NR e1 R f1 、 31)-NR e1 -SO2-R f1 、 32)-NR g1 -SO2-NR e1 R f1 、 33)-C(=O)OR e1 、 34)-C(=S)OR e1 、 35)-C(=S)NR e1 R f1 、 36)-C(=S)NR e1 OR f1 、 37)-C(=S)NR g1 -NR e1 R f1 、 38)-C(=NR e1 )R f1 、 39)-C(=N-OR e1 )R f1 、 40)-C(=NR h1 )NR g1 -NR e1 R f1 、 41)-C(=N-OR h1 )NR g1 -NR e1 R f1 、 42)-NRe1 R f1 , 43)-NR g1 -NR e1 R f1 , 44)-NR e1 OR f1 , 45)-NR e1 -C(=O)R f1 , 46)-C(=O)NR e1 R f1 , 47)-C(=O)NR e1 OR f1 , 48)-C(=O)NR g1 -NR e1 R f1 , 49)-C(=O)R e1 , 50)-C(=NR g1 )NR e1 R f1 ,or 51)-C(=N-OR h1 )NR e1 R f1 Either R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and Ring A is an optionally substituted 4- to 20-membered non-aryl heterocycle, L 3 teeth, 1) oxygen atom, 2) sulfur atoms, 3)-NR d2 -, 4)-NR d2 C(=O)-, 5)-NR d2 SO2-, 6) C1-6 an alkylene group, 7) C 3-10 a cycloalkylene group, 8) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents in 6) to 8) above may be substituted), 9)-C(=O)-, 10)-S(=O)-, or 11)-S(=O)2- Either L 4 teeth, 1) a single bond, 2) C 1-6 an alkylene group, 3) C 3-10 a cycloalkylene group, 4) C 6-10 Arylene group 5) a 5- or 6-membered heteroarylene group; 6) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents in 2) to 6) above may be substituted), or 7)-C(=N-OR h1 )- Either R 5 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) 4-10 membered non-aryl heterocycle, 5) C 6-10 aryl, 6) 5- to 10-membered heteroaryl, 7) C 1-6 alkylthio groups, (However, each of the substituents 2) to 7) above may be substituted, and when two substituents further substituted with the substituents 1), 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a fused ring structure.) 8)-NR e1 OH, 9) Carboxyl group (-C(=O)OH) 10) Carboxylic acid equivalents (wherein the carboxylic acid equivalent is an ester group -C(=O)OR 20a including 11) sulfo group (sulfonic acid group), 12)-SO2R e1 , 13)-SO2-NR e1 R f1 , 14)-S(=O)(=NR f1 )R e1 , 15)-NR e1 -C(=O)R f1 , 16)-NR e1 -C(=O)OR f1 , 17)-NR g1 -C(=O)NR e1 R f1 , 18)-NR e1 -SO2-R f1 , 19)-NR g1 -SO2-NR e1 R f1 , 20)-N=S(=O)R e1 R f1 , 21)-C(=O)NR 50 R 51 ,or 22)-NR e1 R f1 (However, R 5 When the substituent of 22) is -L 3 -L 4 -R 5 is -(CH2) 1-4 NR e1 R f1 (In the formula, R e1 , R f1 is a hydrogen atom, optionally substituted C 1-4 Alkyl, optionally substituted C 3-7 Alicyclic groups, optionally substituted 4-10 membered non-aryl heterocyclic groups, optionally substituted C 6-10aryl, or optionally substituted 5-10 membered heteroaryl) Either R 20a teeth, 1) C 1-6 alkyl groups, 2) C 3-10 alicyclic group, 3) C 6-10 aryl, 4) a 5- or 6-membered heteroaryl, or 5) 4-10 membered non-aryl heterocycle (However, each of the substituents 1) to 5) above may be substituted.) Either R 50 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) hydroxyl group, 4) C 1-6 alkoxy groups, 5) C 3-6 cycloalkoxy groups, 6) C 3-6 alicyclic group, 7) 4- to 6-membered non-aryl heterocycles, 8) C 6-10 aryl, 9) 5- to 10-membered heteroaryl 10) 4-6 membered non-aryl heterocycle oxy, 11)C 6-10 aryloxy, 12) 5- to 10-membered heteroaryloxy, 13)C 1-6 alkylsulfonyl groups, 14)C 3-6 a cycloalkoxysulfonyl group, or 15) 4-6-membered non-aryl heterocyclic sulfonyl group (However, each of the substituents in 2) and 4) to 15) above may be substituted.) represents one of the following: R 51 teeth, 1) hydrogen atom, 2) C1-6 alkyl groups, 3) C 3-6 alicyclic group, 4) 4-6 membered non-aryl heterocycle, 5) C 6-10 aryl, or 6) 5- to 10-membered heteroaryl (However, each of the substituents 2) to 6) above may be substituted.) represents one of the following: Alternatively, R 50 and R 51 and may be taken together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle, (R 1 , R 2 and R 3 the remaining two are independently the same or different and are each a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, optionally substituted C 1-6 Alkoxy group, optionally substituted C 1-6 an alkylthio group, an optionally substituted 5- or 6-membered heteroaryl, or —NR a3 R b2 and R d1 , R d2 , R e1 , R f1 , R g1 , R h1 , R i1 and R j are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R e1 and R f1 When the combination of the following is bound to the same nitrogen atom, they may be taken together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L 6 -R 8 (In the above formulas 1) and 2), R 8 is -NR a5 R b4 , -NR a5 -L 7 -B(OR m1 )2, -OR m1 , or optionally substituted C 1-6 is an alkyl group, and L 6 is a single bond or -NR a6 -is), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted 5-membered heteroaryl; 7) an optionally substituted 5-membered non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a3 , R a4 , R a5 , R a6 , R b2 , R b3 and R b4 are each independently the same or different and represent R a1 , R a2 and R b1 where R a3 and Rb2 , R a4 and R b3 or R a5 and R b4 When the combination of the following is bonded to the same nitrogen atom, they may be combined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R m1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 C 2-4 The alkylene may be taken together with the boron atom and two oxygen atoms to form a 5- to 7-membered non-aryl heterocycle (the alkylene portion of the non-aryl heterocycle may be substituted), R m2 is a hydrogen atom, optionally substituted C 1-6 alkyl group or optionally substituted C 3-10 is an alicyclic group, L 7 may be substituted C 1-3 is an alkylene group, R 61 , R 62 and R 63 Each independently represents a hydrogen atom, a halogen atom, or an optionally substituted C 1-6 is an alkyl group, R 64 is a hydrogen atom, a halogen atom, or an optionally substituted C 1-6 Alkyl group, or -L 1 -L 2 -Z.] The compound according to item B1, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Section B3]L 3 but, 1) C 1-6 an alkylene group, 2) C 3-10 a cycloalkylene group, 3) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents 1) to 3) above may be substituted.) Either L 4 is a single bond or an optionally substituted C 1-5 The compound according to item B1 or B2, wherein the alkylene group is an alkylene group, or a pharmaceutically acceptable salt thereof. [Section B4]L 3 may be substituted C 1-4 is an alkylene group, L 4 is a single bond or an optionally substituted C 1-3 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B3, wherein the group is an alkylene group. [Section B5]L 3 But, -(CR 30 R 31 ) n1 - and R 30 and R 31 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a7 R a8 , 3) C 1-4 alkyl groups, 4) C 6-10 aryl, 5) 5- to 10-membered heteroaryl, 6) C 3-6 alicyclic group, 7) 4-10 membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR c2 or R 30 and R 31 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a7 and R a8 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group, or 15)-OR c3 , (However, each of the substituents in 2) to 14) above may be substituted), Here, R a7 and R a8 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c2 and R c3 are each independently 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), n1 is an integer of 1, 2, 3, or 4; L 4 But, -(CR 40 R 41 ) n2 - and R 40 and R 41 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a9 R a10 , 3) C 1-4 alkyl groups, 4) C 6-10 aryl, 5) 5- to 10-membered heteroaryl, 6) C 3-6 alicyclic group 7) 4-10 membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR c4 or R 40 and R 41 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a9 and R a10 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) 5- or 6-membered heteroarylsulfonyl group (However, each of the substituents in 2) to 14) above may be substituted), or 15)-OR c5 , Either Here, R a9 and R a10 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c4 and R c5 are each independently the above R c2 and R c3 is synonymous with n2 is 0 (i.e., L 4 is a single bond), is an integer of 1, 2 or 3, The compound according to any one of items B1 to B4 or a pharmaceutically acceptable salt thereof. [Section B6]-L 3 -L 4 -, but optionally substituted C 1-2 The compound according to any one of items B1 to B5, wherein the group is an alkylene group, or a pharmaceutically acceptable salt thereof. [Section B7]-L 3 -L 4 -But C 1-3 It may be substituted with one or more of an alkyl group, an amino group, or a hydroxymethyl group, which may be the same or different (wherein two C 1-3When alkyl groups are attached to the same carbon atom, they together with the carbon atom to which they are attached form a C 3-6 (may form an alicyclic group)C 1-2 The compound according to any one of items B1 to B6, wherein the group is an alkylene group, or a pharmaceutically acceptable salt thereof. [Section B8]R 5 but, 1) C 3-10 alicyclic group, 2) C 6-10 aryl, 3) 5- to 10-membered heteroaryl, 4) C 1-6 alkylthio groups, (However, each of the substituents 1) to 4) above may be substituted, and when two substituents which are further substituted on the substituents 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a fused ring structure.) 5)-NR e1 OH, 6)-C(=O)NR 50 R 51 , 7)-SO2-NR e1 R f1 , 8)-NR e1 -SO2-R f1 , 9)-C(=O)OR 20 ,or 10)-NR e1 R f1 (However, R 5 When the substituent of 10) is L 3 and / or L 4 is always substituted with one or more groups other than hydrogen atoms 1-6 an alkylene group (where L 3 or L 4 together with the substituent, C 3-10 It may form an alicyclic group or a 4- to 10-membered non-aryl heterocycle. Either R 20 teeth, 1) hydrogen atom, 2) C 1-6alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either The compound according to any one of items B1 to B7 or a pharmaceutically acceptable salt thereof. [Section B9]R 5 teeth, 1) C 6-10 aryl, 2) 5- to 10-membered heteroaryl, 3)-C(=O)NR 50 R 51 , 4)-C(=O)OR 20 ,or 5)-NR e1 R f1 (However, R 5 When the substituent is the substituent of 5), L 3 and / or L 4 is always substituted with one or more groups other than hydrogen atoms 1-6 an alkylene group, and together with the substituent, at least one C 3-10 Forms an alicyclic group or a 4- to 10-membered non-aryl heterocycle (However, each of the substituents in 1) and 2) above may be substituted, and when any two of these groups are bonded to adjacent atoms in the ring, they may be joined together to form a fused ring structure.) Either The compound according to any one of items B1 to B8 or a pharmaceutically acceptable salt thereof. [Section B10] ZL 2 -L 1 may be replaced by C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B9, wherein R is an alkylthio group. [Section B11]R 61 , R62 , R 63 and R 64 are each independently a hydrogen atom, a fluorine atom, or C optionally substituted with a fluorine atom. 1-3 The compound according to any one of items B1 to B10, or a pharmaceutically acceptable salt thereof, wherein the compound is an alkyl group. [Section B12]R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom or a fluorine atom, or a pharmaceutically acceptable salt thereof. [Item B13] The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B12, wherein G is an oxygen atom. [Item B14] X is a hydroxyl group or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B13, wherein R is an alkoxy group. [Item B15] The compound or a pharmaceutically acceptable salt thereof according to any one of Items B1 to B14, wherein X is a hydroxyl group. [Item B16] The compounds of formula (1a) and (1b) are represented by the following formulas (3a) and (3b), respectively: [ka] [In formulas (3a) and (3b), X, R 1 , R 2 and R 3 is as defined in any one of paragraphs B1 to B15, R 4 teeth, 1)-C(=O)OR m1 (where R m1 is a hydrogen atom, C 1-6 Alkyl group, C 3-10 Alicyclic group, C 6-10 aryl, 5- or 6-membered heteroaryl, or 4- to 10-membered non-aryl heterocycle, 1-6 Alkyl group, the C 3-10 Alicyclic group, said C 6-10the aryl, the 5- or 6-membered heteroaryl, and the 4- to 10-membered non-aryl heterocycle may each be substituted, and 2) Bioequivalent of 1) is selected from the group consisting of: The compound according to any one of items B1 to B15, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Section B17]R 4 teeth, 1) -C(=O)OH (i.e., a carboxyl group), or 2) Carboxylic acid equivalent The compound according to any one of items B1 to B16, wherein: [Item B18] The compounds of formula (1a) and (1b) or the compounds of formula (3a) and (3b) are represented by the following formulas (4a) and (4b), respectively: [ka] [In formulas (4a) and (4b), X, R 4 , Y, Ring A, L 3 , L 4 , and R 5 is as defined in any one of paragraphs B1 to B17, R 1 and R 2 are each independently the same or different and represent a hydrogen atom, a halogen atom, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Alkylthio group (provided that the C 1-6 Alkyl group, C 1-6 Alkoxy groups and C 1-6 The alkylthio group may be optionally substituted. The compound according to any one of items B1 to B17, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item B19] The compound according to any one of Items B1 to B18, or a pharmaceutically acceptable salt thereof, wherein Ring A is an optionally substituted 4- to 10-membered non-aryl heterocycle. [Item B20] The compound according to any one of Items B1 to B19, or a pharmaceutically acceptable salt thereof, wherein Ring A is an optionally substituted 4- to 7-membered non-aryl heterocycle. [Item B21] The compound or a pharmaceutically acceptable salt thereof according to any one of Items B1 to B20, wherein Y is an oxygen atom or a sulfur atom. [Item B22] The compound or a pharmaceutically acceptable salt thereof according to any one of Items B1 to B21, wherein Y is an oxygen atom. [Item B23] The compounds of formula (1a) and (1b), or the compounds of formula (3a) and (3b), or the compounds of formula (4a) and (4b) are represented by the following formulas (5a) and (5b), respectively: [ka] [In formulas (5a) and (5b), R 1 , R 2 , Y., L. 3 , L 4 , and R 5 is as defined in any one of items B1 to B22, and ring A is an optionally substituted 4- to 6-membered nitrogen-containing non-aryl heterocycle.] The compound according to any one of items B1 to B22, which is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Section B24]L 3 The compound or a pharmaceutically acceptable salt thereof according to any one of Items B1 to B2 and Items 10 to 23, wherein is -C(=O)- or -S(=O)2-. [Section B25]L 3 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2 and items B10 to B24, wherein is —C(═O)—. [Section B26]L 4 is a single bond, -C(=N-OR h1 )- or optionally substituted C 1-6 an alkylene group, where R h1 is optionally substituted C 1-6The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2 and B10 to B25, wherein the compound is an alkyl group. [Section B27]R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C 1-6 alkyl groups, 4) C 1-6 an alkoxy group, and 5) C 1-6 Alkylthio group (However, each of the substituents 3) to 5) above may be substituted.) The compound according to any one of items B1 to B26, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section B28]R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C 1-6 alkyl groups, 4) C 1-6 an alkoxy group, and 5) C 1-6 Alkylthio group (However, each of the substituents 3) to 5) above may be substituted with a halogen atom.) The compound according to any one of items B1 to B27, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section B29]R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C optionally substituted with a halogen atom 1-6 alkyl groups, The compound according to any one of items B1 to B28, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section B30]R 1 and R 2are each independently the same or different, 1) hydrogen atom, 2) fluorine atoms, 3) C optionally substituted with a fluorine atom 1-3 alkyl groups, The compound according to any one of items B1 to B29, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section B31]R 1 and R 2 and R are both hydrogen atoms, or a pharmaceutically acceptable salt thereof according to any one of items B1 to B30. [Item B32] Compounds of formula (1a) and (1b), compounds of formula (3a) and (3b), compounds of formula (4a) and (4b), or compounds of formula (5a) and (5b), respectively: Formulas (6a) and (6b) below: [ka] [In formulas (6a) and (6b), L 3 , L 4 , and R 5 is any of items B1 to B31 as defined in paragraph 1, m is an integer of 1, 2, or 3; n is an integer of 1, 2, or 3; m+n is 2, 3, or 4. The compound according to any one of items B1 to B31, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item B33] The compounds of formula (6a) and (6b) are, respectively: Formulas (7a) and (7b) below: [ka] Or, the following formulas (8a) and (8b): [ka] [In formulas (7a), (7b), (8a) and (8b), L 3 , L4 , and R 5 is as defined in any one of paragraphs B1 to B32, m and n are defined in paragraph B32.] or a pharmaceutically acceptable salt thereof. [Item B34] The compound according to any one of Items B1 to B33, wherein m is 1 or 2, n is 1 or 2, and m+n is 2 or 3, or a pharmaceutically acceptable salt thereof. [Item B35] The compound according to any one of Items B1 to B34, wherein m is 1 and n is 1, or a pharmaceutically acceptable salt thereof. [Section B36]L 3 But, -(CR 30 R 31 ) n1 - and R 30 and R 31 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2) optionally substituted C 1-4 an alkyl group, or 3) optionally substituted C 6-10 Aryl represents one of the following: n1 is 1, 2 or 3; L 4 is -(CR 40 R 41 ) n2 - and R 40 and R 41 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a9 R a10 , 3) optionally substituted C 1-4 an alkyl group, or 4)-OR c4 or R 40 and R 41together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a9 , R a10 and R c4 are each independently the same or different, 1) hydrogen atom, 2) optionally substituted C 1-6 alkyl groups, 3) optionally substituted C 3-10 alicyclic group, Either Here, R a9 and R a10 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, n2 is 0, 1 or 2; The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B5, B8 to B23, and B27 to B35. [Item B37] n1 is 1 or 2, and n2 is 0 or 1. The compound according to Item B36 or a pharmaceutically acceptable salt thereof. [Section B38]L 3 But, -CR 30 R 31 - and R 30 and R 31 are each independently 1) hydrogen atom, 2) C 1-4 Alkyl groups (the groups are halogen, -NR a11 R a12 , or -OR c6 substituted with 3) C6 aryl (the group is halogen, -NR a13 R a14 , -OR c7 , or C 1-3 Alkyl groups (the groups are halogen, -NR a15 R a16 , or -OR c8 (optionally substituted with) (optionally substituted with) represents one of the following: L 4 is -(CR 40 R 41 ) n2 - and R 40 and R 41 are each independently 1) hydrogen atom, 2)-NR a9 R a10 , 3) C 1-4 Alkyl groups (the groups are halogen, -NR a17 R a18 , or -OR c9 substituted with 4)-OR c4 or R 40 and R 41 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group, R a9 , R a10 , R a11 , R a12 , R a13 , R a14 , R a15 , R a16 , R a17 , R a18 , R c4 , R c6 , R c7 , R c8 and R c9 are each independently the same or different, 1) hydrogen atom, 2) C 1-4 Alkyl groups (the groups are halogen, -NR a19 R a20 , or -OR c10 (which may be substituted with), represents one of the following: R a19 , R a20 and R c10 are each independently the same or different, 1) a hydrogen atom, or 2) C 1-4an alkyl group (which may be substituted with halogen); represents one of the following: Here, R a9 and R a10 , R a11 and R a12 , R a13 and R a14 , R a15 and R a16 , R a17 and R a18 , or R a19 and R a20 may be combined together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle; n2 is 0 or 1, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B5, B8 to B23, and B27 to B37. [Section B39]L 3 is -CH2-, -CH(CH2NH2)-, or -CH(CH2OH)-, L 4 is a single bond, -CH2-, -CH(NH2)-, -CMe(NH2)-, -CEt(NH2)-, -C(iso-Pr)(NH2)-, -CH(CH2NH2)-, -CH(OH)-, -CH(CH2OH)-, or [ka] The compound according to any one of items B1 to B5, B8 to B23, and B27 to B38, or a pharmaceutically acceptable salt thereof. [Section B40]R 5 teeth, 1) C 6-10 aryl, or 2) 5- to 10-membered heteroaryl, (However, each of the substituents 1) and 2) above may be substituted, and when two substituents further substituted with the substituents 1) or 2) are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a condensed ring structure.) The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23 and items B27 to B39. [Section B41]R 5 is a C6 aryl (i.e., phenyl) or a 5-, 6-, 9-, or 10-membered heteroaryl; These R 5 Each group in the formula (I) is R at all chemically substitutable positions on the carbon or nitrogen atoms in the ring. 6a or R 6b and Here, R is a substituent on a carbon atom. 6a If there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C 1-4 alkyl groups, 6) C 3-10 alicyclic group, 7) C 1-4 alkoxy groups, 8) C 3-10 alicyclic oxy groups, 9) C 6-10 aryloxy groups, 10) 5- or 6-membered heteroaryloxy groups, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO2-NR e2 R f2 , 13)-NR g2 -CR e2 (=NR f2 ), 14)-NR g2 -CR e2 (=N-OR f2 ), 15)-NR h2 -C(=NR g2 )NR e2 R f2 , 16)-NR h2-C(=N-OR g2 )NR e2 R f2 、 17)-NR i2 -C(=NR h2 )NR g2 -NR e2 R f2 、 18)-NR i2 -C(=N-OR h2 )NR g2 -NR e2 R f2 、 19)-C(=NR e2 )R f2 、 20)-C(=N-OR e2 )R f2 、 21)-C(=NR h2 )-NR e2 R f2 、 22)-C(=NR h2 )NR g2 -NR e2 R f2 、 23)-C(=N-OR h2 )NR g2 -NR e2 R f2 、 24)-NR e2 R f2 、 25)-NR g2 -NR e2 R f2 、 26)-NR e2 OR f2 、 27)-NR e2 -C(=O)R f2 、 28)-C(=O)NR e2 R f2 、 29)-C(=O)NR e2 OR f2 、 30)-C(=O)NR g2 -NR e2 R f2 、 31)-C(=O)Re2 , 32)-C(=O)OR e2 , and 33)-C(=N-OR h2 )NR e2 R f2 selected from the group consisting of R is a substituent on the nitrogen atom 6b If there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl group, 3) C 1-4 alkyl groups, (However, the alkyl group may be substituted.) 4) C 3-10 alicyclic group, (However, the alicyclic group may be substituted.) 5)-C(=NR e2 )R f2 , 6)-C(=N-OR e2 )R f2 , 7)-SO2-NR e2 R f2 , 8)-C(=NR h2 )-NR e2 R f2 , 9)-C(=NR h2 )NR g2 -NR e2 R f2 , 10)-C(=N-OR h2 )NR g2 -NR e2 R f2 , 11)-C(=O)NR e2 R f2 , 12)-C(=O)NR e2 OR f2 , 13)-C(=O)NR g2 -NR e2 R f2 , 14)-C(=O)R e2 , and 15)-C(=N-OR h2 )NR e2 R f2 selected from the group consisting of Or two R's 6a or R 6a and R 6b When the combination of the following is substituted on adjacent atoms in a ring, the two substituents may be taken together to form an optionally substituted 5- to 6-membered heteroaryl ring or an optionally substituted 5- to 7-membered non-aryl heterocycle which is further fused to the bond between the adjacent atoms in the ring; R e2 , R f2 , R g2 , R h2 , and R i2 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R e2 and R f2 When the combination of the following is bound to the same nitrogen atom, they may be taken together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle. The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23 and items B27 to B40. [Section B42]R 5 is as follows: [ka] [ka] [ka] [ka] [ka] C aryl or a 5-, 6-, 9-, or 10-membered heteroaryl selected from the group consisting of: d is R 6a is the number of chemically substitutable positions on the ring of each group, Each R 6a and each R 6b is as defined in paragraph B41, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23 and items B27 to B41. [Section B43]R 6a If there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , -C(=O)OR f2 , -C(=O)NR e2 R f2 , -C(=O)NR e2 (OR f2 ), or may be substituted with a hydroxyl group) 5) C 1-4 alkoxy group 6)-NR e2 R f2 , 7)-C(=O)NR e2 R f2 , and 8)-C(=O)OR e2 selected from the group consisting of Each R 6b If there are multiple instances of a ring, they are all independently 1) hydrogen atom, 2) hydroxyl groups, and 3) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , -C(=O)OR f2 , -C(=O)NR e2 R f2 , -C(=O)NR e2 (OR f2 ), or may be substituted with a hydroxyl group) The compound according to item B41 or B42, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section B44]R e2 and R f2 are each independently the same or different and represent a hydrogen atom, an optionally substituted C 1-6 alkyl group or optionally substituted C 3-10 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23 and B27 to B43, wherein the group is an alicyclic group. [Section B45]R e2 and R f2 are each independently the same or different and represent a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23 and B27 to B44, wherein the compound is an alkyl group. [Section B46]R e2 and R f2 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23 and B27 to B45, wherein is a hydrogen atom. [Section B47]R 6a is -NR e2 R f2 and R e2 and R f2 is a hydrogen atom on one side and a C atom on the other side. 1-4 The compound according to any one of items B41 to B46, wherein the alkyl group is an alkyl group (which may be substituted with an amino group or a hydroxyl group), or a pharmaceutically acceptable salt thereof. [Section B48]R 5 is C(=O)NR 50 R51 The compound according to any one of items B1 to B23 and B27 to B39, or a pharmaceutically acceptable salt thereof. [Section B49]R 50 teeth, 1) hydrogen atom, 2) optionally substituted C 1-4 alkyl groups, 3) hydroxyl group, 4) optionally substituted C 1-4 an alkoxy group, or 5) optionally substituted C 1-6 alkylsulfonyl groups, represents one of the following: R 51 teeth, 1) a hydrogen atom, or 2) optionally substituted C 1-4 Alkyl group represents one of the following: Alternatively, R 50 and R 51 may be joined together to form a 4- to 6-membered nitrogen-containing non-aryl heterocycle; The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23, B27 to B39, and B48. [Section B50]R 50 teeth, 1) hydrogen atom, 2) C 1-4 Alkyl groups (the groups are halogen, C 3-6 Alicyclic group, -NR a21 R a22 , or -OR c11 (which may be substituted with), 3) hydroxyl group, 4) C 1-4 Alkoxy groups (the groups are halogen, C 3-6 Alicyclic group, -NR a23 R a24 , or -OR c12 substituted with 5) C 1-4 Alkylsulfonyl group (the group is halogen, C 3-6 Alicyclic group, -NR a21 Ra22 , or -OR c11 (which may be substituted with), represents one of the following: R a21 , R a22 , R a23 , R a24 , R c11 and R c12 are each independently the same or different, 1) a hydrogen atom, or 2) C 1-4 an alkyl group (which may be substituted with halogen); represents one of the following: Here, R a21 and R a22 , or R a23 and R a24 may be combined together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle; R 51 is a hydrogen atom or C 1-4 alkyl (which may be substituted with halogen); The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23, B27 to B39, and B48 to B49. [Section B51] R 50 teeth, 1) hydrogen atom, 2) C 1-4 an alkyl group (which may be substituted with a cyclopropyl group, -NH, -NHMe or -hydroxyl group); 3) a hydroxyl group, or 4) C 1-4 an alkoxy group (which may be substituted with a cyclopropyl group, -NH, -NHMe or -hydroxyl group); 5) C 1-4 alkylsulfonyl groups, represents one of the following: R 51 is a hydrogen atom, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23, B27 to B39, and B48 to B50. [Section B52]R 5 But -C(=O)OR 20 The compound according to any one of items B1 to B23 and B27 to B39, or a pharmaceutically acceptable salt thereof. [Section B53]R 20 teeth, 1) a hydrogen atom, or 2) optionally substituted C 1-4 alkyl groups, or a pharmaceutically acceptable salt thereof. [Section B54]L 3 is -CH2-, L 4 is -CH(NH2)- or -CMe(NH2)- The compound according to item B53, wherein: [Section B55]L 4 but, [ka] , [ka] [ka] or [ka] The compound according to item B54, wherein: or a pharmaceutically acceptable salt thereof. [Section B56]L 4 but, [ka] or [ka] The compound according to item B54 or B55, wherein: [Section B57]R 20is a hydrogen atom, or a pharmaceutically acceptable salt thereof. The compound according to any one of items B52 to B56, wherein [Section B58]R 5 But, -NR e1 R f1 and L 3 is -CH2-, L 4 -CR 40 R 41 - and R 40 and R 41 together with the carbon atoms to which they are attached form C 3-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B23 and B27 to B39, which forms an alicyclic group. [Section B59]R e1 and R f1 are each independently the same or different, 1) a hydrogen atom, or 2) optionally substituted C 1-3 alkyl groups, Either L 4 teeth, [ka] The compound according to item B58, wherein: [Section B60]L 4 is a single bond or -NR 21 R 22 or =NOR 23 C optionally substituted with 1-6 an alkylene group, where R 21 , R 22 and R 23 each independently represents a hydrogen atom, an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2 and items B10 to B35, wherein R is an alkyl group or an optionally substituted 4- to 10-membered non-aryl heterocyclic carbonyl group. [Section B61]L 4is a single bond, -CH2-, -CH(NH2)-, -CMe(NH2)-, -CH(NHMe)-, -CD(NH2)- (wherein D represents a deuterium atom), -CH2CH2-, or -CH(NH2)-CH2-, where L 4 If an amino group is present in the 3 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B60, which is bound to: [Section B62]L 3 is -C(=O)-, L 4 The compound according to item B61, wherein is -CH(NH2)- or -CMe(NH2)-, or a pharmaceutically acceptable salt thereof. [Section B63]L 4 but, [ka] , [ka] , [ka] or [ka] The compound according to item B62, or a pharmaceutically acceptable salt thereof, which has any one of the isomeric structures: [Section B64]L 4 but, [ka] or [ka] The compound according to Item B62 or B63, wherein: [Section B65]R 5 is a hydrogen atom, optionally substituted C 1-6alkyl group, an optionally substituted 4- to 10-membered non-aryl heterocycle, an optionally substituted C 6-10 Aryl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted C 1-6 Alkylthio group, or -NR e1 OH, where R e1 is a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B60 to B64, wherein the compound is an alkyl group. [Section B66]R 5 is an optionally substituted 5- or 6-membered heteroaryl or an optionally substituted C 6-10 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B60 to B65, wherein R is aryl. [Section B67]R 5 is an optionally substituted 5- or 6-membered heteroaryl; or a pharmaceutically acceptable salt thereof. [Section B68]R 5 is an optionally substituted 4- to 10-membered non-aryl heterocycle, or a pharmaceutically acceptable salt thereof. [Section B69]L 4 is a single bond, and R 5 is -NR e1 OH, where R e1 is a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B60 to B65, which is an alkyl group. [Section B70]L 4 teeth, 1)-(CH2) p -CR 10 (NHR 11 )-, 2)-(CH2)q -CR 12 R 13 -,or 3)-(CH2) p -CR 10 (NHR 11 )-(CH2) q -CR 12 R 13 - (wherein p and q are independently 0 or 1); R 10 teeth, 1) hydrogen atom, 2) carboxyl group, 3)-C(=O)NR 10a R 10b and R 11 teeth, 1) hydrogen atom, 2)-C(=O)R 11a ,or 3) an optionally substituted 5- or 6-membered non-aryl heterocyclic carbonyl group, However, R 10 -C(=O)NR 10a R 10b When R 10b and R 11 may be taken together to form -CHCH-, R 12 teeth, 1) a hydrogen atom, or 2) optionally substituted C 1-4 is an alkyl group, R 13 teeth, 1) hydrogen atom, 2) Hydroxyl group 3) optionally substituted C 1-4 Alkyl group 4) sulfanyl group, 5) carboxyl group, 6) optionally substituted C 1-4 alkylthio groups, 7)-NR 13a R 13b , 8)-NR 13a -C(=O)R 13b , 9) an optionally substituted 5- or 6-membered non-aryl heterocyclic carbonylamino group 10)-NR 13a -C(=O)NR 13b R 13c , 11)-C(=O)NR 13a R 13b , 12)-C(=O)NR 13a OR 13b , 13)-S(=O)2-R 13a , 14)-S(=O)2-NR 13a R 13b , 15)-C(=O)NR 13a -S(=O)2-R 13b or 16)-C(=O)NR 13a -S(=O)2-NR 13b R 13c and R 10a , R 10b , R 11a , R 13a , R 13b and R 13c are each independently a hydrogen atom or an optionally substituted C 1-4 is an alkyl group, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2 and items B10 to B35. [Section B71]R 5 is a hydrogen atom or an optionally substituted C 1-4 is an alkyl group, The compound according to Item B70 or a pharmaceutically acceptable salt thereof. [Section B72]R 5 is as follows: [ka] [ka] selected from the group consisting of The subscript d stands for R 5is the number of substitutable positions on the ring of Each R 6a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) a nitro group, 5) halogens, 6) C 1-4 alkyl groups, 7) C 3-10 alicyclic group, 8) C 1-4 alkoxy groups, 9) C 3-10 alicyclic oxy groups, 10) C 6-10 aryloxy groups, 11) 5- or 6-membered heteroaryloxy groups, 12) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 6) to 12) above may be substituted.) 13)-SO2-NR e2 R f2 , 14)-NR g2 -CR e2 (=NR f2 ), 15)-NR g2 -CR e2 (=N-OR f2 ), 16)-NR h2 -C(=NR g2 )NR e2 R f2 , 17)-NR h2 -C(=N-OR g2 )NR e2 R f2 , 18)-NR i2 -C(=NR h2 )NR g2 -NR e2 R f2 , 19)-NR i2 -C(=N-OR h2 )NR g2 -NR e2 R f2 , 20)-C(=NR e2 )R f2 , 21)-C(=N-OR e2 )R f2 , 22)-C(=NR h2 )-NR e2 R f2 , 23)-C(=NR h2 )NR g2 -NR e2 R f2 , 24)-C(=N-OR h2 )NR g2 -NR e2 R f2 , 25)-NR e2 R f2 , 26)-NR g2 -NR e2 R f2 , 27)-NR e2 OR f2 , 28)-NR e2 -C(=O)R f2 , 29)-C(=O)NR e2 R f2 , 30)-C(=O)NR e2 OR f2 , 31)-C(=O)NR g2 -NR e2 R f2 , 32)-C(=O)R e2 , 33)-C(=O)OR e2 , and 34)-C(=N-OR h2 )NR e2 R f2 selected from the group consisting of Each R 6b is independent, 1) hydrogen atom, 2) hydroxyl group, 3) C 1-4 alkyl groups, (However, the alkyl group may be substituted.) 4) C 3-10 alicyclic group, (However, the alicyclic group may be substituted.) 5)-C(=NR e2 )R f2 , 6)-C(=N-OR e2 )R f2 , 7)-SO2-NR e2 R f2 , 8)-C(=NR h2 )-NR e2 R f2 , 9)-C(=NR h2 )NR g2 -NR e2 R f2 , 10)-C(=N-OR h2 )NR g2 -NR e2 R f2 , 11)-C(=O)NR e2 R f2 , 12)-C(=O)NR e2 OR f2 , 13)-C(=O)NR g2 -NR e2 R f2 , 14)-C(=O)R e2 , and 15)-C(=N-OR h2 )NR e2 R f2 The compound according to any one of items B1 to B2, B10 to B35, and B60 to B67, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section B73]R 5 is as follows: [ka] [ka] is a 5- or 6-membered aryl or heteroaryl selected from the group consisting of The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 6a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR f2 or hydroxyl group) 5) C 1-4 alkoxy group 6)-NR e2 R f2 , and 7)-C(=O)OR e2 selected from the group consisting of Each R 6b is independent, 1) hydrogen atom, 2) hydroxyl groups, and 3) C 1-4 alkyl groups, (However, the alkyl group is NR e2 R f2 , -C(=O)NR e2 R f2 , -C(=O)OR f2 or may be substituted with a hydroxyl group) The compound according to any one of items B1 to B2, B10 to B35, B60 to B67, and B72, selected from the group consisting of: or a pharmaceutically acceptable salt thereof. [Section B74]R 5 but, [ka] The compound according to any one of items B1 to B2, B10 to B35, B60 to B67, and B72 to B73, or a pharmaceutically acceptable salt thereof. [Section B75]R e2 and R f2 are each independently the same or different and represent a hydrogen atom, an optionally substituted C 1-6 alkyl group or optionally substituted C 3-10 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, B60 to B67, and B72 to B73, wherein the group is an alicyclic group. [Section B76]R e2 and R f2 are each independently the same or different and represent a hydrogen atom or an optionally substituted C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, B60 to B67, B72 to B73, and B75, wherein the compound is an alkyl group. [Section B77]R e2 and R f2 is a hydrogen atom, or a pharmaceutically acceptable salt thereof. [Section B78]R 6a is -NR e2 R f2 and R e2 and R f2 is a hydrogen atom on one side and a C atom on the other side. 1-4 The compound according to any one of items B72 to B73 and items B75 to B76, wherein the alkyl group is an alkyl group (which may be substituted with an amino group or a hydroxyl group), or a pharmaceutically acceptable salt thereof. [Section B79]R 5 is as follows: [ka] is a 4- to 6-membered non-aryl heterocycle selected from the group consisting of The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 7a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C 1-4 alkyl groups, 6) C 3-10 alicyclic group, 7) C 1-4 alkoxy groups, 8) C 3-10 alicyclic oxy groups, 9) C 6-10 aryloxy groups, 10) 5- or 6-membered heteroaryloxy groups, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO2-NR e3 R f3 , 13)-NR g2 -CR e3 (=NR f3 ), 14)-NR g2 -CR e3 (=N-OR f3 ), 15)-NR h2 -C(=NR g2 )NR e3 R f3 , 16)-NR h2 -C(=N-OR g2 )NR e3 R f3 , 17)-NR i2 -C(=NR h2 )NR g2 -NR e3 R f3 , 18)-NR i2 -C(=N-OR h2 )NR g2 -NR e3 R f3 , 19)-C(=NR e3 )R f3 , 20)-C(=N-OR e3)R f3 , 21)-C(=NR h2 )-NR e3 R f3 , 22)-C(=NR h2 )NR g2 -NR e3 R f3 , 23)-C(=N-OR h2 )NR g2 -NR e3 R f3 , 24)-NR e3 R f3 , 25)-NR g2 -NR e3 R f3 , 26)-NR e3 OR f3 , 27)-NR e3 -C(=O)R f3 , 28)-C(=O)NR e3 R f3 , 29)-C(=O)NR e3 OR f3 , 30)-C(=O)NR g2 -NR e3 R f3 , 31)-C(=O)R e3 , 32)-C(=O)OR e3 , and 33)-C(=N-OR h2 )NR e3 R f3 selected from the group consisting of Each R 7b is independent, 1) hydrogen atom, 2) hydroxyl group, 3) C 1-4 alkyl groups, (However, the alkyl group may be substituted.) 4) C 3-10 alicyclic group, (However, the alicyclic group may be substituted.) 5)-C(=NR e3 )R f3 , 6)-C(=N-OR e3 )R f3 , 7)-SO2-NR e3 R f3 , 8)-C(=NR h2 )-NR e3 R f3 , 9)-C(=NR h2 )NR g2 -NR e3 R f3 , 10)-C(=N-OR h2 )NR g2 -NR e3 R f3 , 11)-C(=O)NR e3 R f3 , 12)-C(=O)NR e3 OR f3 , 13)-C(=O)NR g2 -NR e3 R f3 , 14)-C(=O)R e3 , and 15)-C(=N-OR h2 )NR e3 R f3 selected from the group consisting of R e3 and R f3 is the R described in Section B2 e2 and R f2 The compound according to any one of items B1 to B2, B10 to B35, B60 to B65, and B68, which has the same meaning as the compound or a pharmaceutically acceptable salt thereof. [Section B80]R 5 is as follows: [ka] is a 4- to 6-membered non-aryl heterocycle selected from the group consisting of The subscript d stands for R 5 is the number of substitutable positions on the ring of Each R 7a is independent, 1) hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C 1-4 alkyl groups, (However, the alkyl group is NR e3 R f3 , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR f3 or may be substituted with a hydroxyl group) 5) C 1-4 alkoxy group 6)-NR e3 R f3 , 7)-C(=O)OR e3 , and 8) C 6-10 Aryl 9)-C(=O)NR e3 R f3 selected from the group consisting of Each R 7b is independent, 1) hydrogen atom, 2) hydroxyl groups, and 3) C 1-4 alkyl groups, (However, the alkyl group is NR e3 R f3 , -C(=O)OR f3 or may be substituted with a hydroxyl group) selected from the group consisting of R e3 and R f3 is R according to any one of items B75 to B77 e2 and R f2 The compound according to any one of items B1 to B2, B10 to B35, B60 to B65, B68, and B79, which has the same meaning as the compound or a pharmaceutically acceptable salt thereof. [Section B81]L 4 -CH(NH2)-CHR13 -, and the carbon to which the NH2 is bonded is L 3 binds to R 5 is a hydrogen atom, R 13 teeth, 1) -NH-C(=O)CH3, 2) -NH-C(=O)NH2, 3)-NH-C(=O)CH(NH2)-CH2C(=O)NH2, 4) -NH-C(=O)CH2-NH2, 5) -NH-C(=O)CH(NH2)-CH2OH, or 6) a pyrrolidin-2-ylcarbonylamino group; The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B82]L 4 -CH(NH2)-CR 12 R 13 -, and the carbon to which the NH2 is bonded is L 3 binds to R 5 is a hydrogen atom or methyl, R 12 is a hydrogen atom or methyl, R 13 is a benzylthio group or a sulfanyl group, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B83]L 4 is -CH(NH2)-(CH2) q -CHR 13 -, q is 0 or 1, and the carbon to which the NH2 is bonded is L 3 binds to R 5 is a hydrogen atom, R 13 teeth, 1) carboxyl group, 2) -C(=O)NH2, 3) -C(=O)NH(CH3), 4)-C(=O)N(CH3)2, 5) -C(=O)NH-(CH2)2-OH, 6) -C(=O)NH-(CH2)2-NH2, 7) -C(=O)NH-S(=O)2-CH3, 8)-C(=O)NHOH, 9)-S(=O)2-NH2, 10)-S(=O)2-CH3, or 11) a hydroxyl group; The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B84]L 4 -CH(NHR 11 )-CH2-, and the NHR 11 The carbon bonded to L 3 binds to R 5 is hydrogen, R 11 teeth, 1)-C(=O)CH(NH2)-CH2C(=O)NH2, 2) -C(=O)CH2-NH2, 3) -C(=O)CH(CH3)-NH2, 4) -C(=O)CH(NH2)-CH2OH, or 5) pyrrolidin-2-ylcarbonyl; The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B85]L 4 -CH(NHR 11 )-CH(COOH)-, and the NHR 11 The carbon bonded to L 3 binds to R 5 is hydrogen, R 11 teeth, 1)-C(=O)CH(NH2)-CH2C(=O)NH2, 2) -C(=O)CH2-NH2, 3) -C(=O)CH(CH3)-NH2, 4) -C(=O)CH(NH2)-CH2OH, or 5) pyrrolidin-2-ylcarbonyl; The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B86]L 4 Ha-CHR 13 - or -CH2-CHR 13 - and R 5 is hydrogen, R 13 is -C(=O)NH2, or -C(=O)NHOH; The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B87]L 4 Ha-CH2-CR 10 (NH2)-, and the CH2 group is L 3 binds to R 5 is hydrogen, R 10 is a carboxy group or -C(=O)NH2, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B88]L 4 Ha-(CH2) p -CR 10 (NHR 11 )-(CH2) q -CHR 13 -or- CHR 13 -(CH2) q -CR 10 (NHR 11 )-(CH2) p where q is 0 or 1; R 5 is hydrogen, (1)L 4 Ga-CHR 13 -(CH2) q -CR 10 (NHR11 )-(CH2) p -When -CHR 13 - group carbon is L 3 binds to p is 0, R 10 is a hydrogen atom, a carboxyl group, or -C(=O)NHR 10b and R 11 is a hydrogen atom, R 10b is a hydrogen atom, However, R 10 -C(=O)NHR 10b When R 10b and R 11 may be taken together to form -CHCH-, R 13 is a hydrogen atom, (2)L 4 Ga-(CH2) p -CR 10 (NHR 11 )-(CH2) q -CHR 13 -When -(CH2) p - group carbon is L 3 binds to p is 1, R 10 and R 11 are both hydrogen atoms, R 13 is a carboxyl group, or -C(=O)NR 13a R 13b and R 13a and R 13b are each independently a hydrogen atom or an optionally substituted C 1-4 is an alkyl group, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Section B89]L 4 -CR 12 (NH2)-, R12 is a hydrogen atom or a methyl group, R 5 is C optionally substituted with one hydroxyl group 1-4 is an alkyl group, The compound or a pharmaceutically acceptable salt thereof according to any one of items B1 to B2, B10 to B35, and B70 to B71. [Item B90] A compound according to Item B1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds represented by the following names or structural formulas: 5-({1-[amino(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-[2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , 5-({1-(2-amino-2-carboxypropyl)azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-(2-amino-2-carboxylatepropyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2R)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2R)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(7),8,10-triene-8-carboxylate [ka] , 5-({1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , 9-[1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aS,7bR)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2R,4S)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , (2S,4R)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] , (1aR,7bS)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid [ka] , and (2S,4R)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 2,4 ]Undeca-1(11),7,9-triene-8-carboxylic acid [ka] . [Item B91] The following formula (11): [ka] [In formula (11), R G is a hydroxyl group, a thiol group, or -NHR a1and R a1 , X, R 1 , R 2 , R 3 , R 4 , R 61 , R 62 , R 63 and R 64 has the same definition as in any one of items B1 to B15, and formula (1a) has the same definition as in item B1. or a pharmaceutically acceptable salt thereof. [Item B92] The compound of formula (11) is represented by the following formula (12): [ka] [In formula (12), X, R 1 , R 2 , R 3 , and R 4 has the same meaning as in paragraph B16 or paragraph B17] The compound according to Item B91, represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item B93] The compound of formula (11) or formula (12) is a compound of formula (13): [ka] [In formula (13), X, Y, rings A, L 3 , L 4 , R 1 , R 2 , R 4 , and R 5 has the same meaning as defined in any one of items B18 to B22 and items B28 to B31, or a pharmaceutically acceptable salt thereof according to item B91 or B92. [Section B94] X and R G is a hydroxyl group, and R 4 is a carboxyl group, and ring A is an optionally substituted 4- to 6-membered nitrogen-containing non-aryl heterocycle, or a pharmaceutically acceptable salt thereof. [Item B95] The compound of formula (11), formula (12) or formula (13) is a compound of formula (14): [ka] [In formula (14), X, L 3 , L 4 , m, n, and R 5 has the same meaning as defined in any one of items B32 to B59. The compound according to any one of items B91 to B94, wherein the compound is represented by the following formula: or a pharmaceutically acceptable salt thereof. [Item B96] The compound of formula (14) is a compound of the following formula (15): [ka] Or the following equation (16): [ka] [In formulas (15) and (16), X, L 3 , L 4 , m, n, and R 5 has the same meaning as defined in any one of items B32 to B59. or a pharmaceutically acceptable salt thereof. [Section B97]R G is a hydroxyl group or a thiol group, or a pharmaceutically acceptable salt thereof. [Section B98]R G is a hydroxyl group, or a pharmaceutically acceptable salt thereof. [Item B99] X is a hydroxyl group or C 1-6 The compound or a pharmaceutically acceptable salt thereof according to any one of items B91 to B98, wherein R is an alkoxy group. [Item B100] The compound or a pharmaceutically acceptable salt thereof according to any one of Items B91 to B99, wherein X is a hydroxyl group. [Section B101] The compound according to any one of items B95 to B100, wherein m is 1 or 2, n is 1 or 2, and m+n is 2 or 3, or a pharmaceutically acceptable salt thereof. [Section B102] The compound according to any one of items B95 to B101, wherein m is 1 and n is 1, or a pharmaceutically acceptable salt thereof. [Section B103] L 3 is the compound or a pharmaceutically acceptable salt thereof according to any one of items B91 to B102, which has the same meaning as defined in item B24 or B25. [Section B104] L 4 and R 5 is the compound or a pharmaceutically acceptable salt thereof according to any one of items B91 to B103, which has the same meaning as defined in any one of items B26 and B60 to B89. [Item B105] A compound according to Item B92 or a pharmaceutically acceptable salt thereof, selected from the group consisting of compounds represented by the following names or structural formulas: 6-({1-[amino(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-Amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-(2-amino-2-carboxypropyl)azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] , and 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid [ka] . [Item B106] A medicine containing the compound according to any one of items B1 to B105 or a pharmaceutically acceptable salt thereof. [Item B107] The pharmaceutical agent according to Item B106, which is a therapeutic or preventive agent for bacterial infections. [Item B108] A β-lactamase inhibitor comprising, as an active ingredient, the compound according to any one of items B1 to B105 or a pharmaceutically acceptable salt thereof. [Item B109] A pharmaceutical composition comprising the compound according to any one of items B1 to B105 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. [Item B110] The pharmaceutical composition according to Item B109, further comprising an additional agent. [Item B111] A pharmaceutical composition according to Item B110, wherein the additional agent is selected from the group consisting of antibacterial agents, antifungal agents, antiviral agents, anti-inflammatory agents and antiallergic agents. [Item B112] The pharmaceutical composition according to Item B110 or Item B111, wherein the additional drug is a β-lactam drug. [Section B113] The additional drug beta-lactam is amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), epicillin, carbenicillin (carindacillin), ticarcillin, temocillin, azlocillin, piperacillin, mezlocillin, mecillinam (pivmecillinam), sulbenicillin, benzylpenicillin (G), clometocillin, benzathine benzylpenicillin, procaine Benzylpenicillin, azidocillin, penamecillin, phenoxymethylpenicillin (V), propicillin, benzathine phenoxymethylpenicillin, phenethicillin, cloxacillin (dicloxacillin, flucloxacillin), oxacillin, methicillin, nafcillin, faropenem, biapenem, doripenem, ertapenem, imipenem, meropenem, panipenem, tomopenem, razupenem, cefazolin, cefazolin tolyl, cefadroxil, cephalexin, cephaloglycin, cephalonium, cephaloridine, cephalothin, cephapirin, cefatrizine, cefazedone, cefazaflur, cephradine, cefroxadine, ceftezole, cefaclor, cefamandole, cefminox, cefonicid, ceforanide, cefotiam, cefprozil, cefbuperazone, cefuroxime, cefuzonam, cefoxitin, cefotetan, Cefmetazole, loracarbef, cefixime, ceftazidime, ceftriaxone, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefmenoxime, cefodizime, cefoperazone, cefotaxime, cefpimizole, cefpiramide, cefpodoxime, cefsulodin, cefteram, ceftibuten, ceftiolene, ceftizoxime, flomoxef, latamoxef, cefepime, cefozopran, The pharmaceutical composition according to item B111 or B112, wherein the compound is selected from the group consisting of cefpirome, cefquinome, ceftobiprole, ceftaroline, CXA-101, RWJ-54428, MC-04546, ME1036, BAL30072, SYN2416, ceftiofur, cefquinome, cefovecin, aztreonam, tigenonam, carumonam, RWJ-442831, RWJ-333441, and RWJ-333442. [Item B114] The pharmaceutical composition according to Item B112 or B113, wherein the β-lactam drug is selected from ceftazidime, biapenem, doripenem, ertapenem, imipenem, meropenem, or panipenem. [Item B115] A pharmaceutical composition according to Item B112 or Item B113, wherein the β-lactam drug is selected from aztreonam, tigenonam, BAL30072, SYN2416 or carumonam. [Item B116] The pharmaceutical composition according to Item B109, which is administered together with an additional drug. [Item B117] A pharmaceutical composition according to Item B116, wherein the additional agent is selected from an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, or an antiallergic agent. [Item B118] The pharmaceutical composition according to Item B116 or Item B117, wherein the additional drug is a β-lactam drug. [Section B119] The additional drug beta-lactam is amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), epicillin, carbenicillin (carindacillin), ticarcillin, temocillin, azlocillin, piperacillin, mezlocillin, mecillinam (pivmecillinam), sulbenicillin, benzylpenicillin (G), clometocillin, benzathine benzylpenicillin, procaine Benzylpenicillin, azidocillin, penamecillin, phenoxymethylpenicillin (V), propicillin, benzathine phenoxymethylpenicillin, phenethicillin, cloxacillin (dicloxacillin, flucloxacillin), oxacillin, methicillin, nafcillin, faropenem, biapenem, doripenem, ertapenem, imipenem, meropenem, panipenem, tomopenem, razupenem, cefazolin, cefazolin tolyl, cefadroxil, cephalexin, cephaloglycin, cephalonium, cephaloridine, cephalothin, cephapirin, cefatrizine, cefazedone, cefazaflur, cephradine, cefroxadine, ceftezole, cefaclor, cefamandole, cefminox, cefonicid, ceforanide, cefotiam, cefprozil, cefbuperazone, cefuroxime, cefuzonam, cefoxitin, cefotetan, Cefmetazole, loracarbef, cefixime, ceftazidime, ceftriaxone, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefmenoxime, cefodizime, cefoperazone, cefotaxime, cefpimizole, cefpiramide, cefpodoxime, cefsulodin, cefteram, ceftibuten, ceftiolene, ceftizoxime, flomoxef, latamoxef, cefepime, cefozopran, The pharmaceutical composition according to item B117 or B118, wherein the compound is selected from the group consisting of cefpirome, cefquinome, ceftobiprole, ceftaroline, CXA-101, RWJ-54428, MC-04546, ME1036, BAL30072, SYN2416, ceftiofur, cefquinome, cefovecin, aztreonam, tigenonam, carumonam, RWJ-442831, RWJ-333441, and RWJ-333442. [Item B120] The pharmaceutical composition according to Item B118 or B119, wherein the β-lactam drug is selected from the group consisting of ceftazidime, biapenem, doripenem, ertapenem, imipenem, meropenem, and panipenem. [Item B121] A pharmaceutical composition according to Item B118 or Item B119, wherein the β-lactam drug is selected from the group consisting of aztreonam, tigenonam, BAL30072, SYN2416 and carumonam. [Item B122] A compound according to any one of items B1 to B105 or a pharmaceutically acceptable salt thereof for use in treating a bacterial infection. [Item B123] The compound according to Item B122 or a pharmaceutically acceptable salt thereof, wherein the bacterial infection is a bacterial infection involving a bacterium capable of having β-lactamase. [Item B124] A compound or a pharmaceutically acceptable salt thereof according to Item B122 or B123, wherein the bacterial infection is sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory disease, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infection, lymphangitis / lymphadenitis, secondary infection of trauma / burn, surgical wound, etc., urinary tract infection, genital infection, eye infection or dental infection. [Item B125] A pharmaceutical composition comprising a compound according to any one of items B1 to B105 or a pharmaceutically acceptable salt thereof in combination with at least one drug selected from the group consisting of therapeutic agents for sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infections of chronic respiratory lesions, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infections, lymphangitis / lymphadenitis, secondary infections such as those from trauma, burns, and surgical wounds, urinary tract infections, genital infections, eye infections, and dental infections. [Item B126] A pharmaceutical composition comprising a β-lactam drug, wherein the pharmaceutical composition is administered together with a compound according to any one of Items B1 to B105 or a pharmaceutically acceptable salt thereof. [Item B127] A method for treating a bacterial infection, comprising administering to a patient in need of treatment a therapeutically effective amount of a compound according to any one of items B1 to B105 or a pharmaceutically acceptable salt thereof. [Item B128] The method according to Item B127, wherein the bacterial infection is a bacterial infection involving a bacterium that may have β-lactamase. [Item B129] A method according to Item B127 or B128, wherein the bacterial infection is sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory disease, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infection, lymphangitis / lymphadenitis, secondary infection of trauma / burn and surgical wound, urinary tract infection, genital infection, eye infection or dental infection. [Item B130] The method according to any one of Items B127 to B129, wherein the method is administered together with an additional drug.

[0012] It is contemplated that the present invention may provide one or more of the above-described features in combinations other than those explicitly described. Still further embodiments and advantages of the present invention will be recognized by those skilled in the art upon reading and understanding the following detailed description, if necessary. [Effects of the Invention]

[0013] The compounds of the present invention have excellent inhibitory activity against serine-β-lactamases that have a serine residue in the enzyme active center. In addition, more excellent embodiments of the compounds of the present invention include broad-spectrum β-lactamase inhibitory activity against multiple types of β-lactamases and zinc (Zn 2+ The compound of the present invention is expected to have an inhibitory effect on metallo-β-lactamases having the β-lactamase activity. Therefore, the compound of the present invention, used alone or in combination with a β-lactam drug, is useful as a therapeutic and / or preventive agent for bacterial infections involving bacteria capable of possessing β-lactamase, specifically sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infections of chronic respiratory lesions, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infections, lymphangitis / lymphadenitis, secondary infections of trauma / burns, surgical wounds, etc., urinary tract infections, genital infections, eye infections, and dental infections. DETAILED DESCRIPTION OF THE INVENTION

[0014] The present invention will now be described in further detail. Throughout this specification, the singular form should be understood to include the plural form unless otherwise specified. ", "an", "the", etc.) also include the plural concept unless otherwise stated. It should be understood that the terms used herein, unless otherwise specified, are used in the sense commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. In case of conflict, the present specification (including definitions) shall prevail.

[0015] First, the terms and general techniques used in the present invention will be explained.

[0016] The term "group" refers to a monovalent group unless otherwise specified. Examples of non-monovalent groups include alkylene groups (divalent). In addition, the term "group" may be omitted in the following explanations of substituents, etc.

[0017] In this specification, when defined as "optionally substituted" or "substituted," the number of substituents is not particularly limited as long as substitution is possible, and is one or more. Furthermore, unless otherwise specified, the description of each substituent also applies when that substituent is a part of or a substituent for another substituent.

[0018] The substituent in "optionally substituted" is not particularly limited, but is preferably selected from the following substituent group α, and may be substituted with 1 to 5 identical or different substituents. Although there is no particular limitation on the type of substituent, when the atom to which the substituent is bonded is an oxygen atom, a nitrogen atom, or a sulfur atom, the substituent is limited to one of the following substituents to which the bonded atom is a carbon atom. The substituent group α is 1) Halogen atoms 2) Hydroxyl group 3) Carboxyl group 4) Cyano group 5) C 1-6 Alkyl group 6) C 2-6 Alkenyl group 7) C 2-6 Alkynyl group 8) C 1-6 alkoxy group 9) C 1-6 Alkylthio group 10) C 1-6 Alkylcarbonyl group 11)C 1-6 Alkylsulfonyl group (However, each of the substituents 5) to 11) may be substituted with 1 to 5 identical or different substituents selected from the substituent group β.) 12)C 3-10 alicyclic group 13)C 3-10 Alicyclic oxy group 14)C 6-10 aryloxy group 15) 5- or 6-membered heteroaryloxy group 16) 4-10-membered non-aryl heterocyclic oxy group 17)C 3-10 alicyclic thio group 18)C 6-10 arylthio group 19) 5- or 6-membered heteroarylthio group 20) 4-10-membered non-aryl heterocyclic thio group 21)C 6-10 Aryl 22) 5- or 6-membered heteroaryl 23) 4-10 membered non-aryl heterocycles 24)C 3-10 Alicyclic carbonyl group 25)C 6-10 arylcarbonyl group 26) 5- or 6-membered heteroarylcarbonyl group 27) 4-10-membered non-aryl heterocyclic carbonyl group 28)C 3-10Alicyclic sulfonyl group 29)C 6-10 Arylsulfonyl group 30) 5- or 6-membered heteroarylsulfonyl group 31) 4- to 10-membered non-aryl heterocyclic sulfonyl group (However, each of the substituents in 12) to 31) is 1 to 5 of the substituent group β or the above 1) C 1-6 may be substituted with an alkyl group) 32)-NR 10a R 11a 33)-SO2-NR 10b R 11b 34)-NR 10c -C(=O)R 11c 35)-NR 10d -C(=O)OR 11d 36)-NR 12a -C(=O)NR 10e R 11e 37)-NR 10f -C(=S)R 11f 38)-NR 10g -C(=S)OR 11g , 39)-NR 12b -C(=S)NR 10h R 11h 40)-NR 10i -SO2-R 11i 41)-NR 12c -SO2-NR 10j R 11j 42)-C(=O)OR 10k 43)-C(=O)NR 10l R 11k 44)-C(=O)NR 10m OR 11l 45)-C(=O)NR 12d -NR 10n R 11m 46)-C(=S)OR10o 47)-C(=S)NR 10p R 11n 48)-C(=S)NR 10q OR 11o 49)-C(=S)NR 12e -NR 10r R 11p 50)-C(=NR 13a )R 10s 51)-C(=NR 13b )CHO 52)-C(=NR 13c )NR 10t R 11q 53)-C(=NR 13d )NR 12f -NR 10u R 11r 54)-NR 17c -C(=NR 13k )R 17d 55)-NR 12g -C(=NR 13e )-NR 10v R 11s 56)-NR 14 -C(=NR 13f )-NR 12h -NR 10w R 11t 57)-OC(=O)R 10x 58)-OC(=O)OR 10y 59)-OC(=O)NR 10z1 R 11u 60)-NR 12i -NR 10z2 R 11v 61)-NR 10z3 OR 11w 62)-C(=N-OR 13a )R 10s 63)-C(=N-OR 13b )CHO 64)-C(=N-OR 13c )NR 10t R 11q 65)-C(=N-OR 13d )NR 12f -NR 10u R 11r are listed, The substituent group β is 1) halogen atoms, 2) hydroxyl group, 3) carboxyl group, 4) a cyano group, 5) C 3-10 alicyclic group, 6) C 1-6 alkoxy groups, 7) C 3-10 alicyclic oxy groups, 8) C 1-6 alkylthio groups, 9) a 5- or 6-membered heteroarylthio group; 10) C 6-10 aryl, 11) 5- or 6-membered heteroaryl; 12) 4- to 10-membered non-aryl heterocycles, 13)C 1-6 alkylcarbonyl groups, 14)C 3-10 alicyclic carbonyl groups, 15)C 6-10 arylcarbonyl groups, 16) a 5- or 6-membered heteroarylcarbonyl group, 17) 4- to 10-membered non-aryl heterocyclic carbonyl group, 18)-NR 15a R 16a , 19)-SO2-NR 15b R 16b , 20)-NR 15c -C(=O)R 16c 21)-NR 17a -C(=O)NR 15d R 16d , 22)-C(=O)NR 15eR 16e , 23)-C(=NR 13g )R 15f , 24)-C(=NR 13h )NR 15g R 16f 25)-NR 16g -C(=NR 13i )R 15h 26)-NR 17b -C(=NR 13j )-NR 15i R 16h 27)-C(=N-OR 13g )R 15f , 28)-C(=N-OR 13h )NR 15g R 16f (However, in the substituent group β, each of the substituents 5) to 17) is a halogen atom, a hydroxyl group, a cyano group, a carboxyl group, -NR 18a R 18b and optionally substituted with 1 to 5 substituents selected from the group consisting of R 13a , R 13b , R 13c , R 13d , R 13e , R 13f , R 13g , R 13h , R 13i , R 13j , R 13k are each independently the same or different and represent a hydrogen atom, a hydroxyl group, or C 1-6 Alkyl group, C 1-6 is an alkoxy group, R 10a , R 10b , R 10c , R 10d , R 10e , R 10f , R 10g , R 10h , R 10i , R 10j , R 10k , R 10l , R 10m , R10n 、R 10o 、R 10p 、R 10q 、R 10r 、R 10s 、R 10t 、R 10u 、R 10v 、R 10w 、R 10x 、R 10y 、R 10z1 、R 10z2 、R 10z3 、R 11a 、R 11b 、R 11c 、R 11d 、R 11e 、R 11f 、R 11g 、R 11h 、R 11i 、R 11j 、R 11k 、R 11l 、R 11m 、R 11n 、R 11o 、R 11p 、R 11q 、R 11r 、 11s 、R 11t 、R 11u 、R 11v 、R 11w 、R 12a 、R 12b 、R 12c 、R 12d 、R 12e 、R 12f 、R 12g 、R 12h 、R 12i 、R 14 、R 15a 、R 15b 、R 15c 、R 15d 、R 15e 、R 15f 、R 15g 、R 15h 、R 15i 、R 16a 、R 16b 、R 16c 、R 16d 、R 16e 、R 16f 、R 16g 、R 16h 、R 17a 、R 17b, R 17c , R 17d are each independently the same or different and represent a hydrogen atom or C 1-6 Alkyl groups (these groups include hydroxyl groups, cyano groups, C 1-6 Alkoxy group, -NR 18a R 18b and each of the following may be substituted with 1 to 3 identical or different substituents selected from: R 18a , R 18b are each independently the same or different and represent a hydrogen atom or C 1-6 It is an alkyl group.

[0019] Preferred examples of the substituent in "optionally substituted" include the following substituents. The substituent group α is preferably 1) Halogen atoms 2) Hydroxyl group 3) Carboxyl group 4) Cyano group 5) C 1-6 Alkyl group 6) C 1-6 alkoxy group 7) C 1-6 Alkylthio group 8) C 1-6 Alkylcarbonyl group (However, each of the substituents 5) to 8) may be substituted with 1 to 5 identical or different substituents selected from the substituent group β.) 9) C 3-10 alicyclic group 10) C 3-10 Alicyclic oxy group 11)C 6-10 aryloxy group 12) 5- or 6-membered heteroaryloxy group 13) 4- to 10-membered non-aryl heterocyclic oxy group 14)C 3-10 alicyclic thio group 15)C 6-10 arylthio group 16) 5- or 6-membered heteroarylthio group 17) 4- to 10-membered non-aryl heterocyclic thio group 18)C 6-10 Aryl 19) 5- or 6-membered heteroaryl 20) 4-10 membered non-aryl heterocycles 21)C 3-10 Alicyclic carbonyl group 22)C 6-10 arylcarbonyl group 23) 5- or 6-membered heteroarylcarbonyl group 24) 4- to 10-membered non-aryl heterocyclic carbonyl group (However, each of the substituents in 9) to 24) is 1 to 5 of the substituent group β or the above 1) C 1-6 may be substituted with an alkyl group) 25)-NR 10a R 11a 26)-SO2-NR 10b R 11b 27)-NR 10c -C(=O)R 11c 28)-NR 12a -C(=O)NR 10d R 11d 29)-NR 10e -SO2-R 11e 30)-NR 12b -SO2-NR 10f R 11f 31)-C(=O)NR 10g R 11g 32)-C(=NR 13a )R 10h 33)-C(=NR 13b )NR 10i R 11h 34)-NR 11f -C(=NR 13c )R 10g 35)-NR 12c -C(=NR 13d )-NR 10j R 11i 36)-C(=N-OR13a )R 10h 37)-C(=N-OR 13b )NR 10i R 11h are listed, The substituent group β is preferably 1) Halogen atoms 2) Hydroxyl group 3) Cyano group 4) C 3-10 alicyclic group 5) C 1-6 alkoxy group 6) C 1-6 Alkylthio group 7) 5- or 6-membered heteroarylthio group 8) 5- or 6-membered heteroaryl 9) 4-10 membered non-aryl heterocycle 10) C 1-6 Alkylcarbonyl group 11)C 3-10 Alicyclic carbonyl group 12)C 6-10 arylcarbonyl group 13) 5- or 6-membered heteroarylcarbonyl group 14) 4- to 10-membered non-aryl heterocyclic carbonyl group 15)-NR 15a R 16a 16)-NR 15b -C(=O)R 16b 17)-NR 17a -C(=O)NR 15c R 16c 18)-C(=O)NR 15d R 16d 19)-C(=NR 13e )R 15e 20)-C(=NR 13f )NR 15f R 16e 21)-NR 16f -C(=NR 13g )R 15g 22)-NR 17b -C(=NR 13h )-NR 15h R 16g 23)-C(=N-OR 13e )R 15e 24)-C(=N-OR 13f )NR 15f R 16e (However, in the substituent group β, each of the substituents 4) to 14) is a halogen atom, a hydroxyl group, a cyano group, a carboxyl group, -NR 18a R 18b and optionally substituted with 1 to 5 substituents selected from the group consisting of R 13a , R 13b , R 13c , R 13d , R 13e , R 13f , R 13g , R 13h are each independently the same or different and represent a hydrogen atom, a hydroxyl group, or C 1-6 Alkyl group, C 1-6 is an alkoxy group, R 10a , R 10b , R 10c , R 10d , R 10e , R 10f , R 10g , R 10h , R 10i , R 10j , R 11a , R 11b , R 11c , R 11d , R 11e , R 11f , R 11g , R 11h , R 11i , R 12a , R 12b , R 12c , R 15a , R 15b , R 15c , R 15d , R 15e , R 15f , R 15g , R 15h , R16a , R 16b , R 16c , R 16d , R 16e , R 16f , R 16g , R 17a , R 17b are each independently the same or different and represent a hydrogen atom or C 1-6 Alkyl groups (these groups include hydroxyl groups, cyano groups, C 1-6 Alkoxy group, -NR 18a R 18b and each of the following may be substituted with 1 to 3 identical or different substituents selected from: R 18a , R 18b are each independently the same or different and represent a hydrogen atom or C 1-6 It is an alkyl group.

[0020] More preferred substituents in the term "optionally substituted" include the following substituents. Substituent group α is more preferably 1) Halogen atoms 2) Hydroxyl group 3) Cyano group 4) C 1-6 Alkyl group 5) C 1-6 alkoxy group 6) C 1-6 Alkylthio group 7) C 1-6 Alkylcarbonyl group (However, each of the substituents 4) to 7) may be substituted with 1 to 5 identical or different substituents selected from the substituent group β.) 8) 5- or 6-membered heteroaryloxy group 9) 4- to 10-membered non-aryl heterocyclic oxy group 10) 5- or 6-membered heteroarylthio group 11) 4- to 10-membered non-aryl heterocyclic thio group 12)C 6-10 Aryl 13) 5- or 6-membered heteroaryl 14) 4-10 membered non-aryl heterocycles (However, each of the substituents in 4) to 14) is 1 to 5 of the substituent group β or the above 1) C 1-6 may be substituted with an alkyl group) 15)-NR 10a R 11a 16)-NR 11b -C(=O)R 10b 17)-NR 12a -C(=O)NR 10c R 11c 18)-C(=O)NR 10d R 11d 19)-C(=NR 13a )R 10e 20)-C(=NR 13b )NR 10f R 11e 21)-NR 11f -C(=NR 13c )R 10g 22)-NR 12b -C(=NR 13d )-NR 10h R 11g 23)-C(=N-OR 13a )R 10e 24)-C(=N-OR 13b )NR 10f R 11e are listed, The substituent group β is more preferably 1) halogen atoms, 2) hydroxyl group, 3) a cyano group, 4)-NR 15a R 16a , 5)-NR 15b -C(=O)R 16b , 6)-NR 17a -C(=O)NR 15c R 16c , 7)-C(=O)NR 15d R 16d, 8)-C(=NR 13e )R 15e , 9)-C(=NR 13f )NR 15f R 16e , 10)-NR 16f -C(=NR 13g )R 15g , 11)-NR 17b -C(=NR 13h )-NR 15h R 16g 12)-C(=N-OR 13e )R 15e , 13)-C(=N-OR 13f )NR 15f R 16e and R 13a , R 13b , R 13c , R 13d , R 13e , R 13f , R 13g , R 13h are each independently the same or different and represent a hydrogen atom, a hydroxyl group, or C 1-6 Alkyl group, C 1-6 is an alkoxy group, R 10a , R 10b , R 10c , R 10d , R 10e , R 10f , R 10g , R 10h , R 11a , R 11b , R 11c , R 11d , R 11e , R 11f , R 11g , R 12a , R 12b , R 15a , R 15b , R 15c , R 15d , R 15e , R 15f , R 15g , R 15h , R16a , R 16b , R 16c , R 16d , R 16e , R 16f , R 16g , R 17a , R 17b are each independently the same or different and represent a hydrogen atom or C 1-6 Alkyl groups (these groups include hydroxyl groups, cyano groups, C 1-6 Alkoxy group, -NR 18a R 18b and each of the following may be substituted with 1 to 3 identical or different substituents selected from: R 18a , R 18b are each independently the same or different and represent a hydrogen atom or C 1-6 It is an alkyl group.

[0021] "C 1-6 " means that the number of carbon atoms is 1 to 6. The same applies to other numbers, for example, "C 1-4 " means that the number of carbon atoms is 1 to 4.

[0022] The term "heteroatom" refers to an oxygen atom, a nitrogen atom, a sulfur atom, or the like.

[0023] "Halogen atom" means a fluorine atom, chlorine atom, bromine atom, or iodine atom. A fluorine atom or chlorine atom is preferred. A fluorine atom is more preferred. A "halogen atom" may also be referred to as "halogen."

[0024] "C 1-6 The term "alkyl group" means a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms. 1-6 As the "alkyl group", preferably "C 1-4 alkyl group," and more preferably "C 1-3 alkyl group," and more preferably "C 1-2 "C alkyl group". 1-6Specific examples of the "alkyl group" include, but are not limited to, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tert-butyl, sec-butyl, isopentyl, neopentyl, tert-pentyl, 1,2-dimethylpropyl, and the like.

[0025] "C 2-6 "Alkenyl group" means a straight-chain or branched unsaturated hydrocarbon group containing one or more carbon-carbon double bonds and having 2 to 6 carbon atoms. 2-6 As the "alkenyl group", preferably "C 2-4 "C alkenyl group." 2-6 Specific examples of the "alkenyl group" include, but are not limited to, a vinyl group, a 1-propylenyl group, a 2-propylenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 2-methyl-1-propylenyl group, and a 2-methyl-2-propylenyl group.

[0026] "C 2-6 The term "alkynyl group" refers to a straight-chain or branched unsaturated aliphatic hydrocarbon group having one or more triple bonds. 2-6 As the "alkynyl group", preferably "C 2-4 Specific examples include, but are not limited to, an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 1-methyl-2-propynyl group, a 3-butynyl group, a 1-pentynyl group, and a 1-hexynyl group.

[0027] "C 3-20 The term "alicyclic group" refers to a monocyclic or bicyclic non-aromatic hydrocarbon ring having 3 to 20 carbon atoms, and includes those having a partially unsaturated bond, a partially bridged structure, a partially spiro-bonded structure, and one or more carbonyl structures. The term "alicyclic group" encompasses cycloalkyl groups, cycloalkenyl groups, and cycloalkynyl groups. 3-20 As the "alicyclic group", preferably "C 3-10 alicyclic group," and more preferably "C 3-6 "C" is an alicyclic group.3-20 Specific examples of the "alicyclic group" include, but are not limited to, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclohexadinyl group, a cycloheptadinyl group, a cyclooctadinyl group, adamantyl, and norbornyl.

[0028] "C" with a partially cross-linked structure 3-20 Specific examples of the "alicyclic group" include, but are not limited to, those having the structures shown below. [ka]

[0029] Also, "C 3-20 The "alicyclic group" also includes compounds in which an aromatic ring is condensed. Specific examples include the groups shown below. [ka]

[0030] "C 3-10 Alicyclic group" and "C 3-6 The "alicyclic group" is defined as "C 3-20 Alicyclic group" 3-10 Alicyclic group" and "C 3-6 The "alicyclic group" refers to a substituent that is a monovalent group.

[0031] "C 6-10 "Aryl" means a monocyclic or bicyclic aromatic hydrocarbon ring having 6 to 10 carbon atoms, and specifically, C6 aryl includes phenyl group, C 10 Examples of aryl include 1-naphthyl and 2-naphthyl groups. 6-10 The aryl is preferably C aryl or C 10 Examples of such groups include aryl.

[0032] "Heteroaryl" refers to an aromatic heterocycle containing one or more identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms. Preferred are "5- or 6-membered heteroaryl," "5- to 10-membered heteroaryl," and "9- or 10-membered heteroaryl" as described below.

[0033] The term "5- or 6-membered heteroaryl" refers to a monocyclic aromatic heterocycle consisting of 5 to 6 atoms, containing 1 to 4 identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms. The term "5- or 6-membered heteroaryl" may also be referred to as a "5- to 6-membered heteroaryl ring."

[0034] The term "5- to 10-membered heteroaryl" refers to a monocyclic or bicyclic aromatic heterocycle consisting of 5 to 10 atoms, containing 1 to 4 identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms.

[0035] The term "9- or 10-membered heteroaryl" refers to a bicyclic aromatic heterocycle consisting of 9 to 10 atoms, containing 1 to 4 identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms.

[0036] The term "5- or 6-membered nitrogen-containing heteroaryl" refers to a monocyclic aromatic heterocycle consisting of 5 to 6 atoms, which contains one nitrogen atom and 0 to 3 identical or different heteroatoms selected from the group consisting of oxygen atoms, nitrogen atoms, and sulfur atoms. The term "5- or 6-membered nitrogen-containing heteroaryl" may also be referred to as a "5- to 6-membered nitrogen-containing heteroaryl ring."

[0037] Specific examples of "6-membered heteroaryl" include, but are not limited to, pyridine, pyridazine, pyrimidine, pyrazine, and the like.

[0038] Specific examples of the "5-membered heteroaryl" include, but are not limited to, thiophene, pyrrole, thiazole, isothiazole, pyrazole, imidazole, furan, oxazole, isoxazole, oxadiazole, thiadiazole, triazole, tetrazole, etc., preferably triazole or imidazole, more preferably imidazole.

[0039] Specific examples of the "5- or 6-membered heteroaryl" include the specific examples of the "5-membered heteroaryl" and "6-membered heteroaryl" mentioned above.

[0040] Specific examples of "9-membered heteroaryl" include, but are not limited to, indole, isoindole, indazole, benzimidazole, imidazopyridine, benzothiazole, azaindole, purine, and the like.

[0041] Specific examples of "10-membered heteroaryl" include, but are not limited to, quinoline, isoquinoline, quinazoline, phthalazine, and the like.

[0042] Specific examples of "9- or 10-membered heteroaryl" include the specific examples of "9-membered heteroaryl" and "10-membered heteroaryl" mentioned above.

[0043] The "optionally substituted heteroaryl" may be substituted with the substituents in the "optionally substituted" group as listed above. For example, when pyridine is substituted with a hydroxyl group at the 2-position, tautomers of 2-hydroxypyridine and 2-pyridone exist as shown below. [ka] Therefore, in the present application, 2-pyridone is also included in the “optionally substituted heteroaryl.” The heteroaryl may form a fused ring with an alicyclic group, an aryl, or a non-aryl heterocycle.

[0044] The term "non-aryl heterocycle" refers to a monocyclic or bicyclic non-aromatic heterocycle containing one or more identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms, and includes those having a partially unsaturated bond, a partially bridged structure, and a partially spiro-bonded structure. The non-aryl heterocycle may form a condensed ring with an aryl or heteroaryl, and is preferably a "4- to 20-membered non-aryl heterocycle" described below.

[0045] The term "4-20-membered non-aryl heterocycle" refers to a monocyclic or bicyclic non-aromatic heterocycle consisting of 4 to 20 atoms, containing one or more identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms, and includes those having a partially unsaturated bond, a partially bridged structure, and a partially spiro-bonded structure. The non-aryl heterocycle may form a condensed ring with an aryl or heteroaryl. For example, C 6-10 Non-aryl heterocycles also include those fused with aryls or 5- or 6-membered heteroaryls. The non-aryl heterocycle may contain one or more carbonyls, thiocarbonyls, sulfinyls, or sulfonyls. For example, cyclic groups such as lactams, thiolactams, lactones, thiolactones, cyclic imides, cyclic carbamates, and cyclic thiocarbamates are also included in non-aryl heterocycles. Here, the oxygen atoms of carbonyls, sulfinyls, and sulfonyls and the sulfur atoms of thiocarbonyls are not included in the 4- to 20-membered ring (ring size) and the number of heteroatoms constituting the ring. Specific examples of "4- to 20-membered non-aryl heterocycles" include, but are not limited to, azetidine, pyrrolidine, piperidine, piperazine, morpholine, homopiperidine, oxetane, tetrahydrofuran, tetrahydropyran, and the structures shown below. [ka]

[0046] Specific examples of the "4- to 20-membered non-aryl heterocycle" having a partial bridge and spiro structure include, but are not limited to, those having the structures shown below. [ka]

[0047] The term "nitrogen-containing non-aryl heterocycle" refers to a monocyclic or bicyclic non-aromatic heterocycle containing, in addition to one nitrogen atom, zero or more identical or different heteroatoms selected from the group consisting of oxygen atoms, nitrogen atoms, and sulfur atoms, and includes those having a partially unsaturated bond, those having a partially bridged structure, and those having a partially spiro-bonded structure, and is preferably a "4- to 20-membered nitrogen-containing non-aryl heterocycle" described below.

[0048] The term "4- to 20-membered nitrogen-containing non-aryl heterocycle" refers to a monocyclic or bicyclic non-aromatic heterocycle consisting of 4 to 20 atoms, which contains one nitrogen atom and 0 or 1 heteroatom, which may be the same or different, selected from the group consisting of oxygen atoms, nitrogen atoms, and sulfur atoms, and includes those having a partially unsaturated bond, a partially bridged structure, and a partially spiro-formed heterocycle.

[0049] The "4- to 10-membered non-aryl heterocycle" means a substituent in which the "4- to 10-membered non-aryl heterocycle" is a monovalent group among the above "4- to 20-membered non-aryl heterocycles".

[0050] The terms "4- to 10-membered nitrogen-containing non-aryl heterocycle," "4- to 7-membered nitrogen-containing non-aryl heterocycle," "5- to 7-membered nitrogen-containing non-aryl heterocycle," and "4- to 6-membered nitrogen-containing non-aryl heterocycle" mean substituents of the above-mentioned "4- to 20-membered nitrogen-containing non-aryl heterocycle," in which "4- to 10-membered nitrogen-containing non-aryl heterocycle," "4- to 7-membered nitrogen-containing non-aryl heterocycle," "5- to 7-membered nitrogen-containing non-aryl heterocycle," and "4- to 6-membered nitrogen-containing non-aryl heterocycle" are monovalent groups, respectively.

[0051] The "5- to 7-membered non-aryl heterocycle" means a substituent in which the "5- to 7-membered non-aryl heterocycle" is a monovalent group among the above "4- to 20-membered non-aryl heterocycles".

[0052] The "4- to 7-membered non-aryl heterocycle" and the "4- to 6-membered non-aryl heterocycle" mean substituents of the above "4- to 20-membered non-aryl heterocycle" in which the "4- to 7-membered non-aryl heterocycle" and the "4- to 6-membered non-aryl heterocycle" are monovalent groups, respectively.

[0053] Specific examples of the "four-membered non-aryl heterocycle" include, but are not limited to, azetidine, oxetane, thietane, and the like.

[0054] Specific examples of the "four-membered non-aryl heterocycle" having a partial unsaturated bond include, but are not limited to, those having the structures shown below. [ka]

[0055] Specific examples of the "5-membered non-aryl heterocycle" include, but are not limited to, pyrrolidine, pyrrolidone, oxazolidinone, tetrahydrofuran, tetrahydrothiophene, and the like.

[0056] Specific examples of the "five-membered non-aryl heterocycle" having a partial unsaturated bond include, but are not limited to, those having the structures shown below. [ka]

[0057] Specific examples of the "five-membered non-aryl heterocycle" having a partially bridged structure include, but are not limited to, those having the structures shown below. [ka]

[0058] Specific examples of the "5-membered non-aryl heterocycle" containing carbonyl, thiocarbonyl, etc. include, but are not limited to, those having the structures shown below. [ka]

[0059] Specific examples of the "6-membered non-aryl heterocycle" include, but are not limited to, piperidine, piperazine, morpholine, tetrahydropyran, tetrahydrothiopyran, and the like.

[0060] Specific examples of the "six-membered non-aryl heterocycle" having a partial unsaturated bond include, but are not limited to, those having the structures shown below. [ka]

[0061] Specific examples of the "six-membered non-aryl heterocycle" having a partially bridged structure include, but are not limited to, those having the structures shown below. [ka]

[0062] "C 1-6 "Alkoxy group" is "C 1-6 alkyloxy group, 1-6 The alkyl portion is the C 1-6 It is synonymous with alkyl group. 1-6 As the "alkoxy group", preferably "C 1-4 Alkoxy group," and more preferably "C 1-3 alkoxy group," and more preferably "C 1-2 "Alkoxy group." "C 1-6Specific examples of the "alkoxy group" include, but are not limited to, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, an isopropoxy group, an isobutoxy group, a tert-butoxy group, a sec-butoxy group, an isopentyloxy group, a neopentyloxy group, a tert-pentyloxy group, and a 1,2-dimethylpropoxy group.

[0063] "C 3-10 The "alicyclic oxy group" is (C 3-10 means an alicyclic group)-O- group, 3-10 The alicyclic moiety is C 3-10 It is synonymous with alicyclic group. 3-6 The "alicyclic oxy group" is (C 3-6 means an alicyclic group)-O- group, 3-6 The alicyclic moiety is C 3-6 It is synonymous with alicyclic group. 3-6 As the "alicyclic oxy group", preferably "C 3-5 "C" is an alicyclic oxy group. 3-6 Specific examples of the "alicyclic oxy group" include, but are not limited to, a cyclopropyloxy group, a cyclobutyloxy group, a cyclopentyloxy group, a cyclohexyloxy group, and the like.

[0064] "C 6-10 Aryloxy group" C 6-10 The aryl moiety is C 6-10 Synonymous with aryl. 6-10 The "aryloxy group" is preferably a "C6 or C 10 "Aryloxy groups of C 6-10 Specific examples of the "aryloxy group" include, but are not limited to, a phenoxy group, a 1-naphthyloxy group, and a 2-naphthyloxy group.

[0065] The 5- or 6-membered heteroaryl moiety of the "5- or 6-membered heteroaryloxy group" has the same meaning as the above "5-membered heteroaryl" or "6-membered heteroaryl." Specific examples of the "5- or 6-membered heteroaryloxy group" include, but are not limited to, a pyrazolyloxy group, a triazolyloxy group, a thiazoyloxy group, a thiadiazoyloxy group, a pyridyloxy group, and a pyridazoyloxy group.

[0066] The 4- to 10-membered non-aryl heterocyclic moiety of the "4- to 10-membered non-aryl heterocyclic oxy group" has the same meaning as the above-mentioned "4- to 10-membered non-aryl heterocyclic ring". The "4- to 10-membered non-aryl heterocyclic oxy group" is preferably a "4- to 6-membered non-aryl heterocyclic oxy group". Specific examples of the "4- to 10-membered non-aryl heterocyclic oxy group" include, but are not limited to, a tetrahydrofuranyloxy group, a tetrahydropyranyloxy group, an azetidinyloxy group, a pyrrolidinyloxy group, and a piperidinyloxy group.

[0067] "C 1-6 Alkylthio group C 1-6 The alkyl portion is the C 1-6 It is synonymous with alkyl. 1-6 As the "alkylthio group," preferably "C 1-4 alkylthio group," and more preferably "C 1-3 "C alkylthio group." 1-6 Specific examples of the "alkylthio group" include, but are not limited to, a methylthio group, an ethylthio group, a propylthio group, a butylthio group, an isopropylthio group, an isobutylthio group, a tert-butylthio group, a sec-butylthio group, an isopentylthio group, a neopentylthio group, a tert-pentylthio group, and a 1,2-dimethylpropylthio group.

[0068] "C 3-10 The "alicyclic thio group" is (C 3-10 means an alicyclic group)-S- group, 3-10 The alicyclic moiety is C 3-10 It is synonymous with alicyclic group.3-10 As the "alicyclic thio group", preferably "C 3-6 "C" is an alicyclic thio group. 3-6 Specific examples of the "alicyclic thio group" include, but are not limited to, a cyclopropylthio group, a cyclobutylthio group, a cyclopentylthio group, a cyclohexylthio group, and the like.

[0069] "C 6-10 Arylthio group" C 6-10 The aryl moiety is C 6-10 Synonymous with aryl. 6-10 The "arylthio group" is preferably "C6 or C 10 "Arylthio groups of C" 6-10 Specific examples of the "arylthio group" include, but are not limited to, a phenylthio group, a 1-naphthylthio group, and a 2-naphthylthio group.

[0070] The 5- or 6-membered heteroaryl moiety of the "5- or 6-membered heteroarylthio group" has the same meaning as the above "5-membered heteroaryl" or "6-membered heteroaryl." Specific examples of the "5- or 6-membered heteroarylthio group" include, but are not limited to, a pyrazoylthio group, a triazoylthio group, a thiazoylthio group, a thiadiazoylthio group, a pyridylthio group, and a pyridazoylthio group.

[0071] The 4- to 10-membered non-aryl heterocyclic moiety of the "4- to 10-membered non-aryl heterocyclic thio group" has the same meaning as the above-mentioned "4- to 10-membered non-aryl heterocycle". The "4- to 10-membered non-aryl heterocyclic thio group" is preferably a "4- to 6-membered non-aryl heterocyclic thio group". Specific examples of the "4- to 10-membered non-aryl heterocyclic thio group" include, but are not limited to, a tetrahydropyranylthio group, a piperidinylthio group, and the like.

[0072] "C 1-6 The "alkylcarbonyl group" is the same as the above "C 1-6 "C" means a carbonyl group substituted with an "alkyl group." 1-6As the "alkylcarbonyl group," preferably, "C 1-4 "C alkylcarbonyl group." 1-6 Specific examples of the "alkylcarbonyl group" include, but are not limited to, an acetyl group, a propionyl group, and a butyryl group.

[0073] "C 3-10 The "alicyclic carbonyl group" is the same as the above "C 3-10 "C" means a carbonyl group substituted with an "alicyclic group." 3-10 As the "alicyclic carbonyl group," preferably, "C 3-6 "C" is an alicyclic carbonyl group. 3-10 Specific examples of the "alicyclic carbonyl group" include, but are not limited to, a cyclopropylcarbonyl group, a cyclopentylcarbonyl group, and the like.

[0074] "C 6-10 The "arylcarbonyl group" is the same as the above "C 6-10 "C" means a carbonyl group substituted with "aryl." 6-10 The "arylcarbonyl group" is preferably a "C or C 10 "C" is an arylcarbonyl group. 6-10 Specific examples of the "arylcarbonyl group" include, but are not limited to, a benzoyl group, a 1-naphthylcarbonyl group, a 2-naphthylcarbonyl group, and the like.

[0075] The term "5- or 6-membered heteroarylcarbonyl group" refers to a carbonyl group substituted with the above-mentioned "5- or 6-membered heteroaryl." Specific examples of the "5- or 6-membered heteroarylcarbonyl group" include, but are not limited to, a pyrazoylcarbonyl group, a triazoylcarbonyl group, a thiazoylcarbonyl group, a thiadiazoylcarbonyl group, a pyridylcarbonyl group, and a pyridazoylcarbonyl group.

[0076] The term "4- to 10-membered non-aryl heterocyclic carbonyl group" refers to a carbonyl group substituted with the above-mentioned "4- to 10-membered non-aryl heterocycle." The "4- to 10-membered non-aryl heterocyclic carbonyl group" is preferably a "4- to 6-membered non-aryl heterocyclic carbonyl group." Specific examples of the "4- to 10-membered non-aryl heterocyclic carbonyl group" include, but are not limited to, an azetidinylcarbonyl group, a pyrrolidinylcarbonyl group, a piperidinylcarbonyl group, and a morpholinylcarbonyl group.

[0077] "C 1-6 The "alkylsulfonyl group" is the same as the above "C 1-6 "C" means a sulfonyl group substituted with an alkyl group. 1-6 As the "alkylsulfonyl group", preferably "C 1-4 "C alkylsulfonyl group." 1-6 Specific examples of the "alkylsulfonyl group" include, but are not limited to, a methylsulfonyl group, a propylsulfonyl group, a butylsulfonyl group, and the like.

[0078] "C 3-10 The "alicyclic sulfonyl group" means the above "C 3-10 "C" means a sulfonyl group substituted with an "alicyclic group." 3-10 As the "alicyclic sulfonyl group", preferably "C 3-6 "C" is an alicyclic sulfonyl group. 3-10 Specific examples of the "alicyclic sulfonyl group" include, but are not limited to, a cyclopropylsulfonyl group, a cyclobutylsulfonyl group, a cyclopentylsulfonyl group, a cyclohexylsulfonyl group, and the like.

[0079] "C 6-10 The "arylsulfonyl group" is the same as the above "C 6-10 "C" means a sulfonyl group substituted with "aryl." 6-10 The "arylsulfonyl group" is preferably "C or C 10 "C is an arylsulfonyl group. 6-10Specific examples of the "arylsulfonyl group" include, but are not limited to, a phenylsulfonyl group, a 1-naphthylsulfonyl group, a 2-naphthylsulfonyl group, and the like.

[0080] The term "5- or 6-membered heteroarylsulfonyl group" refers to a sulfonyl group substituted with the above-mentioned "5- or 6-membered heteroaryl." Specific examples of the "5- or 6-membered heteroarylsulfonyl group" include a pyrazoylsulfonyl group, a triazoylsulfonyl group, a thiazoylsulfonyl group, a thiadiazoylsulfonyl group, a pyridylsulfonyl group, and a pyridazoylsulfonyl group.

[0081] "C 1-6 The term "alkylene group" refers to a substituent group that has been divalently formed by removing two hydrogen atoms from a saturated hydrocarbon having 1 to 6 carbon atoms. 1-3 alkylene group" and "C 2-4 The term "alkylene group" refers to a substituent formed into a divalent group by removing two hydrogen atoms from a saturated hydrocarbon having 1 to 3 carbon atoms and a saturated hydrocarbon having 2 to 4 carbon atoms, respectively.

[0082] "C 3-10 The term "cycloalkylene group" refers to a substituent group that has been divalently formed by removing two hydrogen atoms from a saturated cyclic hydrocarbon having 3 to 10 carbon atoms. 3-6 Cycloalkylene group" and "C 4-6 The term "cycloalkylene group" refers to a substituent formed into a divalent group by removing two hydrogen atoms from a saturated cyclic hydrocarbon having 3 to 6 carbon atoms and a saturated cyclic hydrocarbon having 4 to 6 carbon atoms, respectively.

[0083] "C 6-10 The term "arylene group" refers to a substituent that has become a divalent group by removing two hydrogen atoms from an aromatic hydrocarbon having 6 to 10 carbon atoms. The term "C6 arylene group" refers to a substituent that has become a divalent group by removing two hydrogen atoms from an aromatic hydrocarbon having 6 carbon atoms.

[0084] The term "5- or 6-membered heteroarylene group" refers to a substituent that has been divalently formed by removing two hydrogen atoms from a 5- or 6-membered heteroaryl ring. The terms "5-membered heteroarylene group" and "6-membered heteroarylene group" refer to substituents that have been divalently formed by removing two hydrogen atoms from a 5-membered or 6-membered heteroaryl ring, respectively.

[0085] The term "4- to 10-membered non-aryl heterocyclylene group" refers to a divalent substituent formed by removing two hydrogen atoms from a 4- to 10-membered non-aryl heterocycle. The terms "4- to 5-membered non-aryl heterocyclylene group" and "4- to 6-membered non-aryl heterocyclylene group" refer to divalent substituents formed by removing two hydrogen atoms from a 4- to 5-membered or 4- to 6-membered non-aryl heterocycle, respectively.

[0086] As used herein, the term "hydrocarbyl group" refers to a monovalent group formed by removing one hydrogen atom from a hydrocarbon consisting solely of carbon and hydrogen atoms. The hydrocarbyl may be aliphatic (straight or branched chain), alicyclic, or aromatic (aryl). Examples include methyl, ethyl, n-propyl, isopropyl, cyclopentyl, cyclohexyl, and phenyl. The term "optionally substituted hydrocarbyl group" refers to a hydrocarbyl group substituted with the substituents listed above. The term "optionally substituted hydrocarbyl group" may be substituted with an oxo group (=O group), a thioxo group (=S group), or an imino group (=NR), and examples include a formyl group and an acetyl group.

[0087] As used herein, the term "hydrocarbylene group" refers to a divalent group formed by removing two hydrogen atoms from a hydrocarbon consisting solely of carbon and hydrogen atoms. The hydrocarbylene may be aliphatic (straight-chain or branched-chain), alicyclic, or aromatic (aryl). Examples include methylene, ethylene, n-propylene, isopropylene, cyclopentanediyl, cyclohexanediyl, and phenylene groups. The term "optionally substituted hydrocarbylene group" refers to a hydrocarbylene group substituted with the substituents listed above. The term "optionally substituted hydrocarbylene group" may be substituted with an oxo group (=O group), a thioxo group (=S group), or an imino group (=NR).

[0088] As used herein, the term "heterohydrocarbyl group" refers to a hydrocarbyl group in which at least one, and possibly all, of the carbon atoms is replaced with a heteroatom. Heteroatoms include, for example, O, N, S, and P. Heterohydrocarbyl groups include heteroaryls, non-aryl heterocycles, alkoxy groups, alkylthio groups, carboxy groups, carboxylic acid equivalents (where the carboxylic acid equivalent is an ester group, -C(=O)OR 20a including -NR e1 -C(=O)R f1 , -NR e1 -C(=O)OR f1 , -NR g1 -C(=O)NR e1 R f1 -C(=O)NR 50 R 51 -C(=O)NR 50 R 51 (where R 20a , R e1 , R f1 , R g1 , R 50 , R 51is as defined in item 1 or 2 of this specification), and examples thereof include a methoxy group, an ethoxy group, a cyano group, an imidazole group, a pyridinyl group, a pyrazole group, a triazole group, a pyrazinyl group, a pyridazinyl group, and a pyrimidinyl group. An "optionally substituted heterohydrocarbyl group" refers to a heterohydrocarbyl group substituted with the substituents listed above. An "optionally substituted heterohydrocarbyl group" may be substituted with an oxo group (=O group), a thioxo group (=S group), or an imino group (=NR), and examples thereof include a carboxyl group, a methoxycarbonyl group, an aminocarbonyl group, and a hydroxyaminocarbonyl group.

[0089] As used herein, the term "heterohydrocarbylene group" refers to a hydrocarbylene group in which at least one (or all) of its carbon atoms is replaced with a heteroatom. Examples of heteroatoms include O, N, S, and P. Examples of heterohydrocarbylene groups include heteroarylene, non-aryl heterocyclic diyl groups, alkyleneoxy groups, and alkylenethio groups, such as methyleneoxy groups, ethyleneoxy groups, imino groups (-NR- groups), imidazolediyl groups, pyridinediyl groups, pyrazolediyl groups, triazolediyl groups, pyrazinediyl groups, pyridazinediyl groups, and pyrimidinediyl groups. The term "optionally substituted heterohydrocarbylene group" refers to a heterohydrocarbylene group substituted with the substituents listed above. The "optionally substituted heterohydrocarbylene group" may be substituted with an oxo group (=O group), a thioxo group (=S group), or an imino group (=NR), and examples thereof include a carbonyloxy group, a methyleneoxycarbonyl group, an aminocarbonyl group, a hydroxyaminocarbonyl group, an iminocarbonyl group (-NRC(=O)- group), an iminosulfonyl group (-NRSO2- group), an optionally substituted -NH-, and an optionally substituted -NH-SO2-.

[0090] R 5 In the description of the specific structure of 4For bonds that cross a bond between ring atoms, any substitutable position on the monocyclic or fused polycyclic ring that contains that ring atom may have a variable (e.g., R 6a , R 7a In the case of a monocyclic 5-membered ring (heteroaryl), for example, [ka] (where d is 3) is [ka] L 4 is attached to a ring carbon atom of the 5-membered ring. In the case of a monocyclic 6-membered ring (heteroaryl), for example, [ka] (where d is 4) is [ka] L 4 is attached to a ring carbon atom of a six-membered ring. Alternatively, in the case of a monocyclic 5-membered ring (non-aryl heterocycle), for example, [ka] (where d is 7) is [ka] L 4 is attached to a ring carbon atom of the 5-membered ring. In the case of a monocyclic 6-membered ring (non-aryl heterocycle), for example, [ka] (where d is 10) is [ka] L 4 is attached to a ring carbon atom of a six-membered ring. The subscript d stands for R 5 where L is the number of substitutable positions on the ring 4 is the number of substitutable positions excluding the bonding position to

[0091] A "bioisostere" is a compound that, in a drug molecule, has a certain group (e.g., a carboxyl group) attached to it. The term "carboxylic acid equivalent" refers to a partial structure (functional group) that plays the same biological role as an ester group (an ester group) (in the present invention, the concept of bioisosteres also includes prodrug structures). The term "carboxylic acid equivalent" refers to a bioisostere of a carboxylic acid. Examples of the carboxylic acid equivalent include, but are not limited to, an ester group -C(=O)OR 20a , -SO3H, -SO2NHR 19a , -B(OR m1 )2, -PO(OR m1 )(OR m2 ), -CONHR 19a , -CONHSO2R 19a , -CONR 19a CN, -CONHNHSO2R 19a and substituents represented by the following formulae (8A), (8B), (8C), (8D), (8E), (8F), (8G), (8H), (8I), (8J), (8K), (8L), (8M), (8N), (8O), (8P), (8Q), (8R), (8S), (8T), (8U), (8V) and (8W) (each of the substituents has 1 to 3 identical or different R 19b and the like, which may be further substituted with [ka] [In formulas (8V) and (8W), R s is a hydrogen atom, C 1-6 Alkyl group or C 3-10 Alicyclic group (the C 1-6 Alkyl group or C 3-10 The alicyclic group is optionally substituted with 1 to 5 halogen atoms, R t is a hydrogen atom, C 1-6 Alkyl group, C1-6 Alkoxy group (the C 1-6 Alkyl group, C 1-6 The alkoxy group may be substituted with 1 to 5 halogen atoms), C 3-10 Alicyclic group, C 3-10 Alicyclic oxy group, phenyl group, phenoxy group, pyridyl group or pyridyloxy group (the C 3-10 Alicyclic group, C 3-10 Alicyclic oxy group, phenyl group, phenoxy group, pyridyl group, pyridyloxy group are 1 to 5 halogen atoms, C 1-6 Alkyl group, C 1-6 and (optionally substituted with a substituent selected from the group consisting of alkoxy groups), R 19a , R 19b are each independently the same or different and represent a hydrogen atom, a hydroxyl group, or C 1-6 Alkyl group, C 6-10 represents an aryl, a 5- or 6-membered heteroaryl, or a 4- to 10-membered non-aryl heterocycle; R 20a teeth, 1) C 1-6 alkyl groups, 2) C 3-10 alicyclic group, 3) C 6-10 aryl, 4) a 5- or 6-membered heteroaryl, or 5) 4-10 membered non-aryl heterocycle (However, each of the substituents 1) to 5) above may be substituted.) Either R m1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (provided that each of the substituents 2) to 6) above may be substituted), However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 C 2-4 The alkylene may be taken together with the boron atom and two oxygen atoms to form a 5- to 7-membered non-aryl heterocycle (the alkylene portion of the non-aryl heterocycle may be substituted), R m2 is a hydrogen atom, optionally substituted C 1-6 alkyl group or optionally substituted C 3-10 represents an alicyclic group. Preferably, R s is a hydrogen atom or C 1-6 is an alkyl group, R t is a hydrogen atom, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-10 Alicyclic group or C 3-10 and alicyclic oxy groups. Alternatively, and preferably here, R 19a , R 19b are each independently the same or different and represent a hydrogen atom, a hydroxyl group, or C 1-6 It is an alkyl group. Also preferably, R m1 , R m2 are each independently the same or different and represent a hydrogen atom, C 1-6 Alkyl group, or C 3-10 It is an alicyclic group.

[0092] One embodiment of the compound of the present invention is represented by formula (1a) or (1b): [ka] In formula (1a) and (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted alkoxy group, or -NRa2 R b1 and R a1 , R a2 and R b1 are each independently the same or different and represent a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, Here, R a2 and R b1 may be taken together to form an optionally substituted nitrogen-containing non-aryl heterocycle, L 1 is a single bond, an oxygen atom, a sulfur atom, —SO—, —SO2—, an optionally substituted hydrocarbylene group, or an optionally substituted heterohydrocarbylene group, L 2 is a single bond or an optionally substituted hydrocarbylene group, Z is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group; R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and R j is a hydrogen atom, a hydroxyl group, or an optionally substituted hydrocarbyl group, Ring A is an optionally substituted non-aryl heterocycle, L 3 is an oxygen atom, a sulfur atom, an optionally substituted hydrocarbylene group or an optionally substituted heterohydrocarbylene group, an optionally substituted —NH—, an optionally substituted —NH—SO—, or —S(═O)— or —S(═O)—; L 4represents a single bond, an optionally substituted hydrocarbylene group or an optionally substituted heterohydrocarbylene group, or —C(═N—OR h1 )- and R h1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R 5 is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group or an optionally substituted heterohydrocarbyl group, optionally substituted -NHOH, a sulfo group (sulfonic acid group), optionally substituted -SOH, optionally substituted -SO-NH, optionally substituted -S(=O)(=NH)H, optionally substituted -NH-SO-H, optionally substituted -NH-SO-NH, optionally substituted -N=S(=O)H, or optionally substituted -NH; (R 1 , R 2 and R 3 the remaining two (which do not have the structure of formula (2)) are independently the same or different and represent a hydrogen atom, a halogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L 6 -R 8 (In the above formulas 1) and 2), R 8 is a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, and L 6is a single bond or an optionally substituted hydrocarbylene group), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted heteroaryl, 7) an optionally substituted non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 1), 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a4 and R b3 are each independently the same or different and represent R a1 , R a2 and R b1 where R a4 and R b3 are bonded to the same nitrogen atom, they may be joined together to form an optionally substituted nitrogen-containing non-aryl heterocycle, R m1 is a hydrogen atom or an optionally substituted hydrocarbyl group, However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 may, as alkylene, be combined with the boron atom and two oxygen atoms to form a non-aryl heterocycle (the non-aryl heterocycle may have an optionally substituted alkylene portion), R m2 is a hydrogen atom or an optionally substituted hydrocarbyl group, R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom, a halogen atom, an optionally substituted alkyl group, or -L 1 -L 2-Z.

[0093] Another embodiment of the compound of the present invention is a compound represented by formula (1a) or (1b): [ka] In formula (1a) and (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted alkoxy group, or -NR a2 R b1 and R a1 , R a2 and R b1 are each independently the same or different and represent a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, Here, R a2 and R b1 may be taken together to form an optionally substituted nitrogen-containing non-aryl heterocycle, L 1 is a single bond, an oxygen atom, a sulfur atom, —SO—, —SO2—, an optionally substituted hydrocarbylene group, or an optionally substituted heterohydrocarbylene group, L 2 is a single bond or an optionally substituted hydrocarbylene group, Z is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group; R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and R jis a hydrogen atom, a hydroxyl group, or an optionally substituted hydrocarbyl group, Ring A is an optionally substituted non-aryl heterocycle, L 3 is an oxygen atom, a sulfur atom, an optionally substituted hydrocarbylene group or an optionally substituted heterohydrocarbylene group, or —S(═O)— or —S(═O)—; L 4 represents a single bond, an optionally substituted hydrocarbylene group, or -C(=N-OR h1 )- and R h1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R 5 is a hydrogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, (R 1 , R 2 and R 3 the remaining two (which do not have the structure of formula (2)) are independently the same or different and represent a hydrogen atom, a halogen atom, a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L 6 -R 8 (In the above formulas 1) and 2), R 8is a hydroxyl group, an optionally substituted hydrocarbyl group, or an optionally substituted heterohydrocarbyl group, and L 6 is a single bond or an optionally substituted hydrocarbylene group), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted heteroaryl, 7) an optionally substituted non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 1), 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a4 and R b3 are each independently the same or different and represent R a1 , R a2 and R b1 where R a4 and R b3 are bonded to the same nitrogen atom, they may be joined together to form an optionally substituted nitrogen-containing non-aryl heterocycle, R m1 is a hydrogen atom or an optionally substituted hydrocarbyl group, However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 may, as alkylene, be combined with the boron atom and two oxygen atoms to form a non-aryl heterocycle (the non-aryl heterocycle may have an optionally substituted alkylene portion), R m2 is a hydrogen atom or an optionally substituted hydrocarbyl group, R 61 , R 62 , R 63 and R 64are each independently a hydrogen atom, a halogen atom, an optionally substituted alkyl group, or -L 1 -L 2 -Z.

[0094] In some embodiments, in the above formula (1a) or (1b), G is an oxygen atom, a sulfur atom, or -NR a1 - and X is a hydroxyl group, an optionally substituted C 1-6 Alkoxy group, or -NR a2 R b1 and R a1 , R a2 and R b1 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group, or 15)-OR c1 , (However, each of the substituents in 2) to 14) above may be substituted), Here, R a2 and R b1may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), L 1 represents a single bond, oxygen atom, sulfur atom, -SO-, -SO2-, -NR d1 -, -NR d1 C(=O)- or -NR d1 SO2-, L 2 is a single bond or an optionally substituted C 1-6 is an alkylene group, Z is 1) hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) carboxyl group, 5) C 3-10 alicyclic group, 6) C 6-10 aryl, 7) 5- or 6-membered heteroaryl; 8) 4-10 membered non-aryl heterocycle, 9) C 1-6 alkoxy groups, 10) C 3-10 alicyclic oxy groups, 11)C 6-10 aryloxy groups, 12) 5- or 6-membered heteroaryloxy groups, 13) a 4- to 10-membered non-aryl heterocyclic oxy group, 14)C 1-6 alkylthio groups, 15)C 3-10 alicyclic thio group, 16)C 6-10 arylthio groups, 17) 5- or 6-membered heteroarylthio groups, 18) 4- to 10-membered non-aryl heterocyclic thio group, (However, each of the substituents 5) to 18) above may be substituted.) 19)-SO2-NR e1 R f1 , 20)-NR e1 -C(=O)OR f1 , 21)-NR g1 -C(=O)NR e1 R f1 , 22)-NR e1 -C(=S)R f1 , 23)-NR e1 -C(=S)OR f1 , 24)-NR g1 -C(=S)NR e1 R f1 , 25)-NR g1 -CR e1 (=NR f1 ), 26)-NR g1 -CR e1 (=N-OR f1 ), 27)-NR h1 -C(=NR g1 )NR e1 R f1 , 28)-NR h1 -C(=N-OR g1 )NR e1 R f1 , 29)-NR i1 -C(=NR h1 )NR g1 -NR e1 R f1 , 30)-NR i1 -C(=N-OR h1 )NR g1 -NR e1 R f1 , 31)-NR e1 -SO2-R f1 、 32)-NR g1 -SO2-NR e1 R f1 、 33)-C(=O)OR e1 、 34)-C(=S)OR e1 、 35)-C(=S)NR e1 R f1 、 36)-C(=S)NR e1 OR f1 、 37)-C(=S)NR g1 -NR e1 R f1 、 38)-C(=NR e1 )R f1 、 39)-C(=N-OR e1 )R f1 、 40)-C(=NR h1 )NR g1 -NR e1 R f1 、 41)-C(=N-OR h1 )NR g1 -NR e1 R f1 、 42)-NR e1 R f1 、 43)-NR g1 -NR e1 R f1 、 44)-NR e1 OR f1 、 45)-NR e1 -C(=O)R f1 、 46)-C(=O)NR e1 R f1 、 47)-C(=O)NR e1 OR f1 、 48)-C(=O)NR g1 -NRe1 R f1 , 49)-C(=O)R e1 , 50)-C(=NR g1 )NR e1 R f1 ,or 51)-C(=N-OR h1 )NR e1 R f1 Either R 1 , R 2 and R 3 Any one of the following formula (2): [ka] [In formula (2), Y is an oxygen atom, a sulfur atom, or -NR j - and Ring A is an optionally substituted 4- to 20-membered non-aryl heterocycle, L 3 teeth, 1) oxygen atom, 2) sulfur atoms, 3)-NR d2 -, 4)-NR d2 C(=O)-, 5)-NR d2 SO2-, 6) C 1-6 an alkylene group, 7) C 3-10 a cycloalkylene group, 8) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents in 6) to 8) above may be substituted), 9)-C(=O)-, 10)-S(=O)-, or 11)-S(=O)2- Either L 4 teeth, 1) a single bond, 2) C 1-6 an alkylene group, 3) C3-10 a cycloalkylene group, 4) C 6-10 Arylene group 5) a 5- or 6-membered heteroarylene group; 6) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents in 2) to 6) above may be substituted), or 7)-C(=N-OR h1 )- Either R 5 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) 4-10 membered non-aryl heterocycle, 5) C 6-10 aryl, 6) 5- to 10-membered heteroaryl, 7) C 1-6 alkylthio groups, (However, each of the substituents 2) to 7) above may be substituted, and when two substituents further substituted with the substituents 1), 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a fused ring structure.) 8)-NR e1 OH, 9) Carboxyl group (-C(=O)OH) 10) Carboxylic acid equivalents (wherein the carboxylic acid equivalent is an ester group -C(=O)OR 20a including 11) sulfo group (sulfonic acid group), 12)-SO2R e1 , 13)-SO2-NR e1 R f1 , 14)-S(=O)(=NR f1 )R e1 , 15)-NR e1 -C(=O)R f1 , 16)-NRe1 -C(=O)OR f1 , 17)-NR g1 -C(=O)NR e1 R f1 , 18)-NR e1 -SO2-R f1 , 19)-NR g1 -SO2-NR e1 R f1 , 20)-N=S(=O)R e1 R f1 , 21)-C(=O)NR 50 R 51 ,or 22)-NR e1 R f1 (However, R 5 When the substituent of 22) is -L 3 -L 4 -R 5 is -(CH2) 1-4 NR e1 R f1 (In the formula, R e1 , R f1 is a hydrogen atom, optionally substituted C 1-4 Alkyl, optionally substituted C 3-7 Alicyclic groups, optionally substituted 4-10 membered non-aryl heterocyclic groups, optionally substituted C 6-10 aryl, or optionally substituted 5-10 membered heteroaryl) Either R 20a teeth, 1) C 1-6 alkyl groups, 2) C 3-10 alicyclic group, 3) C 6-10 aryl, 4) a 5- or 6-membered heteroaryl, or 5) 4-10 membered non-aryl heterocycle (However, each of the substituents 1) to 5) above may be substituted.) Either R 50 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) hydroxyl group, 4) C 1-6 alkoxy groups, 5) C 3-6 cycloalkoxy groups, 6) C 3-6 alicyclic group, 7) 4- to 6-membered non-aryl heterocycles, 8) C 6-10 aryl, 9) 5- to 10-membered heteroaryl 10) 4-6 membered non-aryl heterocycle oxy, 11)C 6-10 aryloxy, 12) 5- to 10-membered heteroaryloxy, 13)C 1-6 alkylsulfonyl groups, 14)C 3-6 a cycloalkoxysulfonyl group, or 15) 4-6-membered non-aryl heterocyclic sulfonyl group (However, each of the substituents in 2) and 4) to 15) above may be substituted.) represents one of the following: R 51 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-6 alicyclic group, 4) 4-6 membered non-aryl heterocycle, 5) C 6-10 aryl, or 6) 5- to 10-membered heteroaryl (However, each of the substituents 2) to 6) above may be substituted.) represents one of the following: Alternatively, R 50 and R 51 and may be taken together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle, (R 1 , R2 and R 3 the remaining two are independently the same or different and are each a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, optionally substituted C 1-6 Alkoxy group, optionally substituted C 1-6 an alkylthio group, an optionally substituted 5- or 6-membered heteroaryl, or —NR a3 R b2 and R d1 , R d2 , R e1 , R f1 , R g1 , R h1 , R i1 and R j are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R e1 and R f1 When the combination of the following is bound to the same nitrogen atom, they may be taken together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R 4 teeth, 1)-C(=O)R 8 , 2)-SO2-L 6 -R 8 (In the above formulas 1) and 2), R 8 is -NR a5 R b4 , -NR a5 -L 7 -B(OR m1 )2, -ORm1 , or optionally substituted C 1-6 is an alkyl group, and L 6 is a single bond or -NR a6 -is), 3)-NR a4 R b3 , 4)-B(OR m1 )2, 5)-PO(OR m1 )(OR m2 ), 6) optionally substituted 5-membered heteroaryl; 7) an optionally substituted 5-membered non-aryl heterocycle, or 8) Bioequivalents of any of 1) to 7) (However, the above formulas 2), 4), 5) and 6) include carboxylic acid equivalents, and 8) may include these in duplicate.) Either R a3 , R a4 , R a5 , R a6 , R b2 , R b3 and R b4 are each independently the same or different and represent R a1 , R a2 and R b1 where R a3 and R b2 , R a4 and R b3 or R a5 and R b4 When the combination of the following is bonded to the same nitrogen atom, they may be combined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R m1 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), However, R m1 is bonded to the boron atom through an oxygen atom, two R m1 C 2-4 The alkylene may be taken together with the boron atom and two oxygen atoms to form a 5- to 7-membered non-aryl heterocycle (the alkylene portion of the non-aryl heterocycle may be substituted), R m2 is a hydrogen atom, optionally substituted C 1-6 alkyl group or optionally substituted C 3-10 is an alicyclic group, L 7 may be substituted C 1-3 is an alkylene group, R 61 , R 62 and R 63 Each independently represents a hydrogen atom, a halogen atom, or an optionally substituted C 1-6 is an alkyl group, R 64 is a hydrogen atom, a halogen atom, or an optionally substituted C 1-6 Alkyl group, or -L 1 -L 2 -Z.

[0095] In some embodiments, L 3 but, 1) C 1-6 an alkylene group, 2) C 3-10 a cycloalkylene group, 3) 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents 1) to 3) above may be substituted.) Either L 4 is a single bond or an optionally substituted C 1-5 is an alkylene group

[0096] In some embodiments, L3 may be substituted C 1-4 is an alkylene group, L 4 is a single bond or an optionally substituted C 1-3 It is an alkylene group.

[0097] In some embodiments, L 3 But, -(CR 30 R 31 ) n1 - and R 30 and R 31 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a7 R a8 , 3) C 1-4 alkyl groups, 4) C 6-10 aryl, 5) 5- to 10-membered heteroaryl, 6) C 3-6 alicyclic group, 7) 4-10 membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR c2 or R 30 and R 31 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a7 and R a8 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group, or 15)-OR c3 , (However, each of the substituents in 2) to 14) above may be substituted), Here, R a7 and R a8 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c2 and R c3 are each independently 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), n1 is an integer of 1, 2, 3, or 4; L 4 But, -(CR 40 R 41 ) n2 - and R 40 and R 41 are each independently, and if there are multiple of them, all of them are independently, 1) hydrogen atom, 2)-NR a9 R a10 , 3) C 1-4 alkyl groups, 4) C 6-10 aryl, 5) 5- to 10-membered heteroaryl, 6) C 3-6 alicyclic group 7) 4-10 membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR c4 or R 40 and R 41 together with the carbon atoms to which they are attached form C 3-6 forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R a9 and R a10 are each independently the same or different, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycle, 7) C 1-6 alkylcarbonyl groups, 8) C 3-10 alicyclic carbonyl groups, 9) C 6-10 arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11)C 1-6 alkylsulfonyl groups, 12)C 3-10 alicyclic sulfonyl groups, 13)C 6-10 arylsulfonyl groups, 14) 5- or 6-membered heteroarylsulfonyl group (However, each of the substituents in 2) to 14) above may be substituted), or 15)-OR c5 , Either Here, R a9 and R a10 may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R c4 and R c5 are each independently the above R c2 and R c3 is synonymous with n2 is 0 (i.e., L 4 is a single bond), an integer of 1, 2, or 3.

[0098] In some embodiments, -L 3 -L 4 -, but optionally substituted C 1-2 It is an alkylene group.

[0099] In some embodiments, -L 3 -L 4 -But C 1-3 It may be substituted with one or more of an alkyl group, an amino group, or a hydroxymethyl group, which may be the same or different (wherein two C 1-3 When alkyl groups are attached to the same carbon atom, they together with the carbon atom to which they are attached form a C 3-6 (may form an alicyclic group)C 1-2 It is an alkylene group.

[0100] R 5 but, 1) C 3-10 alicyclic group, 2) C 6-10 aryl, 3) 5- to 10-membered heteroaryl, 4) C 1-6 alkylthio groups, (However, each of the substituents 1) to 4) above may be substituted, and when two substituents which are further substituted on the substituents 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a fused ring structure.) 5)-NR e1 OH, 6)-C(=O)NR 50 R 51 , 7)-SO2-NR e1 R f1 , 8)-NR e1 -SO2-R f1 , 9)-C(=O)OR 20 ,or 10)-NR e1 R f1 (However, R 5 When the substituent of 10) is L 3 and / or L 4 is always substituted with one or more groups other than hydrogen atoms 1-6 an alkylene group (where L 3 or L 4 together with the substituent, C 3-10 It may form an alicyclic group or a 4- to 10-membered non-aryl heterocycle. Either R 20 teeth, 1) hydrogen atom, 2) C 1-6 alkyl groups, 3) C 3-10 alicyclic group, 4) C 6-10 aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4-10 membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either:

[0101] In some embodiments, R 5 teeth, 1) C 6-10 aryl, 2) 5- to 10-membered heteroaryl, 3)-C(=O)NR 50 R 51 , 4)-C(=O)OR 20 ,or 5)-NR e1 R f1 (However, R 5 When the substituent is the substituent of 5), L 3 and / or L 4 is always substituted with one or more groups other than hydrogen atoms 1-6 an alkylene group, and together with the substituent, at least one C 3-10 Forms an alicyclic group or a 4- to 10-membered non-aryl heterocycle (However, each of the substituents in 1) and 2) above may be substituted, and when any two of these groups are bonded to adjacent atoms in the ring, they may be joined together to form a fused ring structure.) Either:

[0102] In some embodiments, ZL 2 -L 1 may be replaced by C 1-6 It is an alkylthio group.

[0103] In some embodiments, R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom, a fluorine atom, or C optionally substituted with a fluorine atom. 1-3 It is an alkyl group.

[0104] In some embodiments, R 61 , R 62 , R 63 and R 64 are each independently a hydrogen atom or a fluorine atom.

[0105] In some embodiments, G is an oxygen atom.

[0106] In some embodiments, X is a hydroxyl group or an optionally substituted C 1-6 It is an alkoxy group.

[0107] In some embodiments, X is a hydroxyl group.

[0108] In some embodiments, R 4 teeth, 1) -C(=O)OH (i.e., a carboxyl group), or 2) Carboxylic acid equivalent is.

[0109] In some embodiments, ring A is an optionally substituted 4- to 20-membered non-aryl heterocycle. In some embodiments, ring A is an optionally substituted 4- to 10-membered non-aryl heterocycle. In some embodiments, ring A is an optionally substituted 4- to 7-membered non-aryl heterocycle. In some embodiments, ring A is an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle. In certain embodiments, ring A is [ka] where m is 1, 2 or 3, n is 1, 2 or 3, m+n is 2, 3, 4 or 5, the bond perpendicular to the wavy line represents a bond to Y, and the bond marked with * represents a bond to L 3 In some embodiments, m+n is 2, 3, or 4.

[0110] In some embodiments, ring A is an optionally substituted 4- to 6-membered non-aryl heterocycle. In some embodiments, ring A is an optionally substituted 4- to 6-membered nitrogen-containing non-aryl heterocycle.

[0111] In some embodiments, ring A is [ka] where m+n is 2 or 3. In a preferred embodiment, m+n is 2. In a more preferred embodiment, m=1 and n=1.

[0112] In some embodiments, m is 1 or 2, n is 1 or 2, and m+n is 2 or 3. In some embodiments, m is 1 and n is 1.

[0113] In some embodiments, ring A is an optionally substituted azetidine ring. In certain embodiments within such embodiments, ring A is [ka] where R 26 represents a substituent on the azetidine ring, and R 6a The bond perpendicular to the wavy line indicates a bond with Y, and the bond marked with * indicates L 3 It shows a bond with In a preferred embodiment, R 26 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C 1-6 alkyl groups, 4) C 1-6 alkoxy group (wherein each of the substituents in 3) and 4) may be substituted with a halogen atom) (wherein the halogen atom in 2), 3) and 4) is more preferably a fluorine atom), In a more preferred embodiment, 1) hydrogen atom, 2) halogen atoms, and 3) C optionally substituted with a halogen atom 1-6 alkyl groups, (wherein the halogen atoms in 2) and 3) are more preferably fluorine atoms), Most preferably, it is a hydrogen atom.

[0114] In some embodiments, Y is an oxygen atom or a sulfur atom, In some embodiments, Y is an oxygen atom.

[0115] In some embodiments, L 3 is —C(═O)— or —S(═O)—. In some embodiments, L 3 is -C(=O)-.

[0116] In some embodiments, L 4 is a single bond, -C(=N-OR h1 )- or optionally substituted C 1-6 an alkylene group, where R h1 is optionally substituted C 1-6 It is an alkyl group.

[0117] In some embodiments, R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C 1-6 alkyl groups, 4) C 1-6 an alkoxy group, and 5) C 1-6 Alkylthio group (However, each of the substituents 3) to 5) above may be substituted.) is selected from the group consisting of:

[0118] In some embodiments, R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C 1-6 alkyl groups, 4) C 1-6 an alkoxy group, and 5) C 1-6 Alkylthio group (However, each of the substituents 3) to 5) above may be substituted with a halogen atom.) is selected from the group consisting of:

[0119] In some embodiments, R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) halogen atoms, 3) C optionally substituted with a halogen atom 1-6 alkyl groups, is selected from the group consisting of:

[0120] In some embodiments, R 1 and R 2 are each independently the same or different, 1) hydrogen atom, 2) fluorine atoms, 3) C optionally substituted with a fluorine atom 1-3 alkyl groups, is selected from the group consisting of:

[0121] In some embodiments, R 1 and R 2 are both hydrogen atoms.

[0122] In some embodiments, L 3 But, -(CR 30 R 31 ) n1 - or 4- to 10-membered non-aryl heterocyclylene; R 30 and R 31 are each independently, and if there are multiple of them, all ...

Claims

1. Formula (6a) or (6b): 【Chemical 742】 [In formulas (6a) and (6b), m is 1, n is 1, L ３ teeth, 1) C １－６ an alkylene group, 2) C ３－１０ a cycloalkylene group, 3) a 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents 1) to 3) above may be substituted.) 4) -C(=O)-, Either L ４ teeth, 1) a single bond, 2) C １－６ an alkylene group, 3) C ３－１０ a cycloalkylene group, 4) C ６－１０ Arylene group 5) a 5- or 6-membered heteroarylene group; 6) a 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents 2) to 6) above may be substituted), or 7)-C(=N-OR ｈ１ )- Either R ５ teeth, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－１０ Alicyclic groups, 4) 4-10 membered non-aryl heterocycles; 5) C ６－１０ aryl, 6) 5- to 10-membered heteroaryl; 7) C １－６ alkylthio groups, (However, each of the substituents 2) to 7) above may be substituted, and when two substituents further substituted on the substituents 1), 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a condensed ring structure.) 8)-NR ｅ１ Oh, 9) Carboxyl group (—C(═O)OH) 10) Ester group (—C(═O)OR ２０ａ ), 11) sulfo group (sulfonic acid group), 12)-SO ２ R ｅ１ 、 13)-SO ２ -NR ｅ１ R ｆ１ 、 14)-S(=O)(=NR ｆ１ )R ｅ１ 、 15)-NR ｅ１ -C(=O)R ｆ１ 、 16)-NR ｅ１ -C(=O)OR ｆ１ 、 17)-NR ｇ１ -C(=O)NR ｅ１ R ｆ１ 、 18)-NR ｅ１ -SO ２ -R ｆ１ 、 19)-NR ｇ１ -SO ２ -NR ｅ１ R ｆ１ 、 20)-N=S(=O)R ｅ１ R ｆ１ 、 21)-C(=O)NR ５０ R ５１ ,or 22)-NR ｅ１ R ｆ１ (However, R ５ is the substituent of said 22), -L ３ -L ４ -R ５ is -(CH ２ ) １－４ NR ｅ１ R ｆ１ (In the formula, R ｅ１ , R ｆ１ is a hydrogen atom, an optionally substituted C １－４ Alkyl, optionally substituted C ３－７ an alicyclic group, an optionally substituted 4- to 10-membered non-aryl heterocyclic group, an optionally substituted C ６－１０ aryl, or optionally substituted 5-10 membered heteroaryl) Either R ２０ａ teeth, 1) C １－６ alkyl groups, 2) C ３－１０ Alicyclic groups, 3) C ６－１０ aryl, 4) a 5- or 6-membered heteroaryl, or 5) 4- to 10-membered non-aryl heterocycle (However, each of the substituents 1) to 5) above may be substituted.) Either R ５０ teeth, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) hydroxyl group, 4) C １－６ alkoxy groups, 5) C ３－６ cycloalkoxy groups, 6) C ３－６ Alicyclic groups, 7) 4-6 membered non-aryl heterocycles, 8) C ６－１０ aryl, 9) 5- to 10-membered heteroaryl 10) 4-6 membered non-aryl heterocycleoxy, 11) C ６－１０ aryloxy, 12) 5- to 10-membered heteroaryloxy, 13) C １－６ alkylsulfonyl groups, 14) C ３－６ a cycloalkoxysulfonyl group, or 15) 4- to 6-membered non-aryl heterocyclic sulfonyl group (However, each of the substituents in 2) and 4) to 15) above may be substituted.) represents one of the following: R ５１ teeth, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－６ Alicyclic groups, 4) 4-6 membered non-aryl heterocycles; 5) C ６－１０ aryl, or 6) 5- to 10-membered heteroaryl (However, each of the substituents 2) to 6) above may be substituted.) represents one of the following: Or, R ５０ and R ５１ and may be taken together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle, R ｄ２ , R ｅ１ , R ｆ１ , R ｇ１ and R ｈ１ are each independently the same or different, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－１０ Alicyclic groups, 4) C ６－１０ aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4- to 10-membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R ｅ１ and R ｆ１ When the combination of the following is attached to the same nitrogen atom, they may be taken together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle; The "optionally substituted" substituent is selected from the following substituent group α, and may be substituted with 1 to 5 identical or different substituents. Although there are no particular limitations on the type of substituent, when the atom to which the substituent is bonded is an oxygen atom, a nitrogen atom, or a sulfur atom, the substituent is limited to those listed below in which the atom to which the substituent is bonded is a carbon atom. The substituent group α is 1) Halogen atoms 2) Hydroxyl group 3) Carboxyl group 4) Cyano group 5) C 1-6 alkyl group 6) C2-6 alkenyl group 7) C 2-6 alkynyl group 8) C 1-6 alkoxy group 9) C 1-6 alkylthio group 10) C 1-6 alkylcarbonyl group 11) C 1-6 alkylsulfonyl group (However, each of the substituents 5) to 11) may be substituted with 1 to 5 identical or different substituents selected from Substituent Group β.) 12) C 3-10 alicyclic group 13) C3-10 alicyclic oxy group 14) C 6-10 aryloxy group 15) a 5- or 6-membered heteroaryloxy group 16) 4- to 10-membered non-aryl heterocyclic oxy group 17) C3-10 alicyclic thio group 18) C 6-10 arylthio group 19) a 5- or 6-membered heteroarylthio group 20) 4- to 10-membered non-aryl heterocyclic thio group 21) C6-10 aryl 22) 5- or 6-membered heteroaryl 23) 4- to 10-membered non-aryl heterocycle 24) C3-10 alicyclic carbonyl group 25) C 6-10 arylcarbonyl group 26) a 5- or 6-membered heteroarylcarbonyl group 27) 4- to 10-membered non-aryl heterocyclic carbonyl group 28) C3-10 alicyclic sulfonyl group 29) C 6-10 arylsulfonyl group 30) a 5- or 6-membered heteroarylsulfonyl group 31) 4- to 10-membered non-aryl heterocyclic sulfonyl group (However, each of the substituents 12) to 31) may be substituted with 1 to 5 of the substituent group β or the C 1-6 alkyl group 1). 32)-NR 10a R 11a 33) -SO 2 -NR 10b R 11b 34) -NR 10c -C(=O)R 11c 35) -NR 10d -C(=O)OR 11d 36) -NR 12a -C(=O)NR 10e R 11e 37) -NR 10f -C(=S)R 11f 38) -NR 10g -C(=S)OR 11g, 39) -NR 12b -C(=S)NR 10h R 11h 40) -NR 10i -SO 2 -R 11i 41) -NR 12c -SO 2 -NR 10j R 11j 42)-C(=O)OR 10k 43)-C(=O)NR 10l R 11k 44)-C(=O)NR 10m OR 11l 45) -C(=O)NR 12d -NR 10n R 11m 46)-C(=S)OR 10o 47)-C(=S)NR 10p R 11n 48)-C(=S)NR 10q OR 11o 49) -C(=S)NR 12e -NR 10r R 11p 50)-C(=NR 13a )R 10s 51)-C(=NR 13b )CHO 52) -C (=NR 13c ) NR 10t R 11q 53) -C (=NR 13d )NR 12f -NR 10u R 11r 54) -NR 17c -C (=NR 13k )R 17d 55) -NR 12g -C (=NR 13e) -NR 10v R 11s 56) -NR 14 -C (=NR 13f ) -NR 12h -NR 10w R 11t 57)-OC(=O)R 10x 58)-OC(=O)OR 10y 59)-OC(=O)NR 10z1 R 11u 60) -NR 12i -NR 10z2 R 11v 61)-NR 10z3 OR 11w 62)-C(=N-OR 13a)R 10s 63)-C(=N-OR 13b)CHO 64)-C(=N-OR 13c)NR 10t R 11q 65) -C(=N-OR 13d)NR 12f -NR 10u R 11r are listed, The substituent group β is 1) a halogen atom, 2) hydroxyl group, 3) a carboxyl group, 4) a cyano group, 5) C 3-10 alicyclic group, 6) a C 1-6 alkoxy group, 7) a C 3-10 alicyclic oxy group, 8) a C 1-6 alkylthio group, 9) a 5- or 6-membered heteroarylthio group; 10) C 6-10 aryl, 11) 5- or 6-membered heteroaryl; 12) 4-10 membered non-aryl heterocycles; 13) a C 1-6 alkylcarbonyl group, 14) a C 3-10 alicyclic carbonyl group, 15) a C 6-10 arylcarbonyl group, 16) a 5- or 6-membered heteroarylcarbonyl group, 17) a 4- to 10-membered non-aryl heterocyclic carbonyl group, 18)-NR 15a R 16a , 19) -SO 2 -NR 15b R 16b , 20) -NR 15c -C(=O)R 16c 21) -NR 17a -C(=O)NR 15d R 16d, 22)-C(=O)NR 15e R 16e , 23)-C(=NR 13g )R 15f , 24)-C(=NR 13h)NR 15g R 16f 25) -NR 16g -C(=NR 13i)R 15h 26) -NR 17b -C (=NR 13j ) -NR 15i R 16h 27) -C(=N-OR 13g)R 15f, 28)-C(=N-OR 13h)NR 15g R 16f (wherein, in the substituent group β, each of the substituents 5) to 17) may be substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a carboxyl group, and —NR 18a R 18b ), R 13a , R 13b , R 13c , R 13d , R 13e , R 13f , R 13g , R 13h , R 13i , R 13j and R 13k are each independently the same or different and represent a hydrogen atom, a hydroxyl group, a C 1-6 alkyl group or a C 1-6 alkoxy group; R10a, R10b, R10c, R10d, R10e, R10f, R10g, R10h, R10i, R10j, R10k, R10l, R10m, R10n, R10o, R10p, R 10q , R 10r , R 10s , R 10t , R 10u , R 10v , R 10w , R 10x , R 10y , R 10z1 , R 10z2 , R 10z3 , R 11a , R 11b , R 11c , R 11d , R 11e , R 11f , R 11g , R 11h , R 11i , R 11j , R 11k , R 11l , R 11m , R 11n , R 11o , R 11p , R 11q , R 11r , 11s , R 11t , R 11u , R 11v , R 11w, R 12a, R 12b, R 12c, R 12d, R 12e, R 12f, R 12g, R 12h, R 12i, R 14, R 15a, R 15b, R 15c, R 15d, R 15e, R 15f, R 15g, R 15h, R 15i, R 16a, R 16b, R 16c, R 16d, R 16e, R 16f, R 16g, R 16h, R 17a, R 17b, R 17c and R 17d are each independently the same or different and represent a hydrogen atom or a C 1-6 alkyl group (which may be substituted by 1 to 3 identical or different substituents selected from a hydroxyl group, a cyano group, a C 1-6 alkoxy group and —NR 18a R 18b ); R 18a and R 18b are each independently the same or different and represent a hydrogen atom or a C 1-6 alkyl group.] or a pharmaceutically acceptable salt thereof.

2. L ３ but, 1) C １－６ an alkylene group, 2) C ３－１０ a cycloalkylene group, 3) a 4- to 10-membered non-aryl heterocyclylene group (However, each of the substituents 1) to 3) above may be substituted.) Either L ４ represents a single bond or an optionally substituted C １－５ is an alkylene group, The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

3. L ３ is optionally substituted C １－４ is an alkylene group, L ４ represents a single bond or an optionally substituted C １－３ is an alkylene group, The compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

4. L ３ But, -(CR ３０ R ３１ ) ｎ１ - and R ３０ and R ３１ are each independently, and if there are multiple of them, they are all independently, 1) a hydrogen atom, 2)-NR ａ７ R ａ８ 、 3) C １－４ alkyl groups, 4) C ６－１０ aryl, 5) 5- to 10-membered heteroaryl; 6) C ３－６ Alicyclic groups, 7) 4- to 10-membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR ｃ２ or R ３０ and R ３１ together with the carbon atoms to which they are attached form C ３－６ forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R ａ７ and R ａ８ are each independently the same or different, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－１０ Alicyclic groups, 4) C ６－１０ Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycles; 7) C １－６ alkylcarbonyl groups, 8) C ３－１０ alicyclic carbonyl groups, 9) C ６－１０ arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11) C １－６ alkylsulfonyl groups, 12) C ３－１０ alicyclic sulfonyl groups, 13) C ６－１０ arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group, or 15)-OR ｃ３ 、 (wherein each of the substituents 2) to 14) above may be substituted), Here, R ａ７ and R ａ８ may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R ｃ２ and R ｃ３ are each independently 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－１０ Alicyclic groups, 4) C ６－１０ aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4- to 10-membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted), n1 is an integer of 1, 2, 3, or 4; L ４ But, -(CR ４０ R ４１ ) ｎ２ - and R ４０ and R ４１ are each independently, and if there are multiple of them, they are all independently, 1) a hydrogen atom, 2)-NR ａ９ R ａ１０ 、 3) C １－４ alkyl groups, 4) C ６－１０ aryl, 5) 5- to 10-membered heteroaryl; 6) C ３－６ Alicyclic group 7) 4- to 10-membered non-aryl heterocycle (However, each of the substituents 3) to 7) above may be substituted), or 8)-OR ｃ４ or R ４０ and R ４１ together with the carbon atoms to which they are attached form C ３－６ forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R ａ９ and R ａ１０ are each independently the same or different, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－１０ Alicyclic groups, 4) C ６－１０ Aryl 5) 5- or 6-membered heteroaryl; 6) 4-10 membered non-aryl heterocycles; 7) C １－６ alkylcarbonyl groups, 8) C ３－１０ alicyclic carbonyl groups, 9) C ６－１０ arylcarbonyl groups, 10) a 5- or 6-membered heteroarylcarbonyl group, 11) C １－６ alkylsulfonyl groups, 12) C ３－１０ alicyclic sulfonyl groups, 13) C ６－１０ arylsulfonyl groups, 14) a 5- or 6-membered heteroarylsulfonyl group (However, each of the substituents 2) to 14) above may be substituted), or 15)-OR ｃ５ 、 Either Here, R ａ９ and R ａ１０ may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, R ｃ４ and R ｃ５ are each independently the same as R ｃ２ and R ｃ３ is synonymous with n2 is 0 (i.e., L ４ is a single bond), an integer of 1, 2, or 3, The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

5. -L ３ -L ４ - is optionally substituted C １－２ The compound according to any one of claims 1 to 4, which is an alkylene group, wherein the "optionally substituted" substituent is as defined in claim 1, or a pharmaceutically acceptable salt thereof.

6. -L ３ -L ４ - but C １－３ It may be substituted with any one of an alkyl group, an amino group, and a hydroxymethyl group, or with a plurality of the same or different groups among them (wherein two C １－３ If the alkyl groups are attached to the same carbon atom, then together with the carbon atoms to which they are attached, they form a C ３－６ may form an alicyclic group) C １－２ The compound according to any one of claims 1 to 5, which is an alkylene group, or a pharmaceutically acceptable salt thereof.

7. R ５ but, 1) C ３－１０ Alicyclic groups, 2) C ６－１０ aryl, 3) 5- to 10-membered heteroaryl; 4) C １－６ alkylthio groups, (However, each of the substituents 1) to 4) above may be substituted, and when two substituents further substituted on the substituent 2) or 3) above are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a condensed ring structure.) 5)-NR ｅ１ Oh, 6)-C(=O)NR ５０ R ５１ 、 7)-SO ２ -NR ｅ１ R ｆ１ 、 8)-NR ｅ１ -SO ２ -R ｆ１ 、 9)-C(=O)OR ２０ ,or 10) -NR ｅ１ R ｆ１ (However, R ５ When the substituent of 10) is L ３ and / or L ４ is a C group that is necessarily substituted with one or more groups other than a hydrogen atom １－６ an alkylene group (where L ３ or L ４ together with the substituent, C ３－１０ It may form an alicyclic group or a 4- to 10-membered non-aryl heterocycle. Either R ２０ teeth, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－１０ Alicyclic groups, 4) C ６－１０ aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4- to 10-membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

8. R ５ teeth, 1) C ６－１０ aryl, 2) 5- to 10-membered heteroaryl; 3)-C(=O)NR ５０ R ５１ 、 4)-C(=O)OR ２０ ,or 5) -NR ｅ１ R ｆ１ (However, R ５ When the substituent is the substituent of 5), L ３ and / or L ４ is a C group that is necessarily substituted with one or more groups other than a hydrogen atom １－６ an alkylene group, and together with the substituent, at least one C ３－１０ forming an alicyclic group or a 4- to 10-membered non-aryl heterocycle) (However, each of the substituents in 1) and 2) above may be substituted, and when any two of these groups are bonded to adjacent atoms in the ring, they may be joined together to form a fused ring structure.) Either The compound according to any one of claims 1 to 7, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1, or a pharmaceutically acceptable salt thereof.

9. L ３ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: is —C(═O)—.

10. L ４ is a single bond, -C(=N-OR ｈ１ )- or optionally substituted C １－６ an alkylene group, where R ｈ１ is optionally substituted C １－６ is an alkyl group, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1, or a pharmaceutically acceptable salt thereof.

11. The compounds of formula (6a) and (6b) are each The following formulas (7a) and (7b): 【Chemical 743】 Or, the following formulas (8a) and (8b): 【Chemical 744】 [In formulas (7a), (7b), (8a) and (8b), L ３ , L ４ , R ５ , m and n are defined in any one of claims 1 to 10.] 2. The compound according to claim 1, wherein the compound is any one of the optical isomers represented by the formula:

12. L ３ But, -(CR ３０ R ３１ ) ｎ１ - or 4- to 10-membered non-aryl heterocyclylene; R ３０ and R ３１ are each independently, and if there are multiple of them, they are all independently, 1) a hydrogen atom, 2) optionally substituted C １－４ an alkyl group, or 3) optionally substituted C ６－１０ Aryl represents one of the following: n1 is 1, 2 or 3; L ４ is a single bond or -(CR ４０ R ４１ ) ｎ２ - and R ４０ and R ４１ are each independently, and if there are multiple of them, they are all independently, 1) a hydrogen atom, 2)-NR ａ９ R ａ１０ 、 3) optionally substituted C １－４ an alkyl group, or 4)-OR ｃ４ or R ４０ and R ４１ together with the carbon atoms to which they are attached form C ３－６ forming an alicyclic group or a 4- to 6-membered non-aryl heterocycle, R ａ９ , R ａ１０ and R ｃ４ are each independently the same or different, 1) a hydrogen atom, 2) optionally substituted C １－６ alkyl groups, 3) optionally substituted C ３－１０ alicyclic group, Either Here, R ａ９ and R ａ１０ may be joined together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, n2 is 0, 1 or 2; The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, claims 7 to 8, and claim 11, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

13. n1 is 1 or 2, and n2 is 0 or 1; 13. The compound of claim 12 or a pharmaceutically acceptable salt thereof.

14. L ３ But, -CR ３０ R ３１ - or 4- to 10-membered non-aryl heterocyclylene; R ３０ and R ３１ are each independently 1) a hydrogen atom, 2) C １－４ Alkyl groups (the groups are halogen, -NR ａ１１ R ａ１２ , or -OR ｃ６ (optionally substituted with), or 3) C ６ Aryl (the group is halogen, —NR ａ１３ R ａ１４ , -OR ｃ７ , or C １－３ Alkyl groups (the groups are halogen, -NR ａ１５ R ａ１６ , or -OR ｃ８ (optionally substituted with) (optionally substituted with) represents one of the following: L ４ is a single bond or -(CR ４０ R ４１ ) ｎ２ - and R ４０ and R ４１ are each independently 1) a hydrogen atom, 2)-NR ａ９ R ａ１０ 、 3) C １－４ Alkyl groups (the groups are halogen, -NR ａ１７ R ａ１８ , or -OR ｃ９ (optionally substituted with), or 4)-OR ｃ４ or R ４０ and R ４１ together with the carbon atoms to which they are attached form C ３－６ forming an alicyclic group, R ａ９ , R ａ１０ , R ａ１１ , R ａ１２ , R ａ１３ , R ａ１４ , R ａ１５ , R ａ１６ , R ａ１７ , R ａ１８ , R ｃ４ , R ｃ６ , R ｃ７ , R ｃ８ and R ｃ９ are each independently the same or different, 1) a hydrogen atom, 2) C １－４ Alkyl groups (the groups are halogen, -NR ａ１９ R ａ２０ , or -OR ｃ１０ and optionally substituted with represents one of the following: R ａ１９ , R ａ２０ and R ｃ１０ are each independently the same or different, 1) a hydrogen atom, or 2) C １－４ an alkyl group (which may be substituted with halogen); represents one of the following: Here, R ａ９ and R ａ１０ , R ａ１１ and R ａ１２ , R ａ１３ and R ａ１４ , R ａ１５ and R ａ１６ , R ａ１７ and R ａ１８ , or R ａ１９ and R ａ２０ each combination of may be taken together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle; n2 is 0 or 1; Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, claims 7 to 10, and claims 11 to 13.

15. L ３ But -CH ２ -, -CH(CH ２ NH ２ ) - or -CH(CH ２ OH)—, L ４ is a single bond, -CH ２ -, -CH(NH ２ )-,-CMe(NH ２ )-,-CEt(NH ２ )-, -C(iso-Pr)(NH ２ ) -, -CH(CH ２ NH ２ )-, -CH(OH)-, -CH(CH ２ OH)-, -C(CH ２ OH) ２ -,or 【Chemical 745】 The compound according to any one of claims 1 to 4, 7 to 8, and 11 to 14, wherein:

16. L ３ The compound according to any one of claims 1 to 4, claims 7 to 8, and claims 11 to 14, wherein is a 4- to 10-membered non-arylheterocyclylene, or a pharmaceutically acceptable salt thereof.

17. L ３ The compound according to any one of claims 1 to 4, 7 to 8, 11 to 14, and 16, wherein is a 5-membered non-arylheterocyclylene, or a pharmaceutically acceptable salt thereof.

18. L ３ but, 【Chemical 746】 【Hua747】 【Chemical 748】 or 【Chemical 749】 The compound according to any one of claims 1 to 4, 7 to 8, 11 to 14, and 16 to 17, or a pharmaceutically acceptable salt thereof.

19. L ４ is a single bond, or a pharmaceutically acceptable salt thereof.

20. R ５ teeth, 1) C ６－１０ aryl, or 2) 5- to 10-membered heteroaryl; (wherein each of the substituents 1) and 2) above may be substituted, and when two further substituents on the substituents 1) or 2) are substituted on adjacent atoms in the ring, the two substituents may be joined together to form a condensed ring structure), The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and claims 11 to 15, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

21. R ５ is C ６ aryl (i.e., phenyl) or a 5-, 6-, 9-, or 10-membered heteroaryl; These R ５ Each group of R is substituted at all chemically substitutable positions on the carbon or nitrogen atoms in the ring. ６ａ or R ６ｂ and Here, R is a substituent on a carbon atom. ６ａ If there are multiple instances of a ring, they are all independently 1) a hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C １－４ alkyl groups, 6) C ３－１０ Alicyclic groups, 7) C １－４ alkoxy groups, 8) C ３－１０ alicyclic oxy groups, 9) C ６－１０ aryloxy groups, 10) a 5- or 6-membered heteroaryloxy group, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO ２ -NR ｅ２ R ｆ２ 、 13)-NR ｇ２ -CR ｅ２ (=NR) ｆ２ ) 14)-NR ｇ２ -CR ｅ２ (=N-OR ｆ２ )、 15)-NR ｈ２ -C(=NR) ｇ２ )NR ｅ２ R ｆ２ 、 16)-NR ｈ２ -C(=N-OR ｇ２ )NR ｅ２ R ｆ２ 、 17)-NR ｉ２ -C(=NR) ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 18)-NR ｉ２ -C(=N-OR ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 19)-C(=NR ｅ２ )R ｆ２ 、 20)-C(=N-OR ｅ２ )R ｆ２ 、 21)-C(=NR) ｈ２ )-NR ｅ２ R ｆ２ 、 22)-C(=NR) ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 23)-C(=N-OR ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 24)-NR ｅ２ R ｆ２ 、 25)-NR ｇ２ -NR ｅ２ R ｆ２ 、 26)-NR ｅ２ OR ｆ２ 、 27)-NR ｅ２ -C(=O)R ｆ２ 、 28)-C(=O)NR ｅ２ R ｆ２ 、 29)-C(=O)NR ｅ２ OR ｆ２ 、 30)-C(=O)NR ｇ２ -NR ｅ２ R ｆ２ 、 31)-C(=O)R ｅ２ 、 32)-C(=O)OR ｅ２ , and 33)-C(=N-OR ｈ２ )NR ｅ２ R ｆ２ selected from the group consisting of R is a substituent on the nitrogen atom ６ｂ If there are multiple instances of a ring, they are all independently 1) a hydrogen atom, 2) hydroxyl group, 3) C １－４ alkyl groups, (However, the alkyl group may be substituted.) 4) C ３－１０ Alicyclic groups, (However, the alicyclic group may be substituted.) 5)-C(=NR ｅ２ )R ｆ２ 、 6)-C(=N-OR ｅ２ )R ｆ２ 、 7)-SO ２ -NR ｅ２ R ｆ２ 、 8)-C(=R) ｈ２ )-NR ｅ２ R ｆ２ 、 9)-C(=R) ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 10)-C(=N-OR ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 11)-C(=O)NR ｅ２ R ｆ２ 、 12)-C(=O)NR ｅ２ OR ｆ２ 、 13) - C (=O) NR ｇ２ -NR ｅ２ R ｆ２ 、 14)-C(=O)R ｅ２ , and 15)-C(=N―OR ｈ２ )NR ｅ２ R ｆ２ selected from the group consisting of Or, two R ６ａ or R ６ａ and R ６ｂ when they are each substituted on adjacent atoms in a ring, the two substituents may be taken together to form an optionally substituted 5- to 6-membered heteroaryl ring or an optionally substituted 5- to 7-membered non-aryl heterocycle which is further fused to the bond between the adjacent atoms in the ring; R ｅ２ , R ｆ２ , R ｇ２ , R ｈ２ , and R ｉ２ are each independently the same or different, 1) a hydrogen atom, 2) C １－６ alkyl groups, 3) C ３－１０ Alicyclic groups, 4) C ６－１０ aryl, 5) a 5- or 6-membered heteroaryl, or 6) 4- to 10-membered non-aryl heterocycle (However, each of the substituents 2) to 6) above may be substituted.) Either R ｅ２ and R ｆ２ When the combination of the following is attached to the same nitrogen atom, they may be taken together to form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle; The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and claims 11 to 20, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

22. R ５ is as follows: 【Chemistry 750】 【Chemistry 751】 【Chemical 752】 【Chemical 753】 【Chemical 754】 【Chemistry 755】 C is selected from the group consisting of ６ aryl or 5-, 6-, 9-, or 10-membered heteroaryl; d is R ６ａ is the number of chemically substitutable positions on the ring of each group, Each R ６ａ and each R ６ｂ is as defined in claim 21 The compound according to any one of claims 1 to 8 and 11 to 21, or a pharmaceutically acceptable salt thereof.

23. R ６ａ If there are multiple instances of a ring, they are all independently 1) a hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C １－４ alkyl groups, (However, the alkyl group is NR ｅ２ R ｆ２ , -C(=O)OR ｆ２ , —C(═O)NR ｅ２ R ｆ２ , —C(═O)NR ｅ２ (OR ｆ２ ), or may be substituted with a hydroxyl group) 5) C １－４ alkoxy group 6)-NR ｅ２ R ｆ２ 、 7)-C(=O)NR ｅ２ R ｆ２ , and 8)-C(=O)OR ｅ２ selected from the group consisting of Each R ６ｂ If there are multiple instances of a ring, they are all independently 1) a hydrogen atom, 2) a hydroxyl group, and 3) C １－４ alkyl groups, (However, the alkyl group is NR ｅ２ R ｆ２ , -C(=O)OR ｆ２ , —C(═O)NR ｅ２ R ｆ２ , —C(═O)NR ｅ２ (OR ｆ２ ), or may be substituted with a hydroxyl group) selected from the group consisting of 23. The compound according to claim 21 or 22, or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

24. R ｅ２ and R ｆ２ are each independently the same or different and represent a hydrogen atom, an optionally substituted C １－６ an alkyl group or an optionally substituted C ３－１０ is an alicyclic group, The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and claims 11 to 23, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

25. R ｅ２ and R ｆ２ are each independently the same or different and represent a hydrogen atom or an optionally substituted C １－６ is an alkyl group, The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and claims 11 to 24, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

26. R ｅ２ and R ｆ２ The compound according to any one of claims 1 to 8 and 11 to 25, or a pharmaceutically acceptable salt thereof, wherein: is a hydrogen atom.

27. R ６ａ is -NR ｅ２ R ｆ２ and R ｅ２ and R ｆ２ is a hydrogen atom on one side and a C atom on the other side. １－４ The compound according to any one of claims 21 to 26, wherein the alkyl group is an alkyl group (provided that the alkyl group may be substituted with an amino group or a hydroxyl group), or a pharmaceutically acceptable salt thereof.

28. R ５ is -C(=O)NR ５０ R ５１ The compound according to any one of claims 1 to 8 and 11 to 19, or a pharmaceutically acceptable salt thereof.

29. R ５０ teeth, 1) a hydrogen atom, 2) optionally substituted C １－４ alkyl groups, 3) hydroxyl group, 4) optionally substituted C １－４ an alkoxy group, or 5) optionally substituted C １－６ alkylsulfonyl groups, represents one of the following: R ５１ teeth, 1) a hydrogen atom, or 2) optionally substituted C １－４ Alkyl group represents one of the following: Or, R ５０ and R ５１ may be joined together to form a 4- to 6-membered nitrogen-containing non-aryl heterocycle, The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, 11 to 15, and 28, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

30. R ５０ teeth, 1) a hydrogen atom, 2) C １－４ Alkyl group (the group is halogen, C ３－６ Alicyclic group, -NR ａ２１ R ａ２２ , or -OR ｃ１１ and optionally substituted with 3) hydroxyl group, 4) C １－４ Alkoxy groups (the groups are halogen, C ３－６ Alicyclic group, -NR ａ２３ R ａ２４ , or -OR ｃ１２ (optionally substituted with), or 5) C １－４ Alkylsulfonyl group (the group is halogen, C ３－６ Alicyclic group, -NR ａ２１ R ａ２２ , or -OR ｃ１１ and optionally substituted with represents one of the following: R ａ２１ , R ａ２２ , R ａ２３ , R ａ２４ , R ｃ１１ and R ｃ１２ are each independently the same or different, 1) a hydrogen atom, or 2) C １－４ an alkyl group (which may be substituted with halogen); represents one of the following: Here, R ａ２１ and R ａ２２ , or R ａ２３ and R ａ２４ each combination of may be taken together to form an optionally substituted 4- to 7-membered nitrogen-containing non-aryl heterocycle; R ５１ is a hydrogen atom or C １－４ alkyl (which may be substituted with halogen); Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1 to 8, 11 to 17, and 28 to 29, or a pharmaceutically acceptable salt thereof.

31. R ５０ teeth, 1) a hydrogen atom, 2) C １－４ Alkyl groups (such as cyclopropyl groups, -NH ２ , -NHMe, -C(=O)NH ２ , -C(=O)NHMe, -C(=O)NMe ２ or -hydroxyl group), 3) a hydroxyl group, or 4) C １－４ Alkoxy groups (such as cyclopropyl groups, -NH ２ , -NHMe or -hydroxyl group), 5) C １－４ alkylsulfonyl groups, represents one of the following: R ５１ is a hydrogen atom, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1 to 8, 11 to 17, and 28 to 30, or a pharmaceutically acceptable salt thereof.

32. R ５ is -C(=O)OR ２０ The compound according to any one of claims 1 to 8 and 11 to 15, wherein:

33. R ２０ teeth, 1) a hydrogen atom, or 2) optionally substituted C １－４ alkyl groups, Either 33. The compound according to claim 32, or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent is as defined in claim 1.

34. L ３ But -CH ２ - and L ４ is a single bond, -CH(NH ２ ) - or -CMe(NH ２ 34. The compound according to claim 31 or 33, or a pharmaceutically acceptable salt thereof, wherein:

35. L ４ but, 【Chemical 756】 、 【Chemical 757】 、 【Chemical 758】 or 【Chemical 759】 35. The compound of claim 34, wherein:

36. L ４ but, 【Hua760】 or 【Chemical 761】 36. The compound of claim 34 or claim 35, wherein:

37. R ２０ The compound according to any one of claims 32 to 36, or a pharmaceutically acceptable salt thereof, wherein is a hydrogen atom.

38. R ５ But, -NR ｅ１ R ｆ１ and L ３ But -CH ２ - and L ４ is -CR ４０ R ４１ - and R ４０ and R ４１ each independently represents a C substituted with a hydroxyl group; １－４ alkyl groups or, together with the carbon atom to which they are attached, C ３－６ The compound according to any one of claims 1 to 8 and 11 to 15, or a pharmaceutically acceptable salt thereof, which forms an alicyclic group.

39. R ｅ１ and R ｆ１ are each independently the same or different, 1) a hydrogen atom, or 2) optionally substituted C １－３ alkyl groups, Either L ４ teeth, 【Chemical 762】 and 39. The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent is as defined in claim 1.

40. R ｅ１ and R ｆ１ are each independently the same or different, 1) a hydrogen atom, or 2) optionally substituted C １－３ alkyl groups, Either L ４ is a C substituted with a hydroxyl group １－４ is an alkylene group, 39. The compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein the "optionally substituted" substituent is as defined in claim 1.

41. L ４ is a single bond or -NR ２１ R ２２ Or = NOR ２３ C optionally substituted with １－６ an alkylene group, where R ２１ , R ２２ and R ２３ are each independently a hydrogen atom, an optionally substituted C １－６ an alkyl group or an optionally substituted 4- to 10-membered non-aryl heterocyclic carbonyl group, The compound according to any one of claims 1 and 9 to 11, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1, or a pharmaceutically acceptable salt thereof.

42. L ４ is a single bond, -CH ２ -, -CH(NH ２ )-,-CMe(NH ２ )-, -CH(NHMe)-, -CD(NH ２ )-(wherein D represents a deuterium atom), -CH ２ CH ２ -, or -CH(NH ２ )-CH ２ -, where L ４ When an amino group is present in the ３ 42. The compound according to any one of claims 1, 8 to 11, and 41, or a pharmaceutically acceptable salt thereof, which binds to:

43. L ３ is —C(═O)—, L ４ is a single bond, -CH ２ -, -CH(NH ２ )-,-CMe(NH ２ ) -, or -CH(NH ２ )-CH ２ 43. The compound of claim 42, wherein: - or a pharmaceutically acceptable salt thereof.

44. L ４ but, 【Chemical 763】 、 【Chemical 764】 、 【Chemical 765】 【Chemical 766】 、 【Chemical 767】 、 【Chemical 768】 【Chemical 769】 ,or 【Chemical 770】 or a pharmaceutically acceptable salt thereof.

45. L ４ but, 【Chemical 771】 or 【Chemical 772】 45. The compound of claim 43 or claim 44, wherein:

46. L ４ but, 【Chemical 773】 or 【Chemical 774】 45. The compound of claim 43 or claim 44, wherein:

47. L ４ but, 【Chemical 775】 or 【Chemical 776】 45. The compound of claim 43 or claim 44, wherein:

48. L ４ but, 【Chemical 777】 or 【Chemical 778】 45. The compound of claim 43 or claim 44, wherein:

49. R ５ represents a hydrogen atom, an optionally substituted C １－６ alkyl group, optionally substituted C ３－１０ an alicyclic group, an optionally substituted 4- to 10-membered non-aryl heterocycle, an optionally substituted C ６－１０ Aryl, optionally substituted 5- or 6-membered heteroaryl, optionally substituted C １－６ an alkylthio group, or —NR ｅ１ OH, where R ｅ１ represents a hydrogen atom or an optionally substituted C １－６ is an alkyl group, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, and 41 to 48, or a pharmaceutically acceptable salt thereof.

50. R ５ is an optionally substituted 5- or 6-membered heteroaryl or an optionally substituted C ６－１０ is aryl, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, and 41 to 49, or a pharmaceutically acceptable salt thereof.

51. R ５ is an optionally substituted 5- or 6-membered heteroaryl; Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, and 41 to 50, or a pharmaceutically acceptable salt thereof.

52. R ５ is an optionally substituted C ４－１０ an alicyclic group or an optionally substituted 4- to 10-membered non-aryl heterocycle, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, and 41 to 51, or a pharmaceutically acceptable salt thereof.

53. L ４ is a single bond, and R ５ is -NR ｅ１ OH, where R ｅ１ represents a hydrogen atom or an optionally substituted C １－６ is an alkyl group, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, and 41 to 49, or a pharmaceutically acceptable salt thereof.

54. L ４ teeth, 1))-(CH ２ ) ｐ -CR １０ (NHR １１ )-、 2) -(CH ２ ) ｑ -CR １２ R １３ -,or 3) -(CH ２ ) ｐ -CR １０ (N.H.R. １１ )-(CH ２ ) ｑ -CR １２ R １３ - (wherein p and q are independently 0 or 1); R １０ teeth, 1) a hydrogen atom, 2) a carboxyl group, 3)-C(=O)NR １０ａ R １０ｂ and R １１ teeth, 1) a hydrogen atom, 2) -C(=O)R １１ａ ,or 3) an optionally substituted 5- or 6-membered non-aryl heterocyclic carbonyl group, However, R １０ -C(=O)NR １０ａ R １０ｂ When R １０ｂ and R １１ Let's get together -CH ２ CH ２ - may be formed, R １２ teeth, 1) a hydrogen atom, or 2) optionally substituted C １－４ is an alkyl group, R １３ teeth, 1) a hydrogen atom, 2) Hydroxyl group 3) optionally substituted C １－４ Alkyl group 4) a sulfanyl group, 5) a carboxyl group, 6) optionally substituted C １－４ alkylthio groups, 7)-NR １３ａ R １３ｂ 、 8)-NR １３ａ -C(=O)R １３ｂ 、 9) an optionally substituted 5- or 6-membered non-aryl heterocyclic carbonylamino group 10)-NR １３ａ -C(=O)NR １３ｂ R １３ｃ 、 11)-C(=O)NR １３ａ R １３ｂ 、 12)-C(=O)NR １３ａ OR １３ｂ 、 13)-S(=O) ２ -R １３ａ 、 14)-S(=O) ２ -NR １３ａ R １３ｂ 、 15)-C(=O)NR １３ａ -S(=O) ２ -R １３ｂ or 16)-C(=O)NR １３ａ -S(=O) ２ -NR １３ｂ R １３ｃ and R １０ａ , R １０ｂ , R １１ａ , R １３ａ , R １３ｂ and R １３ｃ are each independently a hydrogen atom or an optionally substituted C １－４ is an alkyl group, The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 and 8 to 11, wherein the "optionally substituted" substituent has the same meaning as defined in claim 1.

55. R ５ represents a hydrogen atom or an optionally substituted C １－４ is an alkyl group, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1.

55. The compound of claim 54, or a pharmaceutically acceptable salt thereof.

56. R ５ is as follows: 【Chemical 779】 【Hua780】 【Chemical 781】 selected from the group consisting of The subscript d is R ５ is the number of substitutable positions on the ring of Each R ６ａ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) a nitro group, 5) halogens, 6) C １－４ alkyl groups, 7) C ３－１０ Alicyclic groups, 8) C １－４ alkoxy groups, 9) C ３－１０ alicyclic oxy groups, 10) C ６－１０ aryloxy groups, 11) a 5- or 6-membered heteroaryloxy group, 12) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 6) to 12) above may be substituted.) 13)-SO ２ -NR ｅ２ R ｆ２ 、 14)-NR ｇ２ -CR ｅ２ (=NR) ｆ２ ) 15)-NR ｇ２ -CR ｅ２ (=N-OR ｆ２ )、 16)-NR ｈ２ -C(=NR) ｇ２ )NR ｅ２ R ｆ２ 、 17)-NR ｈ２ -C(=N-OR ｇ２ )NR ｅ２ R ｆ２ 、 18)-NR ｉ２ -C(=NR) ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 19)-NR ｉ２ -C(=N-OR ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 20)-C(=NR ｅ２ )R ｆ２ 、 21)-C(=N-OR ｅ２ )R ｆ２ 、 22)-C(=NR) ｈ２ )-NR ｅ２ R ｆ２ 、 23)-C(=R) ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 24)-C(=N-OR ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 25)-NR ｅ２ R ｆ２ 、 26)-NR ｇ２ -NR ｅ２ R ｆ２ 、 27)-NR ｅ２ OR ｆ２ 、 28)-NR ｅ２ -C(=O)R ｆ２ 、 29)-C(=O)NR ｅ２ R ｆ２ 、 30)-C(=O)NR ｅ２ OR ｆ２ 、 31)-C(=O)NR ｇ２ -NR ｅ２ R ｆ２ 、 32)-C(=O)R ｅ２ 、 33)-C(=O)OR ｅ２ , and 34)-C(=N-OR ｈ２ )NR ｅ２ R ｆ２ selected from the group consisting of Each R ６ｂ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) C １－４ alkyl groups, (However, the alkyl group may be substituted.) 4) C ３－１０ Alicyclic groups, (However, the alicyclic group may be substituted.) 5)-C(=NR ｅ２ )R ｆ２ 、 6)-C(=N-OR ｅ２ )R ｆ２ 、 7)-SO ２ -NR ｅ２ R ｆ２ 、 8)-C(=R) ｈ２ )-NR ｅ２ R ｆ２ 、 9)-C(=R) ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 10)-C(=N-OR ｈ２ )NR ｇ２ -NR ｅ２ R ｆ２ 、 11)-C(=O)NR ｅ２ R ｆ２ 、 12)-C(=O)NR ｅ２ OR ｆ２ 、 13) - C (=O) NR ｇ２ -NR ｅ２ R ｆ２ 、 14)-C(=O)R ｅ２ , and 15)-C(=N―OR ｈ２ )NR ｅ２ R ｆ２ selected from the group consisting of Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, and 41 to 51, or a pharmaceutically acceptable salt thereof.

57. R ５ is as follows: 【Chemical 782】 【Chemical 783】 【Chemical 784】 is a 5- or 6-membered aryl or heteroaryl selected from the group consisting of The subscript d is R ５ is the number of substitutable positions on the ring of Each R ６ａ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C １－４ alkyl groups, (However, the alkyl group is NR ｅ２ R ｆ２ , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR ｆ２ or hydroxyl group) 5) C １－４ alkoxy group 6) -NR ｅ２ R ｆ２ , and 7)-C(=O)OR ｅ２ selected from the group consisting of Each R ６ｂ is independent, 1) a hydrogen atom, 2) a hydroxyl group, and 3) C １－４ alkyl groups, (However, the alkyl group is NR ｅ２ R ｆ２ , —C(═O)NR ｅ２ R ｆ２ , -C(=O)OR ｆ２ or may be substituted with a hydroxyl group) The compound according to any one of claims 1, 8 to 11, 41 to 51, and 56, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

58. R ５ but, 【Chemical 785】 The compound according to any one of claims 1, 8 to 11, 41 to 51, and 56 to 57, or a pharmaceutically acceptable salt thereof.

59. R ｅ２ and R ｆ２ are each independently the same or different and represent a hydrogen atom, an optionally substituted C １－６ an alkyl group or an optionally substituted C ３－１０ is an alicyclic group, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, 41 to 51, and 56 to 57, or a pharmaceutically acceptable salt thereof.

60. R ｅ２ and R ｆ２ are each independently the same or different and represent a hydrogen atom or an optionally substituted C １－６ is an alkyl group, Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, 41 to 51, 56 to 57, and 59, or a pharmaceutically acceptable salt thereof.

61. R ｅ２ and R ｆ２ is a hydrogen atom, or a pharmaceutically acceptable salt thereof.

62. R ６ａ is -NR ｅ２ R ｆ２ and R ｅ２ and R ｆ２ is a hydrogen atom on one side and a C atom on the other side. １－４ The compound according to any one of claims 56 to 57, and claims 59 to 60, wherein the alkyl group is an alkyl group (provided that the alkyl group may be substituted with an amino group or a hydroxyl group), or a pharmaceutically acceptable salt thereof.

63. R ５ is as follows: 【Chemical 786】 【Chemical 787】 is a 4-6 membered non-aryl heterocycle selected from the group consisting of The subscript d is R ５ is the number of substitutable positions on the ring of Each R ７ａ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C １－４ alkyl groups, 6) C ３－１０ Alicyclic groups, 7) C １－４ alkoxy groups, 8) C ３－１０ alicyclic oxy groups, 9) C ６－１０ aryloxy groups, 10) a 5- or 6-membered heteroaryloxy group, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO ２ -NR ｅ３ R ｆ３ 、 13)-NR ｇ２ -CR ｅ３ (=NR) ｆ３ ) 14)-NR ｇ２ -CR ｅ３ (=N-OR ｆ３ )、 15)-NR ｈ２ -C(=NR) ｇ２ )NR ｅ３ R ｆ３ 、 16)-NR ｈ２ -C(=N-OR ｇ２ )NR ｅ３ R ｆ３ 、 17)-NR ｉ２ -C(=NR) ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 18)-NR ｉ２ -C(=N-OR ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 19)-C(=NR ｅ３ )R ｆ３ 、 20)-C(=N-OR ｅ３ )R ｆ３ 、 21)-C(=NR) ｈ２ )-NR ｅ３ R ｆ３ 、 22)-C(=NR) ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 23)-C(=N-OR ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 24)-NR ｅ３ R ｆ３ 、 25)-NR ｇ２ -NR ｅ３ R ｆ３ 、 26)-NR ｅ３ OR ｆ３ 、 27)-NR ｅ３ -C(=O)R ｆ３ 、 28)-C(=O)NR ｅ３ R ｆ３ 、 29)-C(=O)NR ｅ３ OR ｆ３ 、 30)-C(=O)NR ｇ２ -NR ｅ３ R ｆ３ 、 31)-C(=O)R ｅ３ 、 32)-C(=O)OR ｅ３ , and 33)-C(=N-OR ｈ２ )NR ｅ３ R ｆ３ selected from the group consisting of Each R ７ｂ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) C １－４ alkyl groups, (However, the alkyl group may be substituted.) 4) C ３－１０ Alicyclic groups, (However, the alicyclic group may be substituted.) 5)-C(=NR ｅ３ )R ｆ３ 、 6)-C(=N-OR ｅ３ )R ｆ３ 、 7)-SO ２ -NR ｅ３ R ｆ３ 、 8)-C(=R) ｈ２ )-NR ｅ３ R ｆ３ 、 9)-C(=R) ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 10)-C(=N-OR ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 11)-C(=O)NR ｅ３ R ｆ３ 、 12)-C(=O)NR ｅ３ OR ｆ３ 、 13) - C (=O) NR ｇ２ -NR ｅ３ R ｆ３ 、 14)-C(=O)R ｅ３ , and 15)-C(=N―OR ｈ２ )NR ｅ３ R ｆ３ selected from the group consisting of R ｅ３ , R ｆ３ , R ｇ２ , R ｈ２ and R ｉ２ is R according to claim 1 ｅ２ , R ｆ２ , R ｇ２ , R ｈ２ and R ｉ２ is synonymous with Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, 41 to 49, and 52, or a pharmaceutically acceptable salt thereof.

64. R ５ is as follows: 【Hua788】 【Chemical 789】 is a 4-6 membered non-aryl heterocycle selected from the group consisting of The subscript d is R ５ is the number of substitutable positions on the ring of Each R ７ａ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C １－４ alkyl groups, (However, the alkyl group is NR ｅ３ R ｆ３ , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR ｆ３ or may be substituted with a hydroxyl group) 5) C １－４ alkoxy group 6)-NR ｅ３ R ｆ３ 、 7)-C(=O)OR ｅ３ , and 8) C ６－１０ Aryl 9)-C(=O)NR ｅ３ R ｆ３ selected from the group consisting of Each R ７ｂ is independent, 1) a hydrogen atom, 2) a hydroxyl group, and 3) C １－４ alkyl groups, (However, the alkyl group is NR ｅ３ R ｆ３ , -C(=O)OR ｆ３ or may be substituted with a hydroxyl group) selected from the group consisting of R ｅ３ and R ｆ３ is R according to any one of claims 60 to 62. ｅ２ and R ｆ２ is synonymous with Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, 41 to 49, 52, and 63, or a pharmaceutically acceptable salt thereof.

65. R ５ is as follows: 【Chemical 790】 C selected from the group consisting of ４－６ is cycloalkyl, The subscript d is R ５ is the number of substitutable positions on the ring of Each R ９ａ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) a cyano group, 4) halogens, 5) C １－４ alkyl groups, 6) C ３－１０ Alicyclic groups, 7) C １－４ alkoxy groups, 8) C ３－１０ alicyclic oxy groups, 9) C ６－１０ aryloxy groups, 10) a 5- or 6-membered heteroaryloxy group, 11) a 4- to 10-membered non-aryl heterocyclic oxy group, (However, each of the substituents 5) to 11) above may be substituted.) 12)-SO ２ -NR ｅ３ R ｆ３ 、 13)-NR ｇ２ -CR ｅ３ (=NR) ｆ３ ) 14)-NR ｇ２ -CR ｅ３ (=N-OR ｆ３ )、 15)-NR ｈ２ -C(=NR) ｇ２ )NR ｅ３ R ｆ３ 、 16)-NR ｈ２ -C(=N-OR ｇ２ )NR ｅ３ R ｆ３ 、 17)-NR ｉ２ -C(=NR) ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 18)-NR ｉ２ -C(=N-OR ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 19)-C(=NR ｅ３ )R ｆ３ 、 20)-C(=N-OR ｅ３ )R ｆ３ 、 21)-C(=NR) ｈ２ )-NR ｅ３ R ｆ３ 、 22)-C(=NR) ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 23)-C(=N-OR ｈ２ )NR ｇ２ -NR ｅ３ R ｆ３ 、 24)-NR ｅ３ R ｆ３ 、 25)-NR ｇ２ -NR ｅ３ R ｆ３ 、 26)-NR ｅ３ OR ｆ３ 、 27)-NR ｅ３ -C(=O)R ｆ３ 、 28)-C(=O)NR ｅ３ R ｆ３ 、 29)-C(=O)NR ｅ３ OR ｆ３ 、 30)-C(=O)NR ｇ２ -NR ｅ３ R ｆ３ 、 31)-C(=O)R ｅ３ 、 32)-C(=O)OR ｅ３ , and 33)-C(=N-OR ｈ２ )NR ｅ３ R ｆ３ selected from the group consisting of R ｅ３ , R ｆ３ , R ｇ２ , R ｈ２ and R ｉ２ is R according to claim 21 ｅ２ and R ｆ２ is synonymous with Here, the "optionally substituted" substituent has the same meaning as defined in claim 1. A compound according to any one of claims 1, 8 to 11, 41 to 49, and 52, or a pharmaceutically acceptable salt thereof.

66. R ５ is as follows: 【Chemical 791】 C selected from the group consisting of ４－６ is cycloalkyl, The subscript d is R ５ is the number of substitutable positions on the ring of Each R ９ａ is independent, 1) a hydrogen atom, 2) hydroxyl group, 3) halogens, 4) C １－４ alkyl groups, (However, the alkyl group is NR ｅ３ R ｆ３ , a 5- or 6-membered non-aryl heterocycle, —C(═O)OR ｆ３ or may be substituted with a hydroxyl group) 5) C １－４ alkoxy group 6)-NR ｅ３ R ｆ３ 、 7)-C(=O)OR ｅ３ , and 8) C ６－１０ Aryl 9)-C(=O)NR ｅ３ R ｆ３ selected from the group consisting of R ｅ３ and R ｆ３ is R according to any one of claims 50 to 52. ｅ２ and R ｆ２ The compound according to any one of claims 1, 8 to 11, 41 to 49, 52, and 65, wherein the compound is defined as: or a pharmaceutically acceptable salt thereof.

67. L ４ -CH(NH ２ )-CHR １３ -, and the NH ２ The carbon bonded to L ３ binds to R ５ is a hydrogen atom, R １３ teeth, 11)-NH-C(=O)CH ３ 、 22)-NH-C(=O)NH ２ 、 3)-NH-C(=O)CH(NH ２ )-CH ２ C(=O)NH ２ 、 4)-NH-C(=O)CH ２ -NH ２ 、 5) -NH-C(=O)CH(NH ２ )-CH ２ OH, or 6) a pyrrolidin-2-ylcarbonylamino group; 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

68. L ４ -CH(NH ２ )-CR １２ R １３ -, and the NH ２ The carbon bonded to L ３ binds to R ５ is a hydrogen atom or methyl, R １２ is a hydrogen atom or methyl, R １３ is a benzylthio group or a sulfanyl group, 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

69. L ４ -CH(NH ２ )-(CH ２ ) ｑ -CHR １３ -, q is 0 or 1, and the NH ２ The carbon bonded to L ３ binds to R ５ is a hydrogen atom, R １３ teeth, 1) a carboxyl group, 22)-C(=O)NH ２ 、 3)-C(=O)NH(CH ３ ) 4)-C(=O)N(CH ３ ) ２ 、 5)-C(=O)NH-(CH ２ ) ２ -OH、 6)-C(=O)NH-(CH ２ ) ２ -NH ２ 、 7)-C(=O)NH-S(=O) ２ -CH ３ 、 8)-C(=O)NHOH, 9)-S(=O) ２ -NH ２ 、 10) -S(=O) ２ -CH ３ ,or 11) a hydroxyl group; 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

70. L ４ -CH(NHR １１ )-CH ２ -, and the NHR １１ The carbon bonded to L ３ binds to R ５ is hydrogen, R １１ teeth, 11)-C(=O)CH(NH ２ )-CH ２ C(=O)NH ２ 、 2)-C(=O)CH ２ -NH ２ 、 3)-C(=O)CH(CH ３ )-NH ２ 、 4)-C(=O)CH(NH ２ )-CH ２ OH, or 5) pyrrolidin-2-ylcarbonyl; 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

71. L ４ -CH(NHR １１ )-CH(COOH)-, and the NHR １１ The carbon bonded to L ３ binds to R ５ is hydrogen, R １１ teeth, 11)-C(=O)CH(NH ２ )-CH ２ C(=O)NH ２ 、 2)-C(=O)CH ２ -NH ２ 、 3)-C(=O)CH(CH ３ )-NH ２ 、 4)-C(=O)CH(NH ２ )-CH ２ OH, or 5) pyrrolidin-2-ylcarbonyl; 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

72. L ４ Ha-CHR １３ - or -CH ２ -CHR １３ - and R ５ is hydrogen, R １３ is -C(=O)NH ２ or —C(═O)NHOH; 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

73. L ４ Ha-CH ２ -CR １０ (NH ２ )—, and the CH ２ The group is L ３ binds to R ５ is hydrogen, R １０ is a carboxy group or —C(═O)NH ２ That is, 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

74. L ４ Ha-(CH ２ ) ｐ -CR １０ (N.H.R. １１ )-(CH ２ ) ｑ -CHR １３ -or-CHR １３ - (CH ２ ) ｑ -CR １０ (N.H.R. １１ )-(CH ２ ) ｐ -, where q is 0 or 1; R ５ is hydrogen, (1) L ４ Ga-CHR １３ - (CH ２ ) ｑ -CR １０ (N.H.R. １１ )-(CH ２ ) ｐ -When -CHR １３ The carbon of the - group is L ３ binds to p is 0, R １０ represents a hydrogen atom, a carboxyl group, or —C(═O)NHR １０ｂ and R １１ is a hydrogen atom, R １０ｂ is a hydrogen atom, However, R １０ -C(=O)NHR １０ｂ When R １０ｂ and R １１ Let's get together -CH ２ CH ２ - may be formed, R １３ is a hydrogen atom, (2) L ４ Ga-(CH ２ ) ｐ -CR １０ (N.H.R. １１ )-(CH ２ ) ｑ -CHR １３ -When -(CH ２ ) ｐ The carbon of the - group is L ３ binds to p is 1, R １０ and R １１ are both hydrogen atoms, R １３ represents a carboxyl group or —C(═O)NR １３ａ R １３ｂ and R １３ａ and R １３ｂ are each independently a hydrogen atom or an optionally substituted C １－４ is an alkyl group, 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

75. L ４ is -CR １２ (NH ２ ) - and R １２ is a hydrogen atom or a methyl group, R ５ is a C optionally substituted with one hydroxyl group １－４ is an alkyl group, 56. The compound according to any one of claims 1, 8 to 11, and 54 to 55, or a pharmaceutically acceptable salt thereof.

76. 10. The compound of claim 1, selected from the group consisting of compounds represented by the following names or structural formulas, or pharmaceutically acceptable salts thereof: 5-({1-[amino(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 792】 、 9-[1-[2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemical 793】 、 (1aS,7bR)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 794】 、 (2R,4S)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemical 795】 、 (1aS,7bR)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 796】 、 (2R,4S)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemical 797】 、 (1aR,7bS)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 798】 、 (2S,4R)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemical 799】 、 (1aR,7bS)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 800】 、 (2S,4R)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 801】 、 5-({1-(2-amino-2-carboxypropyl)azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 802】 、 9-[1-(2-amino-2-carboxylatepropyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 803】 、 (1aS,7bR)-5-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 804】 、 (2R,4S)-9-[1-[(2R)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 805】 、 (1aR,7bS)-5-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 806】 、 (2S,4R)-9-[1-[(2R)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemical 807】 、 5-({1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 808】 、 9-[1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 809】 、 (1aS,7bR)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 810】 、 (2R,4S)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemical 811】 、 (1aS,7bR)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 812】 、 (2R,4S)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 813】 、 (1aR,7bS)-5-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 814】 、 (2S,4R)-9-[1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 815】 、 (1aR,7bS)-5-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 816】 , and (2S,4R)-9-[1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 817】 。

77. 3. The compound of claim 1 or claim 2, selected from the group consisting of compounds represented by the following names or structural formulas, or pharmaceutically acceptable salts thereof: 2-hydroxy-5-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 818】 、 5,5-Dihydroxy-9-{1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 819】 、 (1aS,7bR)-2-hydroxy-5-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 820】 、 (2R,4S)-5,5-dihydroxy-9-{1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 821】 、 (1aR,7bS)-2-hydroxy-5-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 822】 、 (2S,4R)-5,5-dihydroxy-9-{1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 823】 、 2-Hydroxy-5-[(1-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 824】 、 5,5-Dihydroxy-9-(1-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 825】 、 (1aS,7bR)-2-hydroxy-5-[(1-D-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 826】 、 (2R,4S)-5,5-dihydroxy-9-(1-D-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 827】 、 (1aS,7bR)-2-hydroxy-5-[(1-L-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 828】 、 (2R,4S)-5,5-dihydroxy-9-(1-L-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 829】 、 (1aR,7bS)-2-hydroxy-5-[(1-D-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 830】 、 (2S,4R)-5,5-dihydroxy-9-(1-D-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 831】 、 (1aR,7bS)-2-hydroxy-5-[(1-L-serylazetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 832】 、 (2S,4R)-5,5-dihydroxy-9-(1-L-serylazetidin-3-yl)oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 833】 、 2-Hydroxy-5-({1-[4-hydroxy-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 834】 、 5,5-Dihydroxy-9-{1-[4-hydroxy-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 835】 、 (1aS,7bR)-2-hydroxy-5-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 836】 、 (2R,4S)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 837】 、 (1aS,7bR)-2-hydroxy-5-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 838】 、 (2R,4S)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemical 839】 、 (1aS,7bR)-2-hydroxy-5-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 840】 、 (2R,4S)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 841】 、 (1aS,7bR)-2-hydroxy-5-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 842】 、 (2R,4S)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 843】 、 (1aR,7bS)-2-hydroxy-5-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 844】 、 (2S,4R)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 845】 、 (1aR,7bS)-2-hydroxy-5-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 846】 、 (2S,4R)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 847】 、 (1aR,7bS)-2-hydroxy-5-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 848】 、 (2S,4R)-5,5-dihydroxy-9-{1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemical 849】 、 (1aR,7bS)-2-hydroxy-5-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 850】 、 (2S,4R)-5,5-dihydroxy-9-{1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 851】 、 2-Hydroxy-5-{[1-(2-methyl-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 852】 、 5,5-Dihydroxy-9-[1-(2-methyl-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 853】 、 (1aS,7bR)-2-hydroxy-5-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 854】 、 (2R,4S)-5,5-dihydroxy-9-[1-(2-methyl-D-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 855】 、 (1aS,7bR)-2-hydroxy-5-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 856】 、 (2R,4S)-5,5-dihydroxy-9-[1-(2-methyl-L-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 857】 、 (1aR,7bS)-2-hydroxy-5-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 858】 、 (2S,4R)-5,5-dihydroxy-9-[1-(2-methyl-D-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 859】 、 (1aR,7bS)-2-hydroxy-5-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 860】 、 (2S,4R)-5,5-dihydroxy-9-[1-(2-methyl-L-seryl)azetidin-3-yl]oxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 861】 、 2-Hydroxy-5-[(1-{[morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 862】 、 5,5-Dihydroxy-9-(1-{[morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 863】 、 (1aS,7bR)-2-hydroxy-5-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 864】 、 (2R,4S)-5,5-dihydroxy-9-(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 865】 、 (1aS,7bR)-2-hydroxy-5-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 866】 、 (2R,4S)-5,5-dihydroxy-9-(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 867】 、 (1aR,7bS)-2-hydroxy-5-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua868】 、 (2S,4R)-5,5-dihydroxy-9-(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 869】 、 (1aR,7bS)-2-hydroxy-5-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 870】 、 (2S,4R)-5,5-dihydroxy-9-(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua 871】 、 (1aS,7bR)-5-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 872】 、 (2R,4S)-9-[1-[(2S)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 873】 、 (1aR,7bS)-5-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 874】 、 (2S,4R)-9-[1-[(2S)-2-amino-2-carboxylatepropyl]azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 875】 、 5-({1-[2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 876】 、 9-(1-{2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 877】 、 (1aS,7bR)-5-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 878】 、 (2R,4S)-9-(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemical 879】 、 (1aS,7bR)-5-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua880】 、 (2R,4S)-9-(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 881】 、 (1aR,7bS)-5-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 882】 、 (2S,4R)-9-(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 883】 、 (1aR,7bS)-5-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 884】 、 (2S,4R)-9-(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 885】 、 5-[(1-{2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 886】 、 9-(1-{2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 887】 、 (1aS,7bR)-5-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 888】 、 (2R,4S)-9-(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 889】 、 (1aS,7bR)-5-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 890】 、 (2R,4S)-9-(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 891】 、 (1aR,7bS)-5-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 892】 、 (2S,4R)-9-(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 893】 、 (1aR,7bS)-5-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemical 894】 、 (2S,4R)-9-(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 895】 、 5-({1-[5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 896】 、 9-{1-[5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemical 897】 、 (1aS,7bR)-5-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua 898】 、 (2R,4S)-9-{1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua 899】 、 (1aS,7bR)-5-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 900】 、 (2R,4S)-9-{1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 901】 、 (1aS,7bR)-5-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 902】 、 (2R,4S)-9-{1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 903】 、 (1aS,7bR)-5-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 904】 、 (2R,4S)-9-{1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 905】 、 (1aR,7bS)-5-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 906】 、 (2S,4R)-9-{1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 907】 、 (1aR,7bS)-5-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 908】 、 (2S,4R)-9-{1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 909】 、 (1aR,7bS)-5-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 910】 、 (2S,4R)-9-{1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【911】 、 (1aR,7bS)-5-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua912】 、 (2S,4R)-9-{1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua913】 、 5-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua914】 、 9-[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua915】 、 (1aS,7bR)-5-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua916】 、 (2R,4S)-9-[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua917】 、 (1aR,7bS)-5-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua918】 、 (2S,4R)-9-[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua919】 、 2-Hydroxy-5-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua920】 、 5,5-dihydroxy-9-(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua921】 、 (1aS,7bR)-2-hydroxy-5-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua922】 、 (2R,4S)-5,5-dihydroxy-9-(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua923】 、 (1aR,7bS)-2-hydroxy-5-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua924】 、 (2S,4R)-5,5-dihydroxy-9-(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua925】 、 5-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua926】 、 9-{1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua927】 、 (1aS,7bR)-5-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua928】 、 (2R,4S)-9-{1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua929】 、 (1aR,7bS)-5-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 930】 、 (2S,4R)-9-{1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua931】 、 5-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua932】 、 9-{1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua933】 、 (1aS,7bR)-5-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua934】 、 (2R,4S)-9-{1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 935】 、 (1aR,7bS)-5-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua936】 、 (2S,4R)-9-{1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua937】 、 2-Hydroxy-5-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua938】 、 5,5-Dihydroxy-9-{1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua939】 、 (1aS,7bR)-2-hydroxy-5-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 940】 、 (2R,4S)-5,5-dihydroxy-9-{1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua941】 、 (1aR,7bS)-2-hydroxy-5-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua942】 、 (2S,4R)-5,5-dihydroxy-9-{1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Hua943】 、 5-{[1-({4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua944】 、 9-[1-({4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua945】 、 (1aS,7bR)-5-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua946】 、 (2R,4S)-9-[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua947】 、 (1aS,7bR)-5-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua948】 、 (2R,4S)-9-[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua949】 、 (1aS,7bR)-5-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 950】 、 (2R,4S)-9-[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 951】 、 (1aS,7bR)-5-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua952】 、 (2R,4S)-9-[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua953】 、 (1aR,7bS)-5-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 954】 、 (2S,4R)-9-[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 955】 、 (1aR,7bS)-5-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua956】 、 (2S,4R)-9-[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua957】 、 (1aR,7bS)-5-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 958】 、 (2S,4R)-9-[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua959】 、 (1aR,7bS)-5-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 960】 、 (2S,4R)-9-[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua961】 、 5-[(1-{2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua962】 、 9-(1-{2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua963】 、 (1aS,7bR)-5-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua964】 、 (2R,4S)-9-(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 965】 、 (1aS,7bR)-5-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua966】 、 (2R,4S)-9-(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua967】 、 (1aR,7bS)-5-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua968】 、 (2S,4R)-9-(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Hua969】 、 (1aR,7bS)-5-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 970】 、 (2S,4R)-9-(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylate 【Chemistry 971】 、 5-[(1-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua972】 、 9-(1-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua973】 、 (1aS,7bR)-5-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua974】 、 (2R,4S)-9-(1-D-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 975】 、 (1aS,7bR)-5-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua976】 、 (2R,4S)-9-(1-L-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua977】 、 (1aR,7bS)-5-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua978】 、 (2S,4R)-9-(1-D-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua979】 、 (1aR,7bS)-5-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 980】 、 (2S,4R)-9-(1-L-histidylazetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 981】 、 5-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 982】 、 9-[1-(2-aminoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 983】 、 (1aS,7bR)-5-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 984】 、 (2R,4S)-9-[1-(2-aminoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 985】 、 (1aR,7bS)-5-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua986】 、 (2S,4R)-9-[1-(2-aminoethyl)azetidin-3-yl]oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua987】 、 5-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua988】 、 9-(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua989】 、 (1aS,7bR)-5-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 990】 、 (2R,4S)-9-(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 991】 、 (1aR,7bS)-5-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua992】 、 (2S,4R)-9-(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua993】 、 5-({1-[2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua994】 、 9-({1-[2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua995】 、 (1aS,7bR)-5-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua996】 、 (2R,4S)-9-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Hua997】 、 (1aS,7bR)-5-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Hua998】 、 (2R,4S)-9-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【999】 、 (1aR,7bS)-5-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【1000】 、 (2S,4R)-9-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1001】 、 (1aR,7bS)-5-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1002】 、 (2S,4R)-9-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1003】 、 5-({1-[2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1004】 、 9-({1-[2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1005】 、 (1aS,7bR)-5-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1006】 、 (2R,4S)-9-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1007】 、 (1aS,7bR)-5-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1008】 、 (2R,4S)-9-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1009】 、 (1aR,7bS)-5-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1010】 、 (2S,4R)-9-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1011】 、 (1aR,7bS)-5-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1012】 、 (2S,4R)-9-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1013】 、 2-hydroxy-5-[(1-{[4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1014】 、 5,5-Dihydroxy-9-[(1-{[(4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 1015】 、 (1aS,7bR)-2-hydroxy-5-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1016】 、 (2R,4S)-5,5-dihydroxy-9-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 1017】 、 (1aS,7bR)-2-hydroxy-5-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1018】 、 (2R,4S)-5,5-dihydroxy-9-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 1019】 、 (1aR,7bS)-2-hydroxy-5-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1020】 、 (2S,4R)-5,5-dihydroxy-9-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 1021】 、 (1aR,7bS)-2-hydroxy-5-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【Chemistry 1022】 、 (2S,4R)-5,5-dihydroxy-9-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【1023】 、 5-[(1-{[4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate 【1024】 、 9-[(1-{[4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1025】 、 (1aS,7bR)-5-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate 【1026】 、 (2R,4S)-9-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【1027】 、 (1aS,7bR)-5-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate 【1028】 、 (2R,4S)-9-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【1029】 、 (1aR,7bS)-5-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate 【Chemistry 1030】 、 (2S,4R)-9-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【Chemistry 1031】 、 (1aR,7bS)-5-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxy-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylate 【1032】 、 (2S,4R)-9-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-5,5-dihydroxy-6-oxa-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(7),8,10-triene-8-carboxylic acid 【1033】 、 2-hydroxy-5-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【1034】 、 5,5-dihydroxy-9-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-5-boranuidatricyclo[5.4.0.02,4]undeca-1(11),7,9-triene-8-carboxylic acid 【Chemistry 1035】 、 (1aR,7bS)-2-hydroxy-5-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【1036】 、 (2S,4R)-5,5-dihydroxy-9-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【1037】 、 (1aS,7bR)-2-hydroxy-5-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-1,1a,2,7b-tetrahydrocyclopropa[c][1,2]benzoxaborinin-4-carboxylic acid 【1038】 , and (2R,4S)-5,5-dihydroxy-9-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)-5-boranuidatricyclo[5.4.0.0 ２，４ ]undeca-1(11),7,9-triene-8-carboxylic acid 【1039】

78. The following formula (14): 【1043】 [In formula (14), X, L ３ , L ４ , m, n, and R ５ has the same meaning as defined in any one of claims 1 to 39. or a pharmaceutically acceptable salt thereof.

79. The compound of formula (14) may be a compound of the following formula (15): 【1044】 Or the following formula (16): 【1045】 [In formulas (15) and (16), X, L ３ , L ４ , m, n, and R ５ is as defined in claim 1.

79. The compound of claim 78, or a pharmaceutically acceptable salt thereof, which is any one of the optical isomers represented by:

80. R Ｇ is a hydroxyl group or a thiol group, or a pharmaceutically acceptable salt thereof.

81. R Ｇ The compound according to any one of claims 78 to 80, or a pharmaceutically acceptable salt thereof, wherein is a hydroxyl group.

82. X is a hydroxyl group or C １－６ The compound according to any one of claims 78 to 81, or a pharmaceutically acceptable salt thereof, which is an alkoxy group.

83. 83. The compound according to any one of claims 78 to 82, or a pharmaceutically acceptable salt thereof, wherein X is a hydroxyl group.

84. L ３ The compound according to any one of claims 78 to 83, wherein R is as defined in claim 9, or a pharmaceutically acceptable salt thereof.

85. L ４ and R ５ The compound according to any one of claims 78 to 84, wherein the formula (I) is as defined in any one of claims 10 and 41 to 75, or a pharmaceutically acceptable salt thereof.

86. 79. The compound of claim 78, selected from the group consisting of compounds named or represented by the following structural formula, or a pharmaceutically acceptable salt thereof: 6-({1-[amino(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid 【1046】 、 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1047】 、 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1048】 、 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1049】 、 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemistry 1050】 、 6-({1-(2-amino-2-carboxypropyl)azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid 【1051】 、 6-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1052】 、 6-({1-[(2R)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1053】 、 6-({1-[2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid 【1054】 、 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1055】 、 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1056】 、 6-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1057】 , and 6-({1-[(2S)-2-amino-2-(1H-imidazol-4-yl)propanoyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1058】 。

87. 79. The compound of claim 78, selected from the group consisting of compounds named or represented by the following structural formula, or a pharmaceutically acceptable salt thereof: 3-(2-boronocyclopropyl)-2-hydroxy-6-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)benzoic acid 【1059】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)benzoic acid 【Chemistry 1060】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)benzoic acid 【1061】 、 3-[2-boronocyclopropyl]-2-hydroxy-6-[(1-serylazetidin-3-yl)oxy]benzoic acid 【1062】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-[(1-D-serylazetidin-3-yl)oxy]benzoic acid 【1063】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-[(1-L-serylazetidin-3-yl)oxy]benzoic acid 【1064】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-[(1-D-serylazetidin-3-yl)oxy]benzoic acid 【1065】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-[(1-L-serylazetidin-3-yl)oxy]benzoic acid 【1066】 、 3-[2-Boronocyclopropyl]-2-hydroxy-6-({1-[4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid 【1067】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid 【1068】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid 【1069】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid 【1070】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid 【1071】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid 【1072】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-L-prolyl]azetidin-3-yl}oxy)benzoic acid 【1073】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4R)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid 【1074】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(4S)-4-hydroxy-D-prolyl]azetidin-3-yl}oxy)benzoic acid 【1075】 、 3-[2-Boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-seryl)azetidin-3-yl]oxy}benzoic acid 【1076】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}benzoic acid 【1077】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}benzoic acid 【1078】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-D-seryl)azetidin-3-yl]oxy}benzoic acid 【1079】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-{[1-(2-methyl-L-seryl)azetidin-3-yl]oxy}benzoic acid 【1080】 、 3-[(2-boronocyclopropyl]-2-hydroxy-6-[(1-{[morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1081】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1082】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1083】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1084】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-morpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1085】 、 6-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1086】 、 6-({1-[(2S)-2-amino-2-carboxypropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1087】 、 6-[(1-{2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【1088】 、 6-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1089】 、 6-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1090】 、 6-[(1-{(2R)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1091】 、 6-[(1-{(2S)-2-amino-3-[(2-hydroxyethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1092】 、 6-[(1-{2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【1093】 、 6-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1094】 、 6-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1095】 、 6-[(1-{(2R)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1096】 、 6-[(1-{(2S)-2-amino-3-[(2-amino-2-oxoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1097】 、 3-[2-boronocyclopropyl]-6-({1-[(5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【1098】 、 3-[(1R,2S)-2-Boronocyclopropyl]-6-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【Chemical 1099】 、 3-[(1R,2S)-2-boronocyclopropyl]-6-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【1100】 、 3-[(1R,2S)-2-Boronocyclopropyl]-6-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【Chemistry 1101】 、 3-[(1R,2S)-2-boronocyclopropyl]-6-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【1102】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-({1-[(3S,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【1103】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-({1-[(3R,5S)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【1104】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-({1-[(3S,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【1105】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-({1-[(3R,5R)-5-carbamoylpyrrolidin-3-yl]azetidin-3-yl}oxy)-2-hydroxybenzoic acid 【1106】 、 6-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【1107】 、 6-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1108】 、 6-{[1-(2-amino-2-oxoethyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1109】 、 3-[(2-boronocyclopropyl]-2-hydroxy-6-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]benzoic acid 【1110】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]benzoic acid 【Chemical 1111】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{2-[(2-hydroxyethoxy)amino]-2-oxoethyl}azetidin-3-yl)oxy]benzoic acid 【Chemical 1112】 、 6-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1113】 、 6-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1114】 、 6-({1-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1115】 、 6-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1116】 、 6-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1117】 、 6-({1-[(1-aminocyclopropyl)methyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1118】 、 3-[2-Boronocyclopropyl]-2-hydroxy-6-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)benzoic acid 【Chemical 1119】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)benzoic acid 【1120】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(1H-1,2,4-triazol-3-yl)methyl]azetidin-3-yl}oxy)benzoic acid 【Chemical 1121】 、 6-{[1-({4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1122】 、 6-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1123】 、 6-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1124】 、 6-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1125】 、 6-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1126】 、 6-{[1-({(1r,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1127】 、 6-{[1-({(1s,4r)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1128】 、 6-{[1-({(1r,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1129】 、 6-{[1-({(1s,4s)-4-[(2-aminoethyl)amino]cyclohexyl}acetyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1130】 、 6-[(1-{2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【1131】 、 6-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1132】 、 6-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1133】 、 6-[(1-{(2R)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1134】 、 6-[(1-{(2S)-2-amino-3-[(2-aminoethyl)amino]-2-methyl-3-oxopropyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1135】 、 3-(2-boronocyclopropyl)-6-[(1-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid 【1136】 、 3-[(1R,2S)-2-boronocyclopropyl]-6-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid 【1137】 、 3-[(1R,2S)-2-Boronocyclopropyl]-6-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid 【1138】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-[(1-D-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid 【1139】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-[(1-L-histidylazetidin-3-yl)oxy]-2-hydroxybenzoic acid 【1140】 、 6-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid 【1141】 、 6-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1142】 、 6-{[1-(2-aminoethyl)azetidin-3-yl]oxy}-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1143】 、 6-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-3-(2-boronocyclopropyl)-2-hydroxybenzoic acid 【Chemical 1144】 、 6-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1145】 、 6-[(1-{[5-(aminomethyl)morpholin-2-yl]acetyl}azetidin-3-yl)oxy]-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【Chemical 1146】 、 6-({1-[2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【1147】 、 6-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1148】 、 6-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1149】 、 6-({1-[(2R)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1150】 、 6-({1-[(2S)-2-amino-2-methyl-3-{[2-(methylamino)-2-oxoethyl]amino}-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1151】 、 6-({1-[2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[2-boronocyclopropyl]-2-hydroxybenzoic acid 【1152】 、 6-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1153】 、 6-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1154】 、 6-({1-[(2R)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1155】 、 6-({1-[(2S)-2-amino-3-{[2-(dimethylamino)-2-oxoethyl]amino}-2-methyl-3-oxopropyl]azetidin-3-yl}oxy)-3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxybenzoic acid 【1156】 、 3-[2-Boronocyclopropyl]-2-hydroxy-6-[(1-{[4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【Chemical 1157】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1158】 、 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【Chemical 1159】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2R)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1160】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-[(1-{[(2S)-4-methylmorpholin-2-yl]acetyl}azetidin-3-yl)oxy]benzoic acid 【1161】 、 3-[2-boronocyclopropyl]-6-[(1-{[4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate 【Chemical 1162】 、 3-[(1R,2S)-2-boronocyclopropyl]-6-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate 【1163】 、 3-[(1R,2S)-2-boronocyclopropyl]-6-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate 【Chemical 1164】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-[(1-{[(2R)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate 【1165】 、 3-[(1S,2R)-2-boronocyclopropyl]-6-[(1-{[(2S)-4,4-dimethylmorpholin-4-ium-2-yl]acetyl}azetidin-3-yl)oxy]-2-hydroxybenzoate 【Chemical 1166】 、 3-(2-boronocyclopropyl)-2-hydroxy-6-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)benzoic acid 【Chemical 1167】 、 3-[(1S,2R)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)benzoic acid 【1168】 , and 3-[(1R,2S)-2-boronocyclopropyl]-2-hydroxy-6-({1-[(3-hydroxy-2-methyl-4-oxopyridin-1(4H)-yl)acetyl]azetidin-3-yl}oxy)benzoic acid 【1169】 。

88. A medicament comprising the compound according to any one of claims 1 to 87 or a pharmaceutically acceptable salt thereof.

89. The pharmaceutical agent of claim 88, which is a therapeutic or preventive agent for a bacterial infection.

90. A β-lactamase inhibitor comprising the compound according to any one of claims 1 to 87 or a pharmaceutically acceptable salt thereof as an active ingredient.

91. A pharmaceutical composition comprising the compound according to any one of claims 1 to 87 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

92. 92. The pharmaceutical composition of claim 91, further comprising an additional agent.

93. 93. The pharmaceutical composition of claim 92, wherein the additional agent is selected from the group consisting of an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, and an antiallergic agent.

94. 94. The pharmaceutical composition of claim 92 or claim 93, wherein the additional agent is a β-lactam agent.

95. Additional medications, beta-lactams, include amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), epicillin, carbenicillin (carindacillin), ticarcillin, temocillin, azlocillin, piperacillin, mezlocillin, mecillinam (pivmecillinam), sulbenicillin, benzylpenicillin (G), clometocillin, benzathine benzylpenicillin, procaine benzylpenicillin, azidocillin, penamecillin, phenoxymethylpenicillin (V), and propionibacterial. Cirrhosis, benzathine phenoxymethylpenicillin, phenethicillin, cloxacillin (dicloxacillin, flucloxacillin), oxacillin, methicillin, nafcillin, faropenem, biapenem, doripenem, ertapenem, imipenem, meropenem, panipenem, tomopenem, razupenem, cefazolin, cephacetrile, cefadroxil, cephalexin, cephaloglycin, cephalonium, cephaloridine, cephalothin, cephapirin, cefatrizine, cefazedone, cefazaflur, cephradine, cefroxacillin ceftezole, cefaclor, cefamandole, cefminox, cefonicid, ceforanide, cefotiam, cefprozil, cefbuperazone, cefuroxime, cefuzonam, cefoxitin, cefotetan, cefmetazole, loracarbef, cefixime, ceftazidime, ceftriaxone, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefmenoxime, cefodizime, cefoperazone, cefotaxime, cefpimizole, cefpiramide, cefpodoxime, cefsulodin, cefteram, cef The pharmaceutical composition of claim 93 or 94, wherein the compound is selected from the group consisting of thibutene, ceftiolene, ceftizoxime, flomoxef, latamoxef, cefepime, cefozopran, cefpirome, cefquinome, ceftobiprole, ceftaroline, CXA-101, RWJ-54428, MC-04546, ME1036, BAL30072, SYN2416, ceftiofur, cefquinome, cefovecin, aztreonam, tigenonam, carumonam, RWJ-442831, RWJ-333441, and RWJ-333442.

96. The pharmaceutical composition of claim 94 or 95, wherein the β-lactam drug is selected from ceftazidime, biapenem, doripenem, ertapenem, imipenem, meropenem, or panipenem.

97. 96. The pharmaceutical composition of claim 94 or claim 95, wherein the beta-lactam agent is selected from aztreonam, tigenonam, BAL30072, SYN2416 or carumonam.

98. 92. The pharmaceutical composition of claim 91, wherein the composition is administered in combination with an additional agent.

99. 99. The pharmaceutical composition of claim 98, wherein the additional agent is selected from an antibacterial agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, or an antiallergic agent.

100. 100. The pharmaceutical composition of claim 98 or claim 99, wherein the additional agent is a β-lactam agent.

101. Additional medications, beta-lactams, include amoxicillin, ampicillin (pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin), epicillin, carbenicillin (carindacillin), ticarcillin, temocillin, azlocillin, piperacillin, mezlocillin, mecillinam (pivmecillinam), sulbenicillin, benzylpenicillin (G), clometocillin, benzathine benzylpenicillin, and procaine benzylpenicillin. Cillin, azidocillin, penamecillin, phenoxymethylpenicillin (V), propicillin, benzathine phenoxymethylpenicillin, phenethicillin, cloxacillin (dicloxacillin, flucloxacillin), oxacillin, methicillin, nafcillin, faropenem, biapenem, doripenem, ertapenem, imipenem, meropenem, panipenem, tomopenem, razupenem, cefazolin, cephacetrile, cefadroxil, cephalexin, cephaloglycin, cephalonium, cephaloridine, cephalothin, cephapirin, cefatrizine, cefazedone, cefazaflur, cephradium , cefroxadine, ceftezole, cefaclor, cefamandole, cefminox, cefonicid, ceforanide, cefotiam, cefprozil, cefbuperazone, cefuroxime, cefuzonam, cefoxitin, cefotetan, cefmetazole, loracarbef, cefixime, ceftazidime, ceftriaxone, cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefmenoxime, cefodizime, cefoperazone, cefotaxime, cefpimizole, cefpiramide, cefpodoxime, cefsulodin, cefteram, ceftibuten, ceftiolene, ceftizoxime, flomoxef, The pharmaceutical composition of claim 99 or 100, wherein the compound is selected from the group consisting of latamoxef, cefepime, cefozopran, cefpirome, cefquinome, ceftobiprole, ceftaroline, CXA-101, RWJ-54428, MC-04546, ME1036, BAL30072, SYN2416, ceftiofur, cefquinome, cefovecin, aztreonam, tigenonam, carumonam, RWJ-442831, RWJ-333441, and RWJ-333442.

102. The pharmaceutical composition of claim 100 or 101, wherein the β-lactam drug is selected from the group consisting of ceftazidime, biapenem, doripenem, ertapenem, imipenem, meropenem, and panipenem.

103. 102. The pharmaceutical composition of claim 100 or 101, wherein the β-lactam drug is selected from the group consisting of aztreonam, tigenonam, BAL30072, SYN2416 and carumonam.

104. 88. A compound according to any one of claims 1 to 87, or a pharmaceutically acceptable salt thereof, for use in treating a bacterial infection.

105. The compound according to claim 104 or a pharmaceutically acceptable salt thereof, wherein the bacterial infection is a bacterial infection involving a bacterium capable of having β-lactamase.

106. 106. The compound according to claim 104 or 105, or a pharmaceutically acceptable salt thereof, wherein the bacterial infection is sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory lesion, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infection, lymphangitis / lymphadenitis, secondary infection of trauma / burn, surgical wound, or the like, urinary tract infection, genital infection, eye infection, or dental infection.

107. 88. A pharmaceutical comprising the compound according to any one of claims 1 to 87 or a pharmaceutically acceptable salt thereof in combination with at least one or more drugs selected from the group consisting of therapeutic agents for sepsis, febrile neutropenia, bacterial meningitis, bacterial endocarditis, otitis media, sinusitis, pneumonia, lung abscess, empyema, secondary infection of chronic respiratory lesions, pharyngitis / laryngitis, tonsillitis, osteomyelitis, arthritis, peritonitis, intraperitoneal abscess, cholecystitis, cholangitis, liver abscess, deep skin infection, lymphangitis / lymphadenitis, secondary infection of trauma / burn, surgical wound, etc., urinary tract infection, genital infection, eye infection, and dental infection.

108. A pharmaceutical composition comprising a β-lactam drug, wherein the pharmaceutical composition is administered together with a compound according to any one of claims 1 to 87 or a pharmaceutically acceptable salt thereof.

Images